U.S. patent application number 11/371964 was filed with the patent office on 2006-07-06 for substituted 1,4-benzodiazepines and uses thereof.
Invention is credited to Raul R. Calvo, Theodore E. JR. Carver, Maxwell D. Cummings, Bruce L. Grasberger, Alexander J. Kim, Louis V. III LaFrance, Tianbao Lu, Karen L. Milkiewicz, Daniel J. Parks.
Application Number | 20060148792 11/371964 |
Document ID | / |
Family ID | 23293137 |
Filed Date | 2006-07-06 |
United States Patent
Application |
20060148792 |
Kind Code |
A1 |
Lu; Tianbao ; et
al. |
July 6, 2006 |
Substituted 1,4-benzodiazepines and uses thereof
Abstract
The present invention is directed to novel 1,4-benzodiazepines,
pharmaceutical compositions thereof, and the use thereof as
inhibitors of HDM2-p53 interactions. Compounds have Formula I:
##STR1## or a solvate, hydrate or pharmaceutically acceptable salt
thereof; wherein: X and Y are independently --C(O)--, --CH.sub.2--
or --C(S)--; R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.7, R.sup.8,
R.sup.b, R.sup.c, R.sup.d and M arm defined herein; R.sup.5 is
hydrogen, alkyl, cycloalkyl, optionally substituted aryl,
optionally substituted heteroaryl, optionally substituted aralkyl,
optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl,
alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl,
alkylaminocarbonyl or alkylaminocarbonylalkyl; R.sup.6 is
cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl,
heteroarylalkyl, or a saturated or partially unsaturated
heterocycle, each of which is optionally substituted; R.sup.9 is
cycloalkyl: aryl, heteroaryl, a saturated or partially unsaturated
heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of
which is optionally substituted; and R.sup.10 is
--(CH.sub.2).sub.n--CO.sub.2R.sup.b, --(CH.sub.2).sub.m--CO.sub.2M,
--(CH.sub.2).sub.i--OH or --(CH.sub.2).sub.j--CONR.sup.cR.sup.d n
is 0-8, m is 0-8, i is 1-8 and j is 0-8.
Inventors: |
Lu; Tianbao; (Kennett
Square, PA) ; LaFrance; Louis V. III; (West Chester,
PA) ; Parks; Daniel J.; (Exton, PA) ;
Milkiewicz; Karen L.; (Exton, PA) ; Calvo; Raul
R.; (Royersford, PA) ; Cummings; Maxwell D.;
(Wayne, PA) ; Kim; Alexander J.; (Philadelphia,
PA) ; Grasberger; Bruce L.; (Trappe, PA) ;
Carver; Theodore E. JR.; (Downingtown, PA) |
Correspondence
Address: |
PHILIP S. JOHNSON;JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933-7003
US
|
Family ID: |
23293137 |
Appl. No.: |
11/371964 |
Filed: |
March 9, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10292876 |
Nov 13, 2002 |
|
|
|
11371964 |
Mar 9, 2006 |
|
|
|
60331235 |
Nov 13, 2001 |
|
|
|
Current U.S.
Class: |
514/221 ;
540/504; 540/505 |
Current CPC
Class: |
A61P 7/06 20180101; A61P
43/00 20180101; C07D 409/04 20130101; A61P 21/00 20180101; A61P
25/28 20180101; A61P 5/14 20180101; A61P 17/00 20180101; A61P 29/00
20180101; A61P 37/08 20180101; A61P 13/12 20180101; A61P 19/02
20180101; A61P 37/00 20180101; A61P 35/00 20180101; A61P 3/10
20180101; C07D 401/04 20130101; A61P 37/02 20180101; A61P 25/00
20180101; C07D 403/10 20130101; A61P 35/02 20180101; A61P 37/06
20180101; A61P 5/00 20180101; C07D 243/14 20130101; A61P 1/04
20180101; C07D 405/04 20130101; A61P 21/04 20180101; A61P 17/04
20180101 |
Class at
Publication: |
514/221 ;
540/504; 540/505 |
International
Class: |
A61K 31/551 20060101
A61K031/551; C07D 243/12 20060101 C07D243/12; C07D 243/18 20060101
C07D243/18 |
Claims
1-35. (canceled)
36. A pharmaceutical composition, comprising a compound of Formula
I: ##STR5## or a pharmaceutically acceptable salt thereof; wherein:
X and Y are independently --C(O)--, --CH.sub.2--or --C(S)--;
R.sup.1, R.sup.3, and R.sup.4 are independently hydrogen, halo,
alkyl, alkenyl, alkynyl, cycloalkyl, optionally substituted aryl,
optionally substituted aralkyl, optionally substituted heteroaryl,
optionally substituted heteroaralkyl, alkoxy, optionally
substituted aryloxy, optionally substituted heteroaryloxy, cyano,
amino, alkanoylamino, nitro, hydroxy, carboxy, or alkoxycarbonyl:
or R.sup.3 and R.sup.4 are taken together to form
--(CH.sub.2).sub.u--, where u is 3-6. --CH.dbd.CH--CH.dbd.CH-- or
--CH.sub.2CH.dbd.CHCH.sub.2--; R.sup.2 is hydrogen, halo, C.sub.1-4
alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
acetylamino, C.sub.1-6 alkoxy, phenyl, halophenyl, hydroxyphenyl,
C.sub.1-6 alkoxyphenyl, C.sub.1-6 alkylphenyl, aminophenyl,
C.sub.1-6 alkylenedioxyphenyl, hydroxycarbonylphenyl, thienyl,
C.sub.1-6 alkylthienyl, furanyl, pyrrolyl, amino, C.sub.1-6
hydroxyalkyl or cyano; R.sup.5 is hydrogen, alkyl, cycloalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
optionally substituted aralkyl, optionally substituted
heteroaralkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,
aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or
alkylaminocarbonylalkyl: R.sup.6 is cycloalkyl, aryl, heteroaryl,
cycloalkylalkyl, heteroarylalkyl, or a saturated or partially
unsaturated heterocycle, each of which is optionally substituted;
R.sup.7 and R.sup.8 are independently hydrogen or alkyl: R.sup.9 is
cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated
heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of
which is optionally substituted; and R.sup.10 is
--(CH.sub.2).sub.n--CO.sub.2R.sup.b, --(CH.sub.2).sub.m--CO.sub.2M,
--(CH.sub.2).sub.i--OH or --(CH.sub.2).sub.j--CONR.sup.cR.sup.d
where R.sup.b is hydrogen, alkyl, optionally substituted
cycloalkyl, or optionally substituted, saturated or partially
unsaturated heterocycle; M is a cation; R.sup.c and R.sup.d are
independently hydrogen, alkyl, hydroxyalkyl, carboxyalkyl,
aminoalkyl, optionally substituted cycloalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, optionally substituted heteroarylalkyl, and
an optionally substituted, saturated or partially unsaturated
heterocycle; and n is 0-8, m is 0-8, i is 1-8 and j is 0-8; and (b)
one or more pharmaceutically-acceptable excipients, further
comprising: (c) at least one additional substance selected from the
group consisting of synergists, stabilizing substances,
antineoplastic agents, anticancer agents, and cytostatic
agents.
37-42. (canceled)
43. A method of inhibiting the binding of p53 to a protein encoded
by hdm2, comprising contacting p53 or one or more proteins encoded
by hdm2, with a compound of Formula I: ##STR6## or a
pharmaceutically acceptable salt thereof; wherein: X and Y are
independently --C(O)--, --CH.sub.2-- or --C(S)--; R.sup.1, R.sup.3,
and R.sup.4 are independently hydrogen, halo, alkyl, alkenyl,
alkynyl, cycloalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, alkoxy, optionally substituted aryloxy,
optionally substituted heteroaryloxy, cyano, amino, alkanoylamino,
nitro, hydroxy, carboxy, or alkoxycarbonyl; or R.sup.3 and R.sup.4
are taken together to form --(CH.sub.2).sub.u--, where u is 3-6,
--CH.dbd.CH--CH.dbd.CH-- or --CH.sub.2CH.dbd.CHCH.sub.2. R.sup.2 is
hydrogen, halo, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, acetylamino, C.sub.1-6 alkoxy, phenyl,
halophenyl, hydroxyphenyl C.sub.1-6 alkoxyphenyl, C.sub.1-6
alkylphenyl, aminophenyl, C.sub.1-6 alkylenedioxyphenyl,
hydroxycarbonylphenyl, thienyl, C.sub.1-6alkylthienyl, furanyl,
pyrrolyl, amino, C.sub.1-6 hydroxyalkyl or cyano: R.sup.5 is
hydrogen, alkyl, cycloalkyl, optionally substituted aryl,
optionally substituted heteroaryl, optionally substituted aralkyl,
optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl,
alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl,
alkylaminocarbonyl or alkylaminocarbonylalkyl; R.sup.6 is
cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heteroarylalkyl, or
a saturated or partially unsaturated heterocycle, each of which is
optionally substituted; R.sup.7 and R.sup.8 are independently
hydrogen or alkyl; R.sup.9 is cycloalkyl, aryl, heteroaryl, a
saturated or partially unsaturated heterocycle, cycloalkyl(alkyl),
aralkyl or heteroarylalkyl, each of which is optionally
substituted; and R.sup.10 is --(CH.sub.2).sub.n--CO.sub.2R.sup.b,
--(CH.sub.2).sub.m, --CO.sub.2M, --(CH.sub.2).sub.i--OH or
--(CH.sub.2).sub.j--CONR.sup.cR.sup.d where R.sup.b is hydrogen,
alkyl, optionally substituted cycloalkyl, or optionally
substituted, saturated or partially unsaturated heterocycle; M is a
cation: R.sup.c and R.sup.d are independently hydrogen, alkyl,
hydroxyalkyl, carboxyalkyl, aminoalkyl, optionally substituted
cycloalkyl, optionally substituted aryl, optionally substituted
aralkyl, optionally substituted heteroaryl, optionally substituted
heteroarylalkyl, and an optionally substituted, saturated or
partially unsaturated heterocycle; and n is 0-8, m is 0-8, i is 1-8
and j is 0-8.
44. A method of treating a condition that results from the
inhibition of one or more functions of a cellular protein that
induces apoptosis, induces cellular death, or regulates the cell
cycle by an HDM2 protein, comprising administering to a patient in
need of such treatment a pharmaceutically-effective amount of a
compound: ##STR7## or a pharmaceutically acceptable salt thereof,
wherein: X and Y are independently --C(O)--, --CH.sub.2-- or
--C(S)--; R.sup.1, R.sup.3, and R.sup.4 are independently hydrogen,
halo, alkyl, alkenyl, alkynyl, cycloalkyl, optionally substituted
aryl, optionally substituted aralkyl, optionally substituted
heteroaryl, optionally substituted heteroaralkyl, alkoxy,
optionally substituted aryloxy, optionally substituted
heteroaryloxy, cyano, amino, alkanoylamino, nitro, hydroxy,
carboxy, or alkoxycarbonyl; or R.sup.3 and R.sup.4 are taken
together to form --(CH.sub.2).sub.u--, where u is 3-6,
--CH.dbd.CH--CH.dbd.CH-- or --CH.sub.2CH.dbd.CHCH.sub.2--; R.sup.2
is hydrogen, halo, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl acetylamino, C.sub.1-6 alkoxy, phenyl,
halophenyl, hydroxyphenyl, C.sub.1-6 alkoxyphenyl, C.sub.1-6
alkylphenyl, aminophenyl, C.sub.1-6 alkylenedioxyphenyl,
hydroxycarbonylphenyl, thienyl, C.sub.1-6alkylthienyl, furanyl,
pyrrolyl, amino, C.sub.1-6 hydroxyalkyl or cyano; R.sup.5 is
hydrogen, alkyl, cycloalkyl, optionally substituted aryl,
optionally substituted heteroaryl, optionally substituted aralkyl,
optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl,
alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl,
alkylaminocarbonyl or alkylaminocarbonylalkyl; R.sup.6 is
cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heteroarylalkyl, or
a saturated or partially unsaturated heterocycle, each of which is
optionally substituted; R.sup.7 and R.sup.8 are independently
hydrogen or alkyl; R.sup.9 is cycloalkyl, aryl, heteroaryl, a
saturated or partially unsaturated heterocycle, cycloalkyl(alkyl),
aralkyl or heteroarylalkyl, each of which is optionally
substituted; and R.sup.10 is --(CH.sub.2).sub.n--CO.sub.2R.sup.b,
--(CH.sub.2).sub.m--CO.sub.2M, --(CH.sub.2).sub.i--OH or
--(CH.sub.2).sub.j--CONR.sup.cR.sup.d where R.sup.b is hydrogen,
alkyl, optionally substituted cycloalkyl, or optionally
substituted, saturated or partially unsaturated heterocycle; M is a
cation; R.sup.c and R.sup.d are independently hydrogen, alkyl,
hydroxyalkyl, carboxyalkyl, aminoalkyl, optionally substituted
cycloalkyl, optionally substituted aryl, optionally substituted
aralkyl, optionally substituted heteroaryl, optionally substituted
heteroarylalkyl, and an optionally substituted, saturated or
partially unsaturated heterocycle; and n is 0-8, m is 0-8, i is 1-8
and j is 0-8.
45. A method of inducing apoptosis, comprising contacting an animal
with a composition comprising a pharmaceutically-effective amount
of at least one compound of Formula I: ##STR8## or a
pharmaceutically acceptable salt thereof; wherein: X and Y are
independently --C(O)--, --CH.sub.2-- or --C(S)--; R.sup.1, R.sup.3,
and R.sup.4 are independently hydrogen, halo, alkyl, alkenyl,
alkynyl, cycloalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, optionally
substituted heteroaralkyl, alkoxy, optionally substituted aryloxy,
optionally substituted heteroaryloxy, cyano, amino, alkanoylamino,
nitro, hydroxy, carboxy, or alkoxycarbonyl; or R.sup.3 and R.sup.4
are taken together to form --(CH.sub.2).sub.u--, where u is 3-6,
--CH.dbd.CH--CH.dbd.CH-- or --CH.sub.2CH=CHCH.sub.2--; R.sup.2 is
hydrogen, halo, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, acetylamino, C.sub.1-6 alkoxy, phenyl,
halophenyl, hydroxyphenyl, C.sub.1-6 alkoxyphenyl, C.sub.1-6
alkylphenyl, aminophenyl, C.sub.1-6 alkylenedioxyphenyl,
hydroxycarbonylphenyl, thienyl, C.sub.1-6 alkylthienyl, furanyl,
pyrrolyl, amino, C.sub.1-6 hydroxyalkyl or cyano; R.sup.5 is
hydrogen, alkyl, cycloalkyl, optionally substituted aryl,
optionally substituted heteroaryl, optionally substituted aralkyl,
optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl,
alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl,
alkylaminocarbonyl or alkylaminocarbonylalkyl; R.sup.6 is
cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heteroarylalkyl, or
a saturated or partially unsaturated heterocycle, each of which is
optionally substituted; R.sup.7 and R.sup.8 are independently
hydrogen or alkyl; R.sup.9 is cycloalkyl, aryl, heteroaryl, a
saturated or partially unsaturated heterocycle, cycloalkyl(alkyl),
aralkyl or heteroarylalkyl, each of which is optionally
substituted; and R.sup.10 is --(CH.sub.2).sub.n--CO.sub.2R.sup.b,
--(CH.sub.2).sub.m--CO.sub.2M, --(CH.sub.2).sub.i--OH or
--(CH.sub.2).sub.j--CONR.sup.cR.sup.d where R.sup.b is hydrogen,
alkyl, optionally substituted cycloalkyl, or optionally
substituted, saturated or partially unsaturated heterocycle; M is a
cation; R.sup.c and R.sup.d are independently hydrogen, alkyl,
hydroxyalkyl, carboxyalkyl, aminoalkyl, optionally substituted
cycloalkyl, optionally substituted aryl, optionally substituted
aralkyl, optionally substituted heteroaryl, optionally substituted
heteroarylalkyl, and an optionally substituted, saturated or
partially unsaturated heterocycle; and n is 0-8, m is 0-8, i is 1-8
and j is 0-8.
46. The method according to claim 45, wherein said composition
further comprises at least one pharmaceutically-acceptable
excipient.
47. A method of preventing or treating cancer or a condition that
results from the uncontrolled proliferation of cells, comprising
contacting an animal with (a) a composition comprising a
pharmaceutically-effective amount of an antineoplastic agent, and
(b) a compound of Formula I: ##STR9## or a pharmaceutically
acceptable salt thereof; wherein: X and Y are independently
--C(O)--, --CH.sub.2-- or --C(S)--; R.sup.1, R.sup.3, and R.sup.4
are independently hydrogen, halo, alkyl, alkenyl, alkynyl,
cycloalkyl, optionally substituted aryl, optionally substituted
aralkyl, optionally substituted heteroaryl, optionally substituted
heteroaralkyl, alkoxy, optionally substituted aryloxy, optionally
substituted heteroaryloxy, cyano, amino, alkanoylamino, nitro,
hydroxy, carboxy, or alkoxycarbonyl; or R.sup.3 and R.sup.4 are
taken together to form --(CH.sub.2).sub.u--, where u is 3-6.
--CH.dbd.CH--CH.dbd.CH-- or --CH.sub.2CH.dbd.CHCH.sub.2--; R.sup.2
is hydrogen, halo, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6
alkelyl, C.sub.2-6 alkynyl, acetylamino, C.sub.1-6 alkoxy, phenyl,
halophenyl, hydroxyphenyl C.sub.1-6 alkoxyphenyl, C.sub.1-6
alkylphenyl, aminophenyl, C.sub.1-6 alkylenedioxyphenyl,
hydroxycarbonylphenyl, thienyl, C.sub.1-6 alkylthienyl, furanyl,
pyrrolyl, amino, C.sub.1-6 hydroxyalkyl or cyano; R.sup.5 is
hydrogen, alkyl, cycloalkyl, optionally substituted aryl,
optionally substituted heteroaryl, optionally substituted aralkyl,
optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl,
alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl,
alkylaminocarbonyl or alkylaminocarbonylalkyl; R.sup.6 is
cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heteroarylalkyl, or
a saturated or partially unsaturated heterocycle, each of which is
optionally substituted; R.sup.7 and R.sup.8 are independently
hydrogen or alkyl; R.sup.9 is cycloalkyl, aryl, heteroaryl, a
saturated or partially unsaturated heterocycle, cycloalkyl(alkyl),
aralkyl or heteroarylalkyl, each of which is optionally
substituted; and R.sup.10 is --(CH.sub.2).sub.n--CO.sub.2R.sup.b ,
--(CH.sub.2).sub.m--CO.sub.2M, --(CH.sub.2).sub.i--or
--(CH.sub.2).sub.j--CONR.sup.cR.sup.d where R.sup.b is hydrogen,
alkyl, optionally substituted cycloalkyl, or optionally
substituted, saturated or partially unsaturated heterocycle; M is a
cation; R.sup.c and R.sup.d are independently hydrogen, alkyl,
hydroxyalkyl, carboxyalkyl, aminoalkyl, optionally substituted
cycloalkyl, optionally substituted aryl, optionally substituted
aralkyl, optionally substituted heteroaryl, optionally substituted
heteroarylalkyl, and an optionally substituted, saturated or
partially unsaturated heterocycle; and n is 0-8, m is 0-8, i is 1-8
and j is 0-8.
48. The method of claim 47, wherein said cancer or condition is
selected from the group consisting of breast cancer, ovarian
cancer, cervical carcinoma, endometrial carcinoma, choriocarcinoma,
soft tissue sarcomas, osteosarcomas, rhabdomyosarcomas, leiomyomas,
leiomyosarcomas, head and neck cancers, lung and bronchogenic
carcinomas, brain tumors, neuroblastomas, esophogeal cancer,
colorectal adenocarcinomas, bladder cancer, urothelial cancers,
leukemia, lymphoma, malignant melanomas, oral squamous carcinoma,
hepatoblastoma, glioblastoma, astrocytoma, medulloblastoma, Ewing's
sarcoma, lipoma, liposarcoma, malignant fibroblast histoma,
malignant Schwannoma, testicular cancers, thyroid cancers, Wilms'
tumor, pancreatic cancers, colorectal adenocarcinoma, tongue
carcinoma, gastric carcinoma, and nasopharyngeal cancers.
49. The method of claim 47, wherein said cancer or condition is
selected from the group consisting of breast cancer,
choriocarcinoma, soft tissue sarcomas, osteosarcomas,
rhabdomyosarcomas, lipoma and liposarcoma.
50. A method of treating an inflammatory condition, comprising
administering to a patient in need of such treatment a
pharmaceutically-effective amount of a compound of Formula I:
##STR10## or a pharmaceutically acceptable salt thereof; wherein: X
and Y are independently --C(O)--, --CH.sub.2-- or --C(S)--;
R.sup.1, R.sup.3, and R.sup.4 are independently hydrogen, halo,
alkyl, alkenyl, alkynyl, cycloalkyl, optionally substituted aryl,
optionally substituted aralkyl, optionally substituted heteroaryl,
optionally substituted heteroaralkyl, alkoxy, optionally
substituted aryloxy, optionally substituted heteroaryloxy, cyano,
amino, alkanoylamino, nitro, hydroxy, carboxy, or alkoxycarbonyl;
or R.sup.3 and R.sup.4 are taken together to form
--(CH.sub.2).sub.u--, where u is 3-6, --CH.dbd.CH--CH.dbd.CH-- or
--CH.sub.2CH.dbd.CHCH.sub.2--; R.sup.2 is hydrogen, halo, C.sub.1-4
alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
acetylamino, C.sub.1-6 alkoxy, phenyl, halophenyl, hydroxyphenyl.
C.sub.1-6 alkoxyphenyl, C.sub.1-6 alkylphenyl, aminophenyl,
C.sub.1-6 alkylenedioxyphenyl, hydroxycarbonylphenyl, thienyl,
C.sub.1-6 alkylthienyl, furanyl, pyrrolyl, amino, C.sub.1-6
hydroxyalkyl or cyano; R.sup.5 is hydrogen, alkyl, cycloalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
optionally substituted aralkyl, optionally substituted
heteroaralkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,
aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or
alkylaminocarbonylalkyl; R.sup.6 is cycloalkyl, aryl, heteroaryl,
cycloalkylalkyl, heteroarylalkyl, or a saturated or partially
unsaturated heterocycle, each of which is optionally substituted;
R.sup.7 and R.sup.8 are independently hydrogen or alkyl; R.sup.9 is
cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated
heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of
which is optionally substituted; and R.sup.10 is
--(CH.sub.2).sub.n--CO.sub.2R.sup.b, --(CH.sub.2).sub.m--CO.sub.2M,
--(CH.sub.2).sub.i--OH or --(CH.sub.2).sub.j--CONR.sup.cR.sup.d
where R.sup.b is hydrogen, alkyl, optionally substituted
cycloalkyl, or optionally substituted, saturated or partially
unsaturated heterocycle; M is a cation; R.sup.c and R.sup.d are
independently hydrogen, alkyl, hydroxyalkyl, carboxyalkyl,
aminoalkyl, optionally substituted cycloalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, optionally substituted heteroarylalkyl, and
an optionally substituted, saturated or partially unsaturated
heterocycle; and n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
51. A method of treating an autoimmune disease or condition,
comprising administering to a patient in need of such treatment a
pharmaceutically-effective amount of a compound of Formula I:
##STR11## or a pharmaceutically acceptable salt thereof; wherein: X
and Y are independently --C(O)--, --CH.sub.2-- or --C(S)--;
R.sup.1, R.sup.3, and R.sup.4 are independently hydrogen, halo,
alkyl, alkenyl, alkynyl, cycloalkyl, optionally substituted aryl,
optionally substituted aralkyl, optionally substituted heteroaryl,
optionally substituted heteroaralkyl, alkoxy, optionally
substituted aryloxy, optionally substituted heteroaryloxy, cyano,
amino, alkanoylamino, nitro, hydroxy, carboxy, or alkoxycarbonyl;
or R.sup.3 and R.sup.4 are taken together to form
--(CH.sub.2).sub.u--, where u is 3-6, --CH.dbd.CH--CH.dbd.CH-- or
--CH.sub.2CH.dbd.CHCH.sub.2--; R.sup.2 is hydrogen, halo, C.sub.1-4
alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
acetylamino, C.sub.1-6 alkoxy, phenyl, halophenyl, hydroxyphenyl,
C.sub.1-6 alkoxyphenyl, C.sub.1-6 alkylphenyl, aminophenyl,
C.sub.1-6 alkylenedioxyphenyl, hydroxycarbonylphenyl, thienyl,
C.sub.1-6 alkylthienyl, furanyl, pyrrolyl, amino, C.sub.1-6
hydroxyalkyl or cyano; R.sup.5 is hydrogen, alkyl, cycloalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
optionally substituted aralkyl, optionally substituted
heteroaralkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,
aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or
alkylaminocarbonylalkyl; R.sup.6 is cycloalkyl, aryl, heteroaryl,
cycloalkylalkyl, heteroarylalkyl, or a saturated or partially
unsaturated heterocycle, each of which is optionally substituted;
R.sup.7 and R.sup.8 are independently hydrogen or alkyl; R.sup.9 is
cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated
heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of
which is optionally substituted; and R.sup.10 is
--(CH.sub.2).sub.n--CO.sub.2R.sup.b, --(CH.sub.2).sub.m--CO.sub.2M,
--(CH.sub.2).sub.i--OH or --(CH.sub.2).sub.j--CONR.sup.cR.sup.d
where R.sup.b is hydrogen, alkyl, optionally substituted
cycloalkyl, or optionally substituted, saturated or partially
unsaturated heterocycle; M is a cation: R.sup.c and R.sup.d are
independently hydrogen, alkyl, hydroxyalkyl, carboxyalkyl,
aminoalkyl, optionally substituted cycloalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, optionally substituted heteroarylalkyl, and
an optionally substituted, saturated or partially unsaturated
heterocycle; and n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
52. The method of claim 51, wherein said autoimmune disease or
condition is selected from the group consisting of Hashimoto's
thyroiditis, Grave's disease, multiple sclerosis, pernicious
anemia, Addison's disease, insulin-dependent diabetes mellitus,
rheumatoid arthritis, systemic lupus erythematosus (SLE or lupus),
and dermatomyositis, Crohn's disease, Wegener's granulomatosis,
Anti-Glomerular Basement Membrane Disease, Antiphospholipid
Syndrome, Dermatitis Herpetiformis, Allergic Encephalomyelitis,
Glomerulonephritis, Membranous Glomerulonephritis, Goodpasture
Syndrome, Lambert-Eaton, Myasthenic Syndrome, Myasthenia Gravis,
Bullous Pemphigoid, Polyendocrinopathies, Reiter's Disease and
Stiff-Man Syndrome.
53. The method of claim 51, wherein said autoimmune disease or
condition is rheumatoid arthritis or systemic lupus
erythematosus.
54. The method according to any of claims 43-53, wherein said
effective amount is between about 1.0 and about 100 milligrams per
kilogram per day.
Description
[0001] This application claims priority under 35 U.S.C. .sctn.
119(c) to U.S. Provisional Application No. 60/331,235, filed Nov.
13, 2001, which is fully incorporated by reference herein.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention is in the area of novel
1,4-benzodiazepines and salts thereof, their syntheses, and their
use as inhibitors of MDM2 and HDM2 oncoproteins.
[0004] 2. Related Art
[0005] This invention relates to compounds that bind to the human
protein HDM2 and interfere with its interaction with other
proteins, especially the tumor suppressor protein p53. HDM2 is the
expression of hdm2, an oncogene that is overexpressed in a variety
of cancers, especially soft tissue sarcomas (Momand, J. et al.,
Nucl. Acids Res. 26:345-3459 (1998)).
[0006] p53 is a transcription factor that plays a pivotal role in
the regulation of the balance between cell proliferation and cell
growth arrest/apoptosis. Under normal conditions, the half-life of
p53 is very short, and consequently the level of p.sup.53 in cells
is low. However, in response to cellular DNA damage, cellular
stress, or other factors, levels of p53 increase. This increase in
p53 levels in turn increases the transcription of a number of genes
which induces the cell to either arrest growth or undergo apoptosis
(i.e., controlled cell death). The function of p53 is to prevent
the uncontrolled proliferation of cells and thus protect the
organism from the development of cancer (for a review, see Levine,
A. J., Cell 88:323-331 (1997)).
[0007] p53 is a latent and short-lived transcription factor which
is induced by, and is an integration point for, a range of cellular
stresses including DNA damage, UV damage, spindle damage, hypoxia,
inflammatory cytokines, viral infection, activated oncogenes, and
ribonucleotide depletion. Activation of p53 mediates a change in
the balance of gene expression such that expression of many genes
involved in proliferation is repressed while a range of genes
involved in growth arrest (such as p21WAF1 and GADD45), repair
(such as p53RE) and apoptosis (such as Bax, Killer/DR5 and PIGs) is
activated. The biological outcome of p53 activation (whether
permanent or transient growth arrest or apoptosis) is dependent on
several factors including the type and strength of the inducing
stress, and the type of cell or tissue.
[0008] p53 and MDM2 exist in a negative regulatory feedback loop in
which p53 stimulates transcription of the mdm2 gene while MDM2
binds to p53 and targets it for degradation by the 26S proteosome.
The key element in the p53 induction process is disruption of the
p53-MDM2 complex which permits p53 to accumulate in the nucleus.
This mechanism appears to be common to all of the pathways by which
p53 becomes activated, although recent evidence has indicated that
there is considerable variation in the molecular events by which
this is actually achieved.
[0009] Inactivation of the p53 tumor suppressor is a frequent event
in human neoplasia. The inactivation can occur by mutation of the
p53 gene or through binding to viral or cellular oncogene proteins,
such as the SV40 large T antigen and MDM2. While the mechanism
through which wild-type p53 suppresses tumor cell growth is as yet
poorly defined, it is clear that one key feature of the growth
suppression is the property of p53 to act as a transcription factor
(Farmer, G., et al., Nature 358: 83-86 (1992); Funk. W. D. et al.,
Mol. Cell. Biol. 12: 2866-2871 (1992); Kern, S. E., et al., Science
256:827-830 (1992)). Currently, considerable effort is being made
to identify growth control genes that are regulated by p53 binding
to sequence elements near or within these genes. A number of such
genes have been identified. In cases such as the muscle creatine
kinase gene (Weintraub, H., et al, Proc. Natl. Acad. Sci. USA.,
88:4570-4571 (1991); Zambetti, G. P., et al, Genes Dev. 6:1143-1152
(1992)) and a GLN retroviral element (Zauberman, A., et al., EMBO
J. 12:2799-2808 (1993)), the role these genes might play in the
suppression of growth control is unclear. Yet there are other
examples, namely mdm2 (Barak, Y., et al. EMBO J. 12:461-468 (1993);
Wu, X., et al., Genes Dev. 7:1126-1132(1993)) GADD 45 (Kastan, M.
B., et al. Cell 71:587-597(1992)) and WAF1 or CIP1 (El-Beiry, W.
S., et al., Cell 75:817-825 (1993); Harper, J. W., et al., Cell
75:805-816 (1993)), where their involvement in the regulation of
cell growth is better understood.
[0010] mdm2, a known oncogene, was originally found on mouse double
minute chromosomes (Cahilly-Snyder., L., et al, Somatic Cell Mol.
Genet. 13:235-244 (1987)). Its protein product was subsequently
found to form a complex with p53, which was first observed in a rat
fibroblast cell line (Clone 6) previously transfected with a
temperature sensitive mouse p53 gene (Michalovitz, D., et al., Cell
62:671-680 (1990)). The rat cell line grew well at 37.degree. C.
but exhibited a G1 arrest when shifted down to 32.degree. C., which
was entirely consistent with an observed temperature dependent
switch in p53 conformation and activity. However, the p53-MDM2
complex was only observed in abundance at 32.degree. C., at which
temperature p53 was predominantly in a functional or "wild-type"
form (Barak, Y. et al., EMBO J. 11:2115-2121 (1992) and Momand, J.,
et al., Cell 69:1237-1245 (1992)). By shifting the rat cell line
down to 32.degree. C. and blocking de novo protein synthesis it was
shown that only "wild-type" p53 induced expression of the mdm2
gene, thereby accounting for the differential abundance of the
complex in terms of p53 transcriptional activity (Barak, Y., et al,
EMBO J. 12:4614 (1993)). The explanation was further developed by
the identification of a DNA binding site for wild-type p53 within
the first intron of the mdm2 gene (Wu, X., et al., Genes Dev.
7:1126-1132 (1993)). Reporter constructs employing this p53 DNA
binding site revealed that they were inactivated when wild-type p53
was co-expressed with MDM2.
[0011] This inhibition of the transcriptional activity of p53 may
be caused by MDM2 blocking the activation domain of p53 and/or the
DNA binding site. Consequently, it was proposed that mdm2
expression is autoregulated, via the inhibitory effect of MDM2
protein on the transcriptional activity of wild-type p53. This
p53-mdm2 autoregulatory feedback loop provided a novel insight as
to how cell growth might be regulated by p53. Up to a third of
human sarcomas are considered to overcome p53-regulated growth
control by amplification of the hdm2 gene (the human homologue of
mdm2) (Oliner, J. D., et al., Nature 358:80-83 (1992)). Hence, the
interaction between p53 and HDM2 represents a key potential
therapeutic target. One mechanism by which MDM2 can promote
tumorogenesis is by its inhibitory action on p53. The tumor
suppressor functions of p53 control a pivotal checkpoint in the
control of cell cycling (reviewed in Levine, A. J., Cell 88:323-331
(1997)). p53 is a transcription factor for a number of proteins
that cause cell cycle arrest or cell death by apoptosis. The level
and transcriptional activity of p53 are increased by damage to
cellular DNA. The MDM2 protein inhibits p53 function by binding to
an amphipathic N-terminal helix of p53, abrogating the interaction
of p53 with other proteins and its transactivation activity. The
interaction with MDM2 also targets p53 for ubiquitin dependent
protein degradation. MDM2 exhibits p53 independent effects on cell
cycling as well, possibly by direct interaction with some of the
downstream effectors such as pRB and EF2 (Reviewed in Zhang, R. and
Wang, H., Cur. Pharm. Des. 6:393-416 (2000)).
[0012] Blocking HDM2 from binding p53 would be therapeutically
useful in restoring cell cycle control to cells that overexpress
HDM2 as a front line cancer treatment. More generally, inhibition
of HDM2 may increase the effectiveness of chemotherapy and
radiation in p53 normal cancers by enhancing apoptosis and growth
arrest signaling pathways.
[0013] A need continues to exist for potent, small molecules that
inhibit the interactions between HDM2 and p53.
SUMMARY OF THE INVENTION
[0014] A first aspect of the present invention is directed to novel
compounds of Formula I.
[0015] A second aspect of the present invention is directed to
pharmaceutical compositions comprising at least one compound of
Formula I, or a salt thereof, and one or more pharmaceutically
acceptable excipients.
[0016] A third aspect of the present invention is directed to a
method of inhibiting the binding of a protein encoded by hdm2 to
p53 protein, comprising contacting p53 or one or more proteins
encoded by mdm2, with one or more compounds of Formula I.
[0017] A fourth aspect of the invention is directed to a method of
inducing apoptosis, comprising contacting an animal with a
composition comprising a pharmaceutically effective amount of at
least one compound of Formula I, or a salt thereof, and one or more
pharmaceutically-acceptable excipients.
[0018] A fifth aspect of the present invention is directed to a
method of treating cancer. The method comprises contacting an
animal with (a) a pharmaceutically effective amount of an
antineoplastic agent and (b) a pharmaceutically effective amount of
at least one compound of Formula I, or a salt thereof, and one or
more pharmaceutically-acceptable excipients.
[0019] A sixth aspect of the present invention is directed to a
method of treating cancer, comprising contacting an animal with a
composition comprising (a) a pharmaceutically effective amount of
at least one compound of Formula I, or a salt thereof, (b) one or
more agents that induce or cause DNA damage, and (c) one or more
pharmaceutically-acceptable excipients.
[0020] A seventh aspect of the present invention is directed to a
method of synthesizing compounds of Formula I.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] A novel class of small molecules that bind to HDM2 and/or
MDM2 has now been discovered. By interfering with HDM2-p53 or
MDM2-p53 interactions, these compounds increase the intracellular
concentration of p53. These small molecules, therefore, have
therapeutic utility in sensitizing tumor cells for chemotherapy. In
tumor types particularly sensitive to an increase in functional
p53, compounds of this type will be sufficient to induce apoptosis.
Compounds of the present invention are also useful in treating
tumor types in which HDM2 or MDM2 is overexpressed.
[0022] Compounds of the present invention include compounds of
Formula I: ##STR2## or a solvate, hydrate or pharmaceutically
acceptable salt thereof; wherein:
[0023] X and Y are independently --C(O)--, --CH.sub.2-- or
--C(S)--;
[0024] R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently
hydrogen, halo, alkyl, alkenyl, alkynyl, cycloalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, optionally substituted heteroaralkyl,
alkoxy, optionally substituted aryloxy, optionally substituted
heteroaryloxy, cyano, amino, alkanoylamino, nitro, hydroxy,
carboxy, or alkoxycarbonyl;
[0025] or R.sup.1 and R.sup.2, or R.sup.2 and R.sup.3, or R.sup.3
and R.sup.4 are taken together to form --(CH.sub.2).sub.u--, where
u is 3-6, --CH.dbd.CH--H.dbd.CH-- or
--CH.sub.2CH.dbd.CHCH.sub.2--;
[0026] R.sup.5 is hydrogen, alkyl, cycloalkyl, optionally
substituted aryl, optionally substituted heteroaryl, optionally
substituted aralkyl, optionally substituted heteroaralkyl,
carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl,
aminocarbonylalkyl, alkylaminocarbonyl or
alkylaminocarbonylalkyl;
[0027] R.sup.6 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl,
aralkyl, heteroarylalkyl, or a saturated or partially unsaturated
heterocycle, each of which is optionally substituted;
[0028] R.sup.7 and R.sup.8 are independently hydrogen or alkyl;
[0029] R.sup.9 is cycloalkyl, aryl, heteroaryl, a saturated or
partially unsaturated heterocycle, cycloalkyl(alkyl) aralkyl or
heteroarylalkyl, each of which is optionally substituted; and
[0030] R.sup.10 is --(CH.sub.2).sub.n--CO.sub.2R.sup.b,
--(CH.sub.2).sub.m--CO.sub.2M, --(CH.sub.2).sub.i--OH or
--(CH.sub.2).sub.j--CONR.sup.cR.sup.d where
[0031] R.sup.b is hydrogen, alkyl, optionally substituted
cycloalkyl, or optionally substituted, saturated or partially
unsaturated heterocycle;
[0032] M is a cation;
[0033] R.sup.c and R.sup.d are independently hydrogen, alkyl,
hydroxyalkyl, carboxyalkyl, aminoalkyl, optionally substituted
cycloalkyl, optionally substituted aryl, optionally substituted
aralkyl, optionally substituted heteroaryl, optionally substituted
heteroarylalkyl, and an optionally substituted, saturated or
partially unsaturated heterocycle; and
[0034] n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
[0035] Preferred compounds include compounds of Formula I, or salts
thereof, wherein:
[0036] R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently
hydrogen, halo, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-7 cycloalkyl, optionally substituted C.sub.6-10
aryl, optionally substituted C.sub.6-10 ar(C.sub.1-6)alkyl,
optionally substituted heteroaryl, optionally substituted
heteroar(C.sub.1-6)alkyl, C.sub.1-6 alkoxy, optionally substituted
C.sub.6-10 aryloxy, optionally substituted heteroaryloxy, cyano,
amino, alkanoyl amino, nitro, hydroxy, carboxy, or C.sub.1-6
alkoxycarbonyl;
[0037] or R.sup.1 and R.sup.2, or R.sup.2 and R.sup.3, or R.sup.3
and R.sup.4 are taken together to form --CH.dbd.CH--CH.dbd.CH-- or
--CH.sub.2CH.dbd.CHCH.sub.2--;
[0038] R.sup.5 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl,
optionally substituted C.sub.6-10 aryl, optionally substituted
heteroaryl, optionally substituted C.sub.6-10 ar(C.sub.1-6)alkyl,
optionally substituted heteroar(C.sub.1-6)alkyl,
carboxy(C.sub.1-6)alkyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6
alkoxycarbonyl(C.sub.1-6)alkyl, aminocarbonyl,
aminocarbonyl(C.sub.1-6)alkyl, or C.sub.1-6
alkylaminocarbonyl(C.sub.1-6)alkyl;
[0039] R.sup.6 is C.sub.3-7 cycloalkyl, C.sub.6-10 aryl,
heteroaryl, a saturated or partially unsaturated heterocycle,
C.sub.3-7 cycloalkyl(C.sub.1-4)alkyl, C.sub.6-10 ar(C.sub.1-6)alkyl
or heteroaryl(C.sub.1-6)alkyl, each of which is optionally ring
substituted by one or more substituents independently selected from
the group consisting of C.sub.1-4 alkyl, C.sub.2-4 alkenyl,
C.sub.2-4 alkynyl, C.sub.6-10 aryl, phenoxy, benzyloxy, 5-10
membered heteroaryl, hydroxy, C.sub.1-4 alkoxy, C.sub.1-4
alkylenedioxy, halo, C.sub.1-4 haloalkyl, C.sub.1-4 alkylthio,
thio, amino, mono(C.sub.1-4)alkylamino, di(C.sub.1-4)alkylamino,
and nitro;
[0040] R.sup.7 is hydrogen or C.sub.1-6 alkyl;
[0041] R.sup.8 is hydrogen or C.sub.1-6 alkyl,
[0042] R.sup.9 is C.sub.3-7 cycloalkyl, a saturated or partially
unsaturated heterocycle, C.sub.6-10 aryl, heteroaryl, C.sub.3-7
cycloalkyl(C.sub.1-6)alkyl, C.sub.6-10ar(C.sub.1-6)alkyl or
heteroaryl(C.sub.1-6)alkyl, each of which is optionally substituted
by one or more substituents independently selected from the group
consisting of C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4
alkynyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, hydroxy,
C.sub.1-4 alkoxy, C.sub.1-4 alkylenedioxy, carboxy, halo, C.sub.1-4
haloalkyl, trifluoromethoxy, C.sub.1-4 alkylthio, thio, amino,
mono(C.sub.1-4)alkylamino, di(C.sub.1-4)alkylamino, and nitro;
and
[0043] R.sup.10 is --(CH.sub.2).sub.n--CO.sub.2R.sup.b,
--(CH.sub.2).sub.m--CO.sub.2M, --(CH.sub.2).sub.i--OH or
--(CH.sub.2).sub.j--CONR.sup.cR.sup.d, where [0044] R.sup.b is
hydrogen, C.sub.1-6 alkyl, optionally substituted C.sub.3-7
cycloalkyl, or an optionally substituted, saturated or partially
unsaturated heterocycle; [0045] M is a cation; [0046] R.sup.c and
R.sup.d are independently hydrogen, C.sub.1-6 alkyl, C.sub.1-6
hydroxyalkyl, C.sub.1-6 carboxyalkyl, aminoalkyl, optionally
substituted C.sub.3-7 cycloalkyl, optionally substituted C.sub.6-10
aryl, optionally substituted C.sub.6-10 ar(C.sub.1-6)alkyl,
optionally substituted heteroaryl, optionally substituted
heteroaryl(C.sub.1-6)alkyl, or an optionally substituted, saturated
or partially unsaturated heterocycle; and
[0047] n is 0-4, m is 0-4, i is 1-4 and j is 0-4.
[0048] In one preferred embodiment
[0049] R.sup.1 and R.sup.4 are both hydrogen;
[0050] R.sup.2 is hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-4
hydroxyalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7
cycloalkyl, acetyl amino, cyano, amino, C.sub.1-6 alkoxy, phenyl,
thienyl, furanyl, and pyrrolyl, wherein said phenyl, thienyl and
furanyl are optionally substituted by one or more substituents
independently selected from the group consisting of halo, C.sub.1-4
alkoxy, C.sub.1-4 alkyl, amino, methylenedioxy, and
ethylenedioxy,
[0051] R.sup.3 is hydrogen, C.sub.1-6 alkyl, phenyl, or halo; or
R.sup.2 and R.sup.3 are taken together to form
--CH.dbd.CH--CH.dbd.CH--;
[0052] R.sup.5 is hydrogen; C.sub.1-6 alkyl; C.sub.1-6
hydroxyalkyl; carboxy(C.sub.1-6)alkyl; C.sub.1-6
alkylcarbamoyl(C.sub.1-6)alkyl; C.sub.1-6
alkoxycarbonylamino(C.sub.1-6)alkyl; C.sub.3-7
cycloalkyl(C.sub.1-6)alkyl; C.sub.6-10 aryl, optionally substituted
by C.sub.1-4 alkyl or halo; C.sub.6-10 ar(C.sub.1-4)alkyl
optionally substituted by C.sub.1-4 alkyl or halo; and
pyridyl(C.sub.1-4)alkyl;
[0053] R.sup.6 is C.sub.6-10 aryl, thienyl, benzothienyl, furanyl,
benzofuranyl, indolyl, pyridyl, quinolinyl, C.sub.3-7 cycloalkenyl
or cubanyl, each of which is optionally substituted by one or more
substituents independently selected from the group consisting of
halo, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.1-4 alkoxy,
halo(C.sub.1-4)alkoxy, trifluoromethyl, trifluoromethoxy, C.sub.1-4
alkylsulfanyl, trifluoromethylsulfanyl, cyano, thienyl, phenyl,
halophenyl, trifluoromethylphenyl, phenoxy, benzyloxy and
pyrrolidinyl;
[0054] R.sup.7 is hydrogen or C.sub.1-6 alkyl;
[0055] R.sup.8 is hydrogen or C.sub.1-6 alkyl;
[0056] R.sup.9 is C.sub.3-7 cycloalkyl, C.sub.6-10 aryl,
heteroaryl, C.sub.3-7 cycloalkyl(C.sub.1-6)alkyl, C.sub.6-10
ar(C.sub.1-6)alkyl or heteroaryl(C.sub.1-6)alkyl, each of which is
optionally substituted on the ring portion; and
[0057] R.sup.10 is --CH.sub.2).sub.n--CO.sub.2R.sup.b or
--(CH.sub.2).sub.m--CO.sub.2M, where R.sup.b is hydrogen, C.sub.1-6
alkyl, optionally substituted C.sub.3-7 cycloalkyl, or optionally
substituted heterocycloalkyl, M is a cation n and m are
independently 0, 1, 2, 3 or 4; or
[0058] R.sup.10 is-(CH.sub.2).sub.i--OH or
--(CH.sub.2).sub.j--CONR.sup.cR.sup.d, where
[0059] R.sup.c and R.sup.d are independently hydrogen, hydroxy,
C.sub.3-7 cycloalkyl, [0060] C.sub.1-6 alkyl, C.sub.1-6
hydroxyalkyl, C.sub.1-6 carboxyalkyl, C.sub.1-6 aminoalkyl,
optionally substituted, phenyl,-or optionally substituted benzyl;
and [0061] i is 1, 2, 3, or 4, and j is 0, 1, 2, 3 or 4.
[0062] Preferred compounds include those wherein R.sup.1 is
hydrogen.
[0063] Preferred compounds include those wherein R.sup.4 is
hydrogen.
[0064] Useful values of R.sup.2 include hydrogen, halo, C.sub.1-4
alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
acetylamino, C.sub.1-6 alkoxy, phenyl, halophenyl, hydroxyphenyl,
C.sub.1-6 alkoxyphenyl, C.sub.1-6 alkylphenyl, aminophenyl,
C.sub.1-6 alkylenedioxyphenyl, hydroxycarbonylphenyl, thienyl,
C.sub.1-6 alkylthienyl, furanyl, pyrrolyl, amino, C.sub.1-6
hydroxyalkyl and cyano.
[0065] Useful values of R.sup.2 also include hydrogen, iodo,
fluoro, chloro, bromo, methyl, ethyl, propyl, isopropyl, t-butyl,
sec-butyl, cyclopropyl, ethynyl, acetylamino, methoxy, phenyl,
3-chlorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 3-methoxyphenyl,
4-methylphenyl, 3-methylphenyl, 3-isopropylphenyl, 3-aminophenyl,
3,4-methylenedioxyphenyl, 4-hydroxycarbonylphenyl, thien-3-yl,
4-methylthien-2-yl, furan-2-yl, 1H-pyrrol-3-yl, amino,
2-hydroxyethyl, hydroxymethyl, furan-3-yl, vinyl and cyano.
[0066] Preferred compounds include those wherein R.sup.2 is halo or
phenyl. More preferred compounds include those wherein R.sup.2 is
iodo.
[0067] Useful values of R.sup.3 include hydrogen, phenyl, fluoro,
chloro, iodo and methyl. Preferred compounds are those wherein
R.sup.3 is hydrogen.
[0068] Useful values of R.sup.5 include hydrogen, C.sub.1-6 alkyl,
C.sub.1-6 hydroxyalkyl, carboxy(C.sub.1-6)alkyl, C.sub.1-6
alkylphenyl, C.sub.1-6 alkylbenzyl, phenethyl,
phenyl(C.sub.1-6)alkyl, naphthyl(C.sub.1-6)alkyl, C.sub.3-7
cycloalkyl(C.sub.1-6)alkyl, pyridyl(C.sub.1-6)alkyl, C.sub.1-6
alkoxycarbonylamino(C.sub.1-6)alkyl, and C.sub.1-6
alkylcarbamoyl(C.sub.1-6)alkyl.
[0069] Useful values of R.sup.5 also include hydrogen, methyl,
carboxymethyl, 3-methylbutyl, 2-methylpropyl, isopropyl,
2-methylphenyl, 3-methylphenyl, 4-methylphenyl, phenyl, benzyl,
phenethyl, 3-phenylpropyl, naphthalen-2-ylmethyl, cyclohexylmethyl,
cyclopentylmethyl, cyclobutylmethyl, pyrid-2-ylmethyl,
pyrid-3-ylmethyl, pyridylmethyl, 2-methylbenzyl, 3-methylbenzyl,
4-methylbenzyl, 2-carboxyethyl, 2-t-butoxycarbonylaminoethyl,
2-pyrid-2-ylethyl, methylcarbamoylmethyl and
2,3-dihydroxypropyl.
[0070] Preferred compounds include those wherein R.sup.5 is
hydrogen.
[0071] Useful values of R.sup.6 include optionally substituted
C.sub.6-10 aryl.
[0072] Useful values of R.sup.6 also include trifluoromethylphenyl,
halophenyl, C.sub.1-6 alkylphenyl, C.sub.1-6 alkoxyphenyl,
halo(C.sub.1-4)alkoxyphenyl, naphthyl, benzyloxyphenyl,
phenoxyphenyl, dihydrobenzodioxinyl, trifluoromethylhalophenyl,
pyridyl, thienyl, C.sub.1-6 alkylthienyl, halothienyl, bithienyl,
C.sub.1-6 alkylbenzothienyl, (halophenyl)furanyl, quinolinyl,
biphenyl, indolyl, (trifluoromethylsulfanyl)phenyl,
(trifluoromethylphenyl)furanyl, halo(C.sub.1-4)alkoxyphenyl,
benzofuranyl, cyanophenyl, halopyridyl, (methylsulfanyl)phenyl,
pyrrolidinylphenyl, C.sub.2-6 alkenyl(C.sub.3-7)cycloalkenyl,
cubanyl and halocubanyl.
[0073] Useful values of R.sup.6 also include
2-trifluoromethylphenyl, 3-trifluoromethylphenyl,
4-trifluoromethylphenyl, 2-chlorophenyl, 3chlorophenyl,
4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl,
4-iodophenyl, 4-methylphenyl, 4-ethylphenyl,
4-trifluoromethoxyphenyl, 4-isopropylphenyl, phenyl,
4-methoxy-phenyl, naphthalen-2-yl, 4-tert-butylphenyl,
4-benzyloxyphenyl, 4-phenoxyphenyl, 3,4-dichlorophenyl,
3,4-dimethoxyphenyl, 2,3-dihydrobenzo[1,4]dioxin-6-yl,
4-bromo-2-fluorophenyl, 2-fluoro-4-trifluoromethylphenyl,
3-fluoro-4-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl,
4-chloro-3-fluorophenyl, pyrid-2-yl, pyrid-3-yl, pyridyl,
thien-3-yl, 5-methylthien-2-yl, 3-methylthien-2-yl,
4-bromothien-2-yl, 5-[2,2']bithienyl,
3-methylbenzo[b]thiophen-2-yl, 5-(2-chlorophenyl)-furan-2-yl,
5-(3-chlorophenyl)-furan-2-yl, quinolin-3-yl, biphen-4-yl,
indol-2-yl, indol-3-yl, 4-trifluoromethylsulfanylphenyl,
5-(3-trifluoromethylphenyl)furan-2-yl,
4-(1,1,2,2-tetrafluoroethoxy)phenyl, 4-difluoromethoxyphenyl,
benzofuran-2-yl, 4-cyanophenyl, 6-chloropyrid-3-yl,
4-methylsulfanylphenyl, 4-pyrrolidin-1-ylphenyl,
5-chlorothien-2-yl, 4-isopropenylcyclohex-1-enyl and
1-chlorocuban-4-yl.
[0074] Preferred compounds include those wherein R.sup.6 is
4-chlorophenyl, 4-bromophenyl, 4-trifluoromethylphenyl or
4-trifluoromethoxyphenyl. More preferred compounds include those
wherein R.sup.6 is 4-chlorophenyl.
[0075] Useful values of R.sup.7 include hydrogen and methyl.
Preferred compounds include those wherein R.sup.7 is hydrogen.
[0076] Useful values of R.sup.8 include hydrogen and methyl.
Preferred compounds include those wherein R.sup.8 is hydrogen.
[0077] Useful values of R.sup.9 include optionally substituted
C.sub.6-10 aryl and optionally substituted C.sub.6-10
ar(C.sub.1-6)alkyl.
[0078] Useful values of R.sup.9 also include phenyl,
4-chlorophenyl, 4-chlorobenzyl, benzyl, cyclohexyl,
cyclohexylmethyl, 4-hydroxyphenyl, pyridylmethyl, 4-fluorophenyl,
4-trifluoromethylphenyl, 4-iodobenzyl, 4-bromobenzyl, thien-2-yl,
thien-2-ylmethyl, naphth-2-ylmethyl, pyrid-2-ylethyl,
3-methylphenyl, 4-methylphenyl, 4-ethylphenyl,
4-chloro-3-fluorophenyl, 2-fluoro-4-trifluoromethylphenyl,
4-hydroxycarbonylphenyl, naphthalen-2-yl, naphthalen-1-yl,
4-iodophenyl, 4-bromophenyl, 3,4-dichlorophenyl, 2-chlorophenyl,
4-tert-butylphenyl, 4-isopropylphenyl, 3-chlorophenyl,
4-trifluoromethoxyphenyl, and 3-hydroxyphenyl, 4-hydroxybenzyl,
4-trifluoromethylbenzyl, naphth-1-ylmethyl, 6-chloropyrid-3-yl and
6-methylpyrid-3-yl.
[0079] Preferred compounds include those wherein R.sup.9 is
halophenyl or halobenzyl. More preferred compounds include those
wherein R.sup.9 is phenyl or 4-chlorophenyl.
[0080] Useful values of R.sup.10 include --COOR.sup.b and
--CH.sub.2--COOR.sup.b, where R.sup.b is hydrogen or C.sub.1-6
alkyl; and --COOM and --CH.sub.2COOM, where M is Na.sup.+ or
K.sup.+.
[0081] Preferred compounds include those wherein R.sup.10 is
--COOR.sup.b or --CH.sub.2--COOR.sup.b, where R.sup.b is hydrogen,
methyl, ethyl, propyl or tert-butyl.
[0082] Preferred compounds also include those wherein R.sup.10 is
--COOH or --COOM, where M is Na.sup.10 or K.sup.+.
[0083] Useful values of R.sup.10 also include --CH.sub.2OH and
--CH.sub.2CH.sub.2OH; and --CH.sub.2--CONR.sup.cR.sup.d and
--CONR.sup.cR.sup.d, where R.sup.c and R.sup.d are independently
hydrogen, methyl, ethyl, propyl, t-butyl, hydroxymethyl,
hydroxyethyl, hydroxypropyl, aminomethyl, aminoethyl, aminopropyl,
carboxymethyl, carboxyethyl, carboxypropyl, cyclopentyl,
cyclohexyl, phenyl or benzyl.
[0084] Preferred compounds include those wherein R.sup.10 is
--CH.sub.2--CONR.sup.cR.sup.d or --CONR.sup.cR.sup.d, where R.sup.c
and R.sup.d are independently hydrogen, methyl, hydroxyethyl,
3-carboxypropyl, 1-carboxy-2-methylpropyl, hydroxy, 4-carboxybutyl,
5-carboxypentyl, 2-(methoxycarbonyl)ethyl or
2-(hydroxyguanidino)ethyl.
[0085] In each of the above embodiments, X and Y are independently
--C(O)--, --CH.sub.2-- or --C(S)--, more preferably --C(O)-- or
--C(S)--, most preferably --C(O)--.
[0086] A second aspect of the present invention is directed to
pharmaceutical compositions comprising
[0087] a) at least one compound of Formula I or a pharmaceutically
acceptable salt thereof; and
[0088] b) one or more pharmaceutically-acceptable excipients.
[0089] Preferably, the pharmaceutical composition is sterile.
[0090] A third aspect of the present invention is directed to a
method of inhibiting the binding of a protein encoded by mdm2 to
p53 protein, comprising contacting p53 or one or more proteins
encoded by mdm2 with one or more compounds of Formula I, wherein
R.sup.1--R.sup.10 are defined as above.
[0091] A fourth aspect of the invention is directed to a method of
inducing apoptosis, comprising contacting an animal with a
composition comprising a pharmaceutically effective amount of at
least one compound of Formula I, or a salt thereof, wherein
R.sup.1--R.sup.10 are defined as above, and optionally one or more
pharmaceutically-acceptable excipients.
[0092] A fifth aspect of the present invention is directed to a
method of treating cancer, comprising contacting an animal with (a)
a pharmaceutically effective amount of an antineoplastic agent, and
(b) a pharmaceutically effective amount of at least one compound of
Formula I, or a salt thereof, wherein R.sup.1-R.sup.10, are defined
as above, and optionally one or more pharmaceutically-acceptable
excipients, in combination with (a), (b), or (a) and (b).
[0093] A sixth aspect of the present invention is directed to a
method of treating cancer, comprising contacting an animal with a
composition comprising (a) a pharmaceutically effective amount of
at least one compound of Formula I, or a salt thereof, (b) one or
more agents that induce or cause DNA damage, and optionally (c) one
or more pharmaceutically-acceptable excipients.
[0094] A seventh aspect of the present invention is directed to a
method of making compounds of Formula I.
[0095] Compounds within the scope of the invention are described in
the Examples. Examples of preferred compounds include:
[0096]
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-te-
trahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid;
[0097]
2-[7-bromo-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[-
e][1,4]diazepin-4-yl]-3-(4-chloro-phenyl)-propionic acid;
[0098]
2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,-
5-tetrahydro-benzo[e][1,4-diazepin-4-yl]-acetamide;
[0099]
[7-chloro-3-(4-chloro-phenyl)-2-dioxo-1,2,3,5-tetrahydro-benzo[e][-
1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid;
[0100]
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-ethynyl-2,5-dioxo-1,2,3,5-
-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid;
[0101]
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][-
1,4]diazepin-4-yl]-p-tolyl-acetic acid;
[0102]
(4-chloro-3-fluorophenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,-
2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid;
[0103]
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-ethyl-2,5-dioxo-1,2,3,5-t-
etrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid;
[0104]
(4-chloro-phenyl)-[3-(4-chlorophenyl)-7-isopropyl-2,5-dioxo-1,2,3,-
5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid;
[0105]
(4-bromo-phenyl)-[3-(4-chloro-phenyl)-7-isopropyl-2,5-dioxo-1,2,3,-
5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid;
[0106]
[3-(4-chloro-3-fluoro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro--
benzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid;
[0107]
[3-(4-chlorophenyl)-7-phenyl-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e]-
[1,4]diazepin-4-yl]-phenylacetic acid;
[0108]
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][-
1,4]diazepin-4-yl]-(4-fluoro-phenyl)-acetic acid;
[0109]
[3-(4-chloro-phenyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1-
,4]diazepin-4-yl]-(4-trifluoromethyl-phenyl)-acetic acid;
[0110]
(4-chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)--
1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]-acetic acid;
[0111]
(4-chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethyl-phenyl)-1-
,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]-acetic acid;
[0112]
[3-(4-bromo-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1-
,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid;
[0113]
[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][-
1,4]diazepin-4-yl]-(4-isopropyl-phenyl)-acetic acid;
[0114]
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-cyano-2,5-dioxo-1,2,3,5-t-
etrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid;
[0115]
3-(4-chloro-phenyl)-4-(3-hydroxy-1-phenyl-propyl)-7-iodo-3,4-dihyd-
ro-1H-benzo[e][1,4]diazepine-2,5-dione;
[0116]
2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,-
5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-N-hydroxy-acetamide;
[0117]
[7-bromo-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e]-
[1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid;
[0118]
[8-chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro--
benzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid;
[0119]
5-{2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2-
,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetylamino}-pentanoic
acid;
[0120]
3-{2-(4-chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2-
,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetylamino)-propionic
acid;
[0121]
5-[4-[carboxy-(4-chloro-phenyl)-methyl]-3-(4-chloro-phenyl)-7-iodo-
-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-yl]-pentanoic
acid;
and pharmaceutically acceptable salts thereof.
[0122] Additional examples of preferred compounds include:
[0123]
(4-chlorophenyl)-[3-(4-chlorophenyl)-7-iodo-5-oxo-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]acetic acid,
[0124]
3-(4-chloro-phenyl)-3-[3-(4-chloro-phenyl)-7-iodo-5-oxo-1,2,3,5-te-
trahydro-benzo[e][1,4]diazepin-4-yl]-propionic acid;
[0125]
(4-chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-5-oxo-2-thioxo-1,2,3-
,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid,
[0126]
3-(4-chloro-phenyl)-4-[1-(4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo-
-1,3,4,5-tetrahydro-benzo[e][1,4]diazepin-2-one;
[0127]
3-(4-chloro-phenyl)-4-[1-(4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo-
-1,2,3,4-tetrahydro-benzo[e][1,4]diazepin-5-one;
[0128] and pharmaceutically-acceptable salts thereof.
[0129] The invention disclosed herein is also meant to encompass
the in vivo metabolic products of the disclosed compounds. Such
products may result for example from the oxidation, reduction,
hydrolysis, amidation, esterification and the like of the
administered compound, primarily due to enzymatic processes.
Accordingly, the invention includes compounds produced by a process
comprising contacting a compound of this invention with a mammal
for a period of time sufficient to yield a metabolic product
thereof. Such products typically are identified by preparing a
radiolabeled compound of the invention, administering it
parenterally in a detectable dose to an animal such as rat, mouse,
guinea pig, monkey, or to man, allowing sufficient time for
metabolism to occur and isolating its conversion products from the
urine, blood or other biological samples.
[0130] Some of the compounds disclosed herein may contain one or
more asymmetric centers and thus give rise to enantiomers,
diastereomers, and other stereoisomeric forms. The present
invention is also meant to encompass all such possible forms as
well as their racemic and resolved forms and mixtures thereof. When
the compounds described herein contain olefinic double bonds or
other centers of geometric asymmetry, and unless specified
otherwise, it is intended to include both E and Z geometric
isomers. All tautomers are intended to be encompassed by the
present invention as well.
[0131] As used herein, the term "stereoisomers" is a general term
for all isomers of individual molecules that differ only in the
orientation of their atoms in space. It includes enantiomers and
isomers of compounds with more than one chiral center that are not
mirror images of one another (diastereomers).
[0132] The term "chiral center" refers to a carbon atom to which
four different groups are attached, or a sulfur atom to which three
different groups are attached, where the sulfur atom and its
attached groups form a sulfoxide, sulfinic ester, sulfonium salt or
sulfite.
[0133] The term "enantiomer" or "enantiomeric" refers to a molecule
that is nonsuperimposable on its mirror image and hence optically
active wherein the enantiomer rotates the plane of polarized light
in one direction and its mirror image rotates the plane of
polarized light in the opposite direction.
[0134] The term "racemic" refers to a mixture of equal parts of
enantiomers and which is optically inactive.
[0135] The term "resolution" refers to the separation or
concentration or depletion of one of the two enantiomeric forms of
a molecule. The phrase "enantomeric excess" refers to a mixture
wherein one enantiomer is present is a greater concentration than
its mirror image molecule.
[0136] The compounds of Formula I may also be solvated, especially
hydrated. Hydration may occur during manufacturing of the compounds
or compositions comprising the compounds, or the hydration may
occur over time due to the hygroscopic nature of the compounds.
[0137] Certain compounds within the scope of Formula I are
derivatives referred to as "prodrugs." The expression "prodrug"
denotes a derivative of a known direct acting drug, which
derivative has enhanced delivery characteristics and therapeutic
value as compared to the drug, and is transformed into the active
drug by an enzymatic or chemical process. Prodrugs are derivatives
of the compounds of the invention which have metabolically
cleavable groups and become by solvolysis or under physiological
conditions the compounds of the invention which are
pharmaceutically active in vivo. For example, ester derivatives of
compounds of this invention are often active in vivo, but not in
vitro. Other derivatives of the compounds of this invention have
activity in both their acid and acid derivative forms, but the acid
derivative form often offers advantages of solubility, tissue
compatibility, or delayed release in the mammalian organism (see,
Bundgard, H, Design of Prodrugs, pp. 7-9, 21-24, Elsevier,
Amsterdam 1985). Prodrugs include acid derivatives well known to
practitioners of the art, such as, for example, esters prepared by
reaction of the parent acid with a suitable alcohol, or amides
prepared by reaction of the parent acid compound with an amine.
Simple aliphatic or aromatic esters derived from acidic groups
pendent on the compounds of this invention are preferred prodrugs.
In some cases it is desirable to prepare double ester type prodrugs
such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl
esters. Useful prodrugs are those where R.sup.b is alkyl, alkenyl,
alkynyl, or arylalkyl.
[0138] When any variable occurs more than one time in any
constituent or in Formula I, its definition on each occurrence is
independent of its definition at every other occurrence. Also,
combinations of substituents and/or variables are permissible only
if such combinations result in stable compounds.
DEFINITIONS
[0139] The term "alkyl" as employed herein by itself or as part of
another group refers to both straight and branched chain radicals
of up to 10 carbons, unless the chain length is otherwise limited,
such as methyl, ethyl, propyl, isopropyl, butyl, i-butyl, isobutyl,
pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl,
2,2,4-trimethylpentyl, nonyl, or decyl.
[0140] The term "alkenyl" is used herein to mean a straight or
branched chain radical of 2-10 carbon atoms, unless the chain
length is otherwise limited, wherein there is at least one double
bond between two of the carbon atoms in the chain, including, but
not limited to, ethenyl, 1-propenyl, 2-propenyl,
2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like.
Preferably, the alkenyl chain is 2 to 8 carbon atoms in length,
most preferably from 2 to 4 carbon atoms in length.
[0141] The term "alkynyl" is used herein to mean a straight or
branched chain radical of 2-10 carbon atoms, unless the chain
length is otherwise limited, wherein there is at least one triple
bond between two of the carbon atoms in the chain, including, but
not limited to, ethynyl, 1-propynyl, 2-propynyl, and the like.
Preferably, the alkynyl chain is 2 to 8 carbon atoms in length,
most preferably from 2 to 4 carbon atoms in length.
[0142] In all instances herein where there is an alkenyl or alkynyl
moiety as a substituent group, the unsaturated linkage, i.e., the
vinyl or ethenyl linkage, is preferably not directly attached to a
nitrogen, oxygen or sulfur moiety.
[0143] The term "alkoxy" or "alkyloxy" refers to any of the above
alkyl groups linked to an oxygen atom. Typical examples are
methoxy, ethoxy, isopropyloxy, sec-butyloxy, and t-butyloxy.
[0144] The term "aryl" as employed herein by itself or as part of
another group refers to monocyclic or bicyclic aromatic groups
containing from 6 to 12 carbons in the ring portion, preferably
6-10 carbons in the ring portion. Typical examples include phenyl,
biphenyl, naphthyl or tetrahydronaphthyl.
[0145] The term "aralkyl" or "arylalkyl" as employed herein by
itself or as part of another group refers to C.sub.1-6 alkyl groups
as discussed above having an aryl substituent, such as benzyl,
phenylethyl or 2-naphthylmethyl.
[0146] The term "heteroaryl" as employed herein refers to groups
having 5 to 14 ring atoms; 6, 10 or 14 pi electrons shared in a
cyclic array, and containing carbon atoms and 1, 2, 3, or 4 oxygen,
nitrogen or sulfur heteroatoms (where examples of heteroaryl groups
are: thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl,
furyl, pyranyl, isobenzofuranyl, benzoxazolyl, chromenyl,
xanthenyl, phenoxathiinyl, 2H-pyrrolyl, pyrrolyl, imidazolyl,
pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl,
indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl,
4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl,
naphthyridinyl, quinazolinyl, cinnolinyl, pteridinyl,
4.alpha.H-carbazolyl, carbazolyl, .beta.-carbolinyl,
phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl,
phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl,
phenoxazinyl, and tetrazolyl groups).
[0147] The phrase "saturated or partially unsaturated heterocycle"
as employed herein, by itself or as part of another group, refers
to a saturated or partially unsaturated ring system having 5 to 14
ring atoms selected from carbon atoms and 1, 2, 3, or 4 oxygen,
nitrogen, or sulfur heteroatoms. Typical saturated examples include
pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl,
tetrahydropyranyl, piperidyl, piperazinyl, quinuclidinyl,
morpholinyl, and dioxacyclohexyl. Typical partially unsaturated
examples include pyrrolinyl, imidazolinyl, pyrazolinyl,
dihydropyridinyl, tetrahydropyridinyl, and dihydropyranyl. Either
of these systems can be optionally fused to a benzene ring.
[0148] The terms "heteroarylalkyl" or "heteroaralkyl" as employed
herein both refer to a heteroaryl group attached to an alkyl group.
Typical examples include 2-(3-pyridyl)ethyl, 3-(2-furyl)-n-propyl,
3-(3-thienyl)-n-propyl, and 4-(1-isoquinolinyl)-n-butyl.
[0149] The term "cycloalkyl" as employed herein by itself or as
part of another group refers to cycloalkyl groups containing 3 to 9
carbon atoms. Typical examples are cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and
cyclononyl.
[0150] The term "cycloalkylalkyl" or "cycloalkyl(alkyl)" as
employed herein, by itself or as part of another group, refers to a
cycloalkyl group attached to an alkyl group. Typical examples are
2-cyclopentylethyl, cyclohexylmethyl, cyclopentylmethyl,
3-cyclohexyl-n-propyl, and 5-cyclobutyl-n-pentyl.
[0151] The term "cycloalkenyl" as employed herein, by itself or as
part of another group, refers to cycloalkenyl groups containing 3
to 9 carbon atoms and 1 to 3 carbon-carbon double bonds. Typical
examples include cyclopropenyl, cyclobutenyl, cyclopentenyl,
cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl,
cyclooctenyl, cyclooctadienyl, cyclooctatrienyl, cyclononenyl, and
cyclononadienyl.
[0152] The term "halogen" or "halo" as employed herein by itself or
as part of another group refers to chlorine, bromine, fluorine or
iodine.
[0153] The term "monoalkylamine" or "monoalkylamino" as employed
herein by itself or as part of another group refers to the group
NH.sub.2 wherein one hydrogen has been replaced by an alkyl group,
as defined above.
[0154] The term "dialkylamine" or "dialkylamino" as employed herein
by itself or as part of another group refers to the group NH.sub.2
wherein both hydrogens have been replaced by alkyl groups, as
defined above.
[0155] The term "hydroxyalkyl" as employed herein refers to any of
the above alkyl groups wherein one or more hydrogens thereof are
substituted by one or more hydroxyl moieties.
[0156] The term "haloalkyl" as employed herein refers to any of the
above alkyl groups wherein one or more hydrogens thereof are
substituted by one or more halo moieties. Typical examples include
fluoromethyl, difluoromethyl, trifluoromethyl, trichloroethyl,
trifluoroethyl, fluoropropyl, and bromobutyl.
[0157] The term "carboxyalkyl" as employed herein refers to any of
the above alkyl groups wherein one or more hydrogens thereof are
substituted by one or more carboxylic acid moieties.
[0158] The term "heteroatom" is used herein to mean an oxygen atom
("O"), a sulfur atom ("S") or a nitrogen atom ("N"). It will be
recognized that when the heteroatom is nitrogen, it may form an
NR.sup.aR.sup.b moiety, wherein R.sup.a and R.sup.b are,
independently from one another, hydrogen or C.sub.1 to C.sub.8
alkyl, or together with the nitrogen to which they are bound form a
saturated or unsaturated 5-, 6-, or 7-membered ring.
[0159] The phrase "optionally substituted" when not explicitly
defined refers to a group or groups being optionally substituted
with one or more substituents independently selected from the group
consisting of hydroxy, nitro, trifluoromethyl, halogen, C.sub.1-6
alkyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkoxy, C.sub.1-6
alkylenedioxy, C.sub.1-6 aminoalkyl, C.sub.1-6 hydroxyalkyl,
C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.6-10 aryl, phenoxy,
benzyloxy, 5-10 membered heteroaryl; C.sub.1-6 aminoalkoxy, amino,
mono(C.sub.1-4)alkylamino, di(C.sub.1-4)alkylamino, C.sub.2-6
alkylcarbonylamino, C.sub.2-6 alkoxycarbonylamino, C.sub.2-6
alkoxycarbonyl, C.sub.2-6 alkoxycarbonylalkyl, carboxy, C.sub.2-6
hydroxyalkoxy, (C.sub.1-6)alkoxy(C.sub.2-6)alkoxy,
mono(C.sub.1-4)alkylamino(C.sub.2-6)alkoxy,
di(C.sub.1-4)alkylamino(C.sub.2-6)alkoxy C.sub.2-10
mono(carboxyalkyl)amino, bis(C.sub.2-10 carboxyalkyl)amino,
C.sub.2-6 carboxyalkoxy, C.sub.2-6 carboxyalkyl, carboxyalkylamino,
guanidinoalkyl, hydroxyguanidinoalkyl, cyano, trifluoromethoxy, or
perfluoroethoxy.
[0160] Preferred optional substituents include one or more
substituents independently selected from the group consisting of
nitro, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, halo,
C.sub.1-4 haloalkyl, C.sub.1-4 alkylthio, thio, amino,
mono(C.sub.1-4)alkylamino, and di(C.sub.1-4)alkylamino.
[0161] "mdm2" is used herein to mean the murine double minute 2
gene, and homologous genes found in other animals.
[0162] "MDM2" is used herein to mean a protein obtained as a result
of expression of the mdm2 oncogene. Within the meaning of this
term, it will be understood that MDM2 encompasses all proteins
encoded by mdm2, mutants thereof, alternative splice proteins
thereof, and phosphorylated proteins thereof. Additionally, as used
herein, it will be understood that the term "MDM2" includes MDM2
homologues of other animals (e.g., HDM2).
[0163] "hdm2" is used herein to mean the human gene which is
homologous to the mouse mdm2.
[0164] "HDM2" is used herein to mean a protein obtained as a result
of expression of the hdm2 oncogene. Within the meaning of this
term, it will be understood that HDM2 encompasses all proteins
encoded by the hdm2, mutants thereof, alternative splice proteins
thereof, and phosphorylated proteins thereof.
[0165] The phrase "antineoplastic agent" is used herein to mean any
agent that is used to treat or prevent cancer or other conditions
comprising uncontrolled proliferation and growth of cells.
Antineoplastic agents include anticancer agents.
[0166] The phrase "contacting one or more proteins" is used herein
to mean placing a compound of the present invention in a solution
with one or more proteins of interest. A compound of Formula I and
one or more proteins of interest may be in solution together in an
aqueous solution, non-aqueous solution, or combination of an
aqueous solution and non-aqueous solution. Other proteins may be
present in solution along with the compound of Formula I and the
protein of interest. Other inorganic or organic molecules may be
present in the solution. Such inorganic and organic molecules
include, but are not limited to, NaCl, HEPES, and octyl glucoside.
The solution may be within an animal cell or outside of an animal
cell.
[0167] The phrase "inhibiting the binding" is used herein to mean
preventing or reducing the direct or indirect association of one or
more molecules, peptides, proteins, enzymes, or receptors; or
preventing or reducing the normal activity of one or more
molecules, peptides, proteins, enzymes, or receptors.
[0168] The phrase "inducing apoptosis" is used herein to mean
causing directly or indirectly a cell of animal origin to undergo
apoptosis, a process of controlled, or programmed, cellular
death.
[0169] The phrase "HDM2 inhibitor" is used herein to describe an
agent which inhibits the function of HDM2 in the assay described in
Example 217.
[0170] The pharmaceutically-acceptable salts of the compounds of
Formula I (in the form of water- or oil-soluble or dispersible
products) include the conventional non-toxic salts or the
quaternary ammonium salts which are formed, e.g., from inorganic or
organic acids or bases. Examples of such acid addition salts
include acetate, adipate, alginate, aspartate, benzoate,
benzenesulfonate, bisulfate, butyrate, citrate, camphorate,
camphorsulfonate, cyclopentanepropionate, digluconate,
dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate,
glycerophosphate, hemisulfate, heptanoate, hexanoate,
hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate,
lactate, maleate, methanesulfonate, 2-naphthalenesulfonate,
nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate,
3-phenylpropionate, picrate, pivalate, propionate, succinate,
sulfate, tartrate, thiocyanate, tosylate, and undecanoate. Base
salts include ammonium salts, alkali metal salts such as sodium and
potassium salts, alkaline earth metal salts such as calcium and
magnesium salts, salts with organic bases such as dicyclohexylamine
salts, N-methyl-D-glucamine, and salts with amino acids such as
arginine, lysine, and so forth. Also, the basic nitrogen-containing
groups may be quaternized with such agents as lower alkyl halides,
such as methyl, ethyl, propyl and butyl chlorides, bromides and
iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and
diamyl sulfates; long chain halides such as decyl, lauryl, myristyl
and stearyl chlorides, bromides and iodides; and aralkyl halides
like benzyl and phenethyl bromides and others. Preferred acids for
forming acid addition salts include HCl, acetic acid,
trifluoroacetic acid and fumaric acid.
Compositions and Methods of Use
[0171] Compositions of the present invention include pharmaceutical
compositions comprising a compound of Formula I, wherein
R.sup.1-R.sup.10 are defined above, and one or more
pharmaceutically acceptable excipients. Preferred compositions of
the present invention are pharmaceutical compositions comprising a
compound selected from a preferred group of compounds of Formula I
as defined above, and one or more pharmaceutically acceptable
excipients.
[0172] The pharmaceutical compositions of the invention can be
administered to any animal that can experience the beneficial
effects of the compounds of the invention. Foremost among such
animals are humans, although the invention is not intended to be so
limited.
[0173] The pharmaceutical compositions of the present invention can
be administered by any means that achieve their intended purpose.
For example, administration can be by subcutaneous, intravenous,
intramuscular, intraperitoneal, buccal, or ocular routes, rectally,
parenterally, intrasystemically, intravaginally, topically (as by
powders, ointments, drops or transdermal patch), or as an oral or
nasal spray. Alternatively, or concurrently, administration can be
by the oral route. The dosage administered will be dependent upon
the age, health, and weight of the recipient, kind of concurrent
treatment, if any, frequency of treatment, and the nature of the
effect desired.
[0174] In addition to the pharmacologically active compounds, the
new pharmaceutical preparations can contain suitable
pharmaceutically acceptable carriers comprising excipients and
auxiliaries that facilitate processing of the active compounds into
preparations that can be used pharmaceutically.
[0175] The pharmaceutical preparations of the present invention are
manufactured in a manner that is, itself, known, for example, by
means of conventional mixing, granulating, dragee-making,
dissolving, or lyophilizing processes. Thus, pharmaceutical
preparations for oral use can be obtained by combining the active
compounds with solid excipients, optionally grinding the resulting
mixture and processing the mixture of granules, after adding
suitable auxiliaries, if desired or necessary, to obtain tablets or
dragee cores.
[0176] Suitable excipients are, in particular, fillers such as
saccharides, for example, lactose or sucrose, mannitol or sorbitol,
cellulose preparations and/or calcium phosphates, for example,
tricalcium phosphate or calcium hydrogen phosphate, as well as
binders, such as, starch paste, using, for example, maize starch,
wheat starch, rice starch, potato starch, gelatin, tragacanth,
methyl cellulose, hydroxypropyl methylcellulose, sodium
carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired,
disintegrating agents can be added, such as, the above-mentioned
starches and also carboxymethyl-starch, cross-linked polyvinyl
pyrrolidone, agar, or alginic acid or a salt thereof, such as,
sodium alginate. Auxiliaries are, above all, flow-regulating agents
and lubricants, for example, silica, talc, stearic acid or salts
thereof, such as, magnesium stearate or calcium stearate, and/or
polyethylene glycol. Dragee cores are provided with suitable
coatings that, if desired, are resistant to gastric juices. For
this purpose, concentrated saccharide solutions can be used, which
can contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene
glycol, and/or titanium dioxide, lacquer solutions and suitable
organic solvents or solvent mixtures. In order to produce coatings
resistant to gastric juices, solutions of suitable cellulose
preparations, such as, acetylcellulose phthalate or
hydroxypropylmethyl-cellulose phthalate, are used. Dye stuffs or
pigments can be added to the tablets or dragee coatings, for
example, for identification or in order to characterize
combinations of active compound doses.
[0177] Other pharmaceutical preparations which can be used orally
include push-fit capsules made of gelatin, as well as soft, sealed
capsules made of gelatin and a plasticizer, such as, glycerol or
sorbitol. The push-fit capsules can contain the active compounds in
the form of granules that may be mixed with fillers such as
lactose, binders such as starches, and/or lubricants such as talc
or magnesium stearate and, optionally, stabilizers. In soft
capsules, the active compounds are preferably dissolved or
suspended in suitable liquids, such as, fatty oils or liquid
paraffin. In addition, stabilizers may be added.
[0178] Suitable formulations for parenteral administration include
aqueous solutions of the active compounds in water-soluble form,
for example, water-soluble salts, alkaline solutions and
cyclodextrin inclusion complexes. Especially preferred alkaline
salts are ammonium salts prepared, for example, with Tris, choline
hydroxide, Bis-Tris propane, N-methylglucamine, or arginine. One or
more modified or unmodified cyclodextrins can be employed to
stabilize and increase the water solubility of compounds of the
present invention. Useful cyclodextrins for this purpose are
disclosed in U.S. Pat. Nos. 4,727,064, 4,764,604, and
5,024,998.
[0179] In addition, suspensions of the active compounds as
appropriate oily injection suspensions can be administered.
Suitable lipophilic solvents or vehicles include fatty oils, for
example, sesame oil, or synthetic fatty acid esters, for example,
ethyl oleate or triglycerides or polyethylene glycol-400 (the
compounds are soluble in PEG-400). Aqueous injection suspensions
can contain substances that increase the viscosity of the
suspension, for example, sodium carboxymethyl cellulose, sorbitol,
and/or dextran. Optionally, the suspension may also contain
stabilizers.
[0180] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups, and elixirs. In addition to the active compounds, the
liquid dosage forms may contain inert diluents commonly used in the
art such as, for example, water or other solvents, solubilizing
agents and emulsifiers such as ethyl alcohol, isopropyl alcohol,
ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols, and fatty acid esters of sorbitan, and mixtures
thereof.
[0181] Suspensions, in addition to the active compounds, may
contain suspending agents as, for example, ethoxylated isostearyl
alcohols, polyoxyethylene sorbitol and sorbitan esters,
microcrystalline cellulose, aluminum metahydroxide, bentonite,
agar-agar, and tragacanth, and mixtures thereof.
[0182] Topical administration includes administration to the skin
or mucosa, including surfaces of the lung and eye. Compositions for
topical administration, including those for inhalation, may be
prepared as a dry powder which may be pressurized or
non-pressurized. In nonpressurized powder compositions, the active
ingredients in finely divided form may be used in admixture with a
larger-sized pharmaceutically acceptable inert carrier comprising
particles having a size, for example, of up to 100 micrometers in
diameter. Suitable inert carriers include sugars such as lactose.
Desirably, at least 95% by weight of the particles of the active
ingredient have an effective particle size in the range of 0.01 to
10 micrometers.
[0183] Alternatively, the composition may be pressurized and
contain a compressed gas, such as nitrogen or a liquefied gas
propellant. The liquefied propellant medium and indeed the total
composition are preferably such that the active ingredients do not
dissolve therein to any substantial extent. The pressurized
composition may also contain a surface-active agent. The
surface-active agent may be a liquid or solid non-ionic
surface-active agent or may be a solid anionic surface-active agent
It is preferred to use the solid anionic surface-active agent in
the form of a sodium salt.
[0184] A further form of topical administration is to the eye. The
compounds and compositions of the present invention are delivered
in a pharmaceutically acceptable ophthalmic vehicle, such that the
compounds are maintained in contact with the ocular surface for a
sufficient time period to allow the compounds to penetrate the
corneal and internal regions of the eye, as for example the
anterior chamber, posterior chamber, vitreous body, aqueous humor,
vitreous humor, cornea, iris/ciliary, lens, choroid/retina and
sclera. The pharmaceutically acceptable ophthalmic vehicle may, for
example, be an ointment, vegetable oil or an encapsulating
material.
[0185] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds of the present invention with suitable non-irritating
excipients or carriers such as cocoa butter, polyethylene glycol or
a suppository wax which are solid at room temperature but liquid at
body temperature and therefore melt in the rectum or vaginal cavity
and release the drugs.
[0186] The compositions of the present invention can also be
administered in the form of liposomes. As is known in the art,
liposomes arm generally derived from phospholipids or other lipid
substances. Liposomes are formed by mono- or multi-lamellar
hydrated liquid crystals that are dispersed in an aqueous medium.
Any non-toxic, physiologically acceptable and metabolizable lipid
capable of forming liposomes can be used. The present compositions
in liposome form can contain, in addition to the compounds of the
present invention, stabilizers, preservatives, excipients, and the
like. The preferred lipids are the phospholipids and the
phosphatidyl cholines (lecithins), both natural and synthetic.
Methods to form liposomes are known in the art (see, for example,
Prescott, Ed., Meth Cell Biol. 14:33 (1976)).
[0187] Compounds of the present invention may be used alone or in
combination with one or more additional antineoplastic agents. When
a compound of the present invention is used along with one or more
additional antineoplastic agents, the compound of the present
invention may be formulated with the other antineoplastic agent or
agents so that a pharmaceutical composition comprising a compound
of Formula I and one or more additional antineoplastic agents is
administered to an animal. Alternatively, the compound of Formula I
can be administered as a separate pharmaceutical composition from
the composition comprising the one or more additional
antineoplastic agents. Antineoplastic agents that may be used in
combination with the compounds of the present invention include
compounds selected from the following compounds and classes of
antineoplastic agents:
[0188] 1. fluoropyrimidines, such as 5-FU (5-fluorouracil),
Fluorodeoxyuridine, Ftorafur, 5'-deoxyfluorouridine, UFT, and S-1
Capecitabine;
[0189] 2. pyrimidine nucleosides, such as Deoxycytidine, Cytosine
Arabinoside, Cytarabine, Azacitidine, 5-Azacytosine, Gencitabine,
and 5-Azacytosine-Arabinoside;
[0190] 3. purines, such as 6-Mercaptopurine, Thioguanine,
Azathioprine, Allopurinol, Cladribine, Fludarabine, Pentostatin,
and 2-Chloroadenosine;
[0191] 4. platinum analogues, such as Cisplatin, Carboplatin,
Oxaliplatin, Tetraplatin, Platinum-DACH, Ormaplatin, and CI-973,
JM-216;
[0192] 5. anthracyclines/anthracenediones, such as Doxorubicin,
Daunorubicin, Epirubicin, Idarubicin, and Mitoxantrone;
[0193] 6. epipodophyllotoxins, such as Etoposide, and
Teniposide;
[0194] 7. camptothecins, such as Irinotecan, Topotecan, 9-Amino
Camptothecin, 10,11-Methylenedioxy Camptothecin, 9-Nitro
Camptothecin, and TAS 103;
[0195] 8. hormones and hormonal analogues, such as
diethylstilbestrol, Tamoxifen, Toremefine, Tolmudex, Thymitaq,
flutamide, fluoxymesterone, bicalutamide, Finasteride, estradiol,
Trioxifene, dexamethasone, leuproelin acetate, estramustine,
Droloxifene, medroxyprogesterone, megesterol acetate,
aminoglutethimide, testolactone, testosterone, diethylstilbestrol,
and hydroxyprogesterone;
[0196] 9. enzymes, proteins and antibodies, such as Asparaginase,
Interleukins, Interferons, Leuprolide, and Pegaspargase;
[0197] 10. vinca alkaloids, such as Vincristine, Vinblastine,
Vinorelbine, and Vindesine;
[0198] 11. taxanes, such as Paclitaxel, Taxotere and Docetaxel.
[0199] Antineoplastic agents that may be used in combination with
compounds of the invention also include compounds selected from the
following Mechanism-Based Classes:
[0200] 1. Antihormonals--See classification for Hormones and
Hormonal Analogs above, Anastrozole, Goserelin, and
Aminoglutethimide;
[0201] 2. Antifolates, such as methotrexate, leucovorin,
aminopterin, trimetrexate, Trimethoprim, pyritrexim, pyrimethamine,
Edatrexate, and MDAM;
[0202] 3. Antimicrotubule Agents, such as Taxanes, Vinca Alkaloids,
and Vinorelbine;
[0203] 4. Alkylating Agents (Classical and Non-Classical), such as
Nitrogen Mustards (Mechlorethamine, Chlorambucil, Melphalan, Uracil
Mustard), Oxazaphosphorines (Ifosfamide, Cyclophosphamide,
Perfosfamide, Trophosphamide), Alkylsulfonates (Busulfan),
Nitrosoureas (Carmustine, Lomustine, Streptozocin), Thiotepa, and
Dacarbazine;
[0204] 5. Antimetabolites, such as Purines, pyrimidines and
nucleoside analogs, listed above;
[0205] 6. Antibiotics, such as Anthracyclines/Anthracenediones,
Bleomycin, Dactinomycin, Mitomycin, Plicamycin, Pentostatin, and
Streptozocin;
[0206] 7. Topoisomerase Inhibitors, such as Camptothecins (Topo I),
Epipodophyllotoxins, AMSA, VP-16 and Ellipticines (Topo II);
[0207] 8. Antivirals, such as AZT, acyclovir, penciclovir,
famcyclovir, didehydrodideoxythymidine, dideoxycytidine, -SddC,
ganciclovir, dideoxyinosine, and viral-specific protease
inhibitors;
[0208] 9. Miscellaneous Cytotoxic Agents, such as Hydroxyurea,
Mitotane, Fusion Toxins, PZA, Bryostatin, Retinoids, Butyric Acid
and derivatives, Pentosan, Fumagillin, Mitoxantrone, Bone Marrow
Growth Factors, and Procarbazine.
[0209] Compounds of the present invention are useful for the
treatment of uncontrolled proliferation of cells and/or cancer. The
compounds of the present invention may produce beneficial
cytostatic and/or cytotoxic effects. The cytostatic effects include
the inhibition of further cell growth and/or cell division. The
cytotoxic effects include the induction of cell death by mechanisms
that include apoptosis and cellular necrosis. Specifically, the
compounds of the present invention are useful in treating the
following cancers: breast cancer, ovarian cancer, cervical
carcinoma, endometrial carcinoma, choriocarcinoma, soft tissue
sarcomas, osteosarcomas, rhabdomyosarcomas, leiomyomas,
leiomyosarcomas, head and neck cancers, lung and bronchogenic
carcinomas, brain tumors, neuroblastomas, esophogeal cancer,
colorectal adenocarcinomas, bladder cancer, urothelial cancers,
leukemia, lymphoma, malignant melanomas, oral squamous carcinoma,
hepatoblastoma, glioblastoma, astrocytoma, medulloblastoina;
Ewing's sarcoma, lipoma, liposarcoma, malignant fibroblast histoma,
malignant Schwannoma, testicular cancers, thyroid cancers, Wilms'
tumor, pancreatic cancers, colorectal adenocarcinoma, tongue
carcinoma, gastric carcinoma and nasopharyngeal cancers.
Preferably, the present invention is used to treat the cancers
selected from the group consisting of breast cancer,
choriocarcinoma, soft tissue sarcomas, osteosarcomas,
rhabdomyosarcomas, lipoma and liposarcoma. The cancers and diseases
listed above are merely meant to be illustrative and are by no
means meant to be a limiting or exhaustive list.
[0210] Additionally, the compounds and compositions described
herein are useful to treat any undesired or detrimental condition
that results from the HDM2 protein or the MDM2 protein inhibiting
the function of p53 or other cellular proteins that induce
apoptosis, induce cellular death, or regulate the cellular
cycle.
[0211] The compounds of the present invention are also useful at
inhibiting the interaction between p53 and HDMX and/or MDMX. MDMX,
also known as MDM4, is a cellular protein involved in the
regulation of the cell cycle. For example, see Riemenschneider et
al., Cancer Res. 59(24):6091-6 (1999).
[0212] The compounds of the present invention are also useful for
the treatment and prevention of inflammatory conditions. The
compounds of the present invention can be administered as
anti-inflammatory agents that reduce the degree of or eliminate
inflammation of tissues.
[0213] The compounds of the present invention are also useful for
the treatment of autoimmune diseases and conditions. The compounds
of the present invention can be administered to reduce or eliminate
the symptoms of an autoimmune disease. Autoimmune diseases include
any disease in which an animal's immune system reacts adversely to
a self-antigen. A self-antigen is any antigen that is normally
found in the animal's body. Representative autoimmune diseases
include Hashimoto's thyroiditis, Grave's disease, multiple
sclerosis, pernicious anemia, Addison's disease, insulin-dependent
diabetes mellitus, rheumatoid arthritis, systemic lupus
erythematosus (SLE or lupus), dermatomyositis, Crohn's disease,
Wegener's granulomatosis, Anti-Glomerular Basement Membrane
Disease, Antiphospholipid Syndrome, Dermatitis Herpetiformis,
Allergic Encephalomyelitis, Glomerulonephritis, Membranous
Glomerulonephritis, Goodpasture Syndrome, Lambert-Eaton, Myasthenic
Syndrome, Myasthenia Gravis, Bullous Pemphigoid,
Polyendocrinopathies, Reiter's Disease, and Stiff-Man Syndrome.
Preferably, the present invention is used to treat rheumatoid
arthritis or systemic lupus erythematosus.
[0214] Inhibitors of the interaction of HDM2 and/or MDM2 and p53
are also useful for treating cancer, inhibiting cell
growth/replication, and inducing cellular apoptosis and necrosis,
when administered along with agents that cause or induce DNA damage
(see Chen et al. Proc. Natl. Acad Sci. USA 95:195-200 (1998)).
Compounds of the present invention may be used to treat cancer,
inhibit cell growth/replication, and induce cellular apoptosis and
necrosis, by administering a compound of the present invention
along with agents that cause or induce DNA damage. Agents that
induce DNA damage include radiation and chemical agents. The
radiation can be administered either internally or externally.
Chemical agents include any compounds or elements that cause or
induce damage to DNA.
[0215] The compounds of the present invention may be administered
in an effective amount within the dosage range of about 0.01 mg/kg
to about 300 mg/kg, preferably between 1.0 mg/kg to 100 mg/kg body
weight. Compounds of the present invention may be administered in a
single daily dose, or the total daily dosage may be administered in
divided doses of two, three or four times daily.
Preparation of Compounds
[0216] The present invention is also concerned with the syntheses
of substituted 1,4-benzodiazepin-2,5-dione carboxylic acids. The
compounds of the present invention can be prepared utilizing the
modification of Ugi condensation products, according to the
synthetic pathway shown in Scheme 1 or Scheme 2 and as detailed in
Keating and Armstrong, J. Am. Chem. Soc., 118: 2574-2583 (1996).
##STR3## ##STR4##
[0217] Appropriately substituted or unsubstituted anthranilic acids
1 or 11, amines 3, aldehydes or ketones 2 can be used to prepare
the compounds of the present invention, wherein R.sup.1, R.sup.2,
R.sup.3, R.sup.4, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10
are defined above. The acid compounds of the present invention can
be prepared by optional hydrolysis of ester using a base, such as
NaOH, in an appropriate solvent, such as methanol/water. In Scheme
2, the standard Suzuki (Miyaura, N; Yanagi, T.; Suzuki, A., Synth.
Commun., 11: 513 (1981)) cross coupling condition can be used to
introduce R.sup.2 (from compound 12 to 6). While R.sup.5 is
selected as a group other than hydrogen, R.sup.5 can be introduced
by using R.sup.5Br in the presence of a base, such as NaH, and a
solvent; such as THF, or by using a standard Mitsunobu coupling
procedure (Mitsunobu, O., Synthesis, 1, (1981)) such as diethyl
azodicarboxylate, and triphenylphosphine in THF. Compound 7 can be
converted into compound 8 or 9 by using an appropriate reducing
reagent, such as BH.sub.3.S(Me).sub.2, in a solvent such as THF.
Compound 10 can be made through reaction of compound 7 with
Lawesson's reagent
(2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide)
in a solvent such as THF.
[0218] The following examples illustrate, but do not limit, the
compounds, methods and compositions of the present invention. Other
suitable modifications and adaptations of the variety of conditions
and parameters normally encountered in clinical therapy and which
are obvious to those skilled in the art are within the spirit and
scope of the invention.
EXAMPLES
[0219] The compounds in the examples below were synthesized by the
following general procedures.
General Procedure for the Synthesis of Non-Commercially Available
Anthranilic Acids
[0220] A solution of the appropriate aniline (50.0 mmol) in acetic
acid (30.0 mL) was heated to 45.degree. C. Bromine (55.5 mmol, 2.8
mL) was then added dropwise at a rate to keep the temperature
between 50-55.degree. C. The temperature was held at 50.degree. C.
for 1.5 h. The reaction was allowed to cool to ambient temperature
and was poured into ice with stirring. Sodium bisulfite (1.0 g) was
added and stirred for 30 min. The solution was extracted with ethyl
acetate (2.times.50.0 mL). The combined organic extracts were
washed with saturated sodium bicarbonate, brine, dried over sodium
sulfate, filtered and concentrated in vacuo to give a dark oil. The
oil was purified by flash chromatography (silica gel, 5-10% ethyl
acetate in hexanes) to give the aryl bromide as a light brown
oil.
[0221] A solution of the aryl bromide (12.0 mmol) in
N,N-dimethylformamide (8.0 mL) was stirred at ambient temperature.
Copper cyanide (15.0 mmol, 13 g) was added and the reaction was
heated to 155.degree. C. for 4 h. The reaction was allowed to cool
and poured into a solution of ethylene diamine (0.1 mL) in water
(130.0 mL) and stirred for 30 min. The solution was extracted with
ethyl acetate (2.times.70.0 mL). The organic extracts were combined
and washed with saturated ammonium chloride and brine, dried with
sodium sulfate and concentrated in vacuo. The residue was then
purified by flash chromatography (silica gel, 10% ethyl acetate in
hexane) to give the aryl cyanide as a orange oil.
[0222] To a solution of the aryl cyanide (1.5 mmol) in acetic acid
(2.0 mL) was added 50% sulfuric acid (6.0 mL), The reaction was
heated to reflux for 2.5 h. The reaction was allowed to cool to
ambient temperature and poured into ice (50.0 g). The solution was
neutralized with potassium hydroxide (6M) and extracted with ethyl
acetate (2.times.40.0 mL). The combined organics were washed with
brine and dried with sodium sulfate, filtered and dried in vacuo to
a solid. The solid was purified by flash chromatography (silica
gel, 15% ethyl acetate in methylene chloride to 8% methanol in
methylene chloride) to give the anthranilic acid as a white
solid.
[0223] To a solution of the anthranilic acid (4.2 mmol) in
1,4-dioxane (20.0 mL) and 10% sodium hydroxide (5.0 m) was added
di-tertbutyl-dicarbonate (12.0 mmol). The reaction was stirred at
ambient temperature for 3 days. The reaction was then concentrated
in vacuo and poured into water (25.0 mL) and ethyl acetate (50.0
mL). It was then acidified with cold 10% citric acid. The organic
layers were washed with brine and dried with sodium sulfate and
filtered. The organics were concentrated in vacuo to a solid and
triturated with hexane. The solids were filtered, and washed with
hexane and dried under high vacuum to give the title compound as a
white solid.
General Procedure for the Synthesis of Benzodiazepine Compounds
[0224] A solution of the aldehyde (0.20 mmol) and amino ester (0.20
mmol) in methanol (2.0 mL) were shaken at ambient temperature for
30 min. To this solution was added a solution of
cyclohexene-1-isontirile (0.21 mmol) in hexanes, followed by the
anthranilic acid (0.20 mmol). The solution was then shaken for 3
days at ambient temperature. The reaction was cooled in a ice bath
and acetyl chloride (0.2 mL) was added slowly. The solution was
then shaken for an additional 3 h and concentrated in vacuo. The
residue was purified using pre-packed silica cartridges (methylene
chloride to 10% ethyl acetate in methylene chloride). The pure
ester was then concentrated back down in vacuo, dissolved in
methanol (1.5 mL), and 10% sodium hydroxide (0.15 mL) was added.
The reaction mixture was shaken overnight at ambient temperature.
The solution was then concentrated in vacuo and acidified with
hydrochloric acid (1M). The precipitates were extracted with ethyl
acetate, separated and the organics were concentrated in vacuo. The
residue was purified using pre-packed silica cartridges (8% ethyl
acetate in methylene chloride to 10% methanol in methylene
chloride) to give the title compounds (0.015-0.050 g).
General Procedure for the Alkylation of Benzodiazepine
Compounds
[0225] To a solution of the benzodiazepine (0.1 mmol) and alcohol
(02 mmol) in tetrahydrofuran (1.0 mL) was added triphenylphosphine
(0.2 mmol, 0.052 g) in tetrahydrofuran (1.0 mL). The solution was
shaken 5 minutes then diisopropyl azodicarboxylate (0.2 mmol, 0.040
mL) was added, and the mixture was shaken at ambient temperature
overnight. The reaction was concentrated in vacuo. The residue was
purified by preparative plate chromatography (silica gel, 20% ethyl
acetate in methylene chloride, bottom band). The isolated ester was
dissolved in methanol (1 mL) and sodium hydroxide (1M, 0.2 mL) was
added and the reaction mixture was shaken at ambient temperature
overnight. The reaction was concentrated in vacuo, water (0.5 mL)
was added, followed by acidification with hydrochloric acid (1M,
0.3 mL). The resulting precipitate was extracted with ethyl acetate
(1 mL) and separated. The organics were dried in vacuo and the
residues purified using a preparative plate chromatography (silica
gel, 8% methanol in methylene chloride, bottom band) to give the
title compounds (0.012-0.030 g).
General Procedure for the Boronic Acid Cross Coupling of
Benzodiazepine Compounds
[0226] Benzodiazepine (0.05 mmol), boronic acid (3 eq, 0.15 mmol),
and Pd(PPh.sub.3).sub.4 (0.04 eq, 0.002 mmol) were placed in a 2 mL
vial equipped with a magnetic stir bar. The vial was fitted with a
rubber septum then evacuated and backflushed with dry N.sub.2.
Tetrahydrofuran (THF, 0.8 mL) and 2M Na.sub.2CO.sub.3 (0.2 mL) were
added to the vial via syringe. The reaction vessel was capped
tightly under a N.sub.2 purge then heated to 50.degree. C. for 12
h. After cooling to ambient temperature, the solvent was removed
under reduced pressure. The residue was then purified by Sep-Pak
(10 g silica gel, methylene chloride to 10% ethyl acetate in
methylene chloride) to give the title compound.
General Procedure for the Reduction of 1,4-benzodiazepines
[0227] 1) The benzodiazepine ester (0.070 mmol) was placed in a 4
mL vial equipped with a magnetic stir bar. The vial was fitted with
a rubber septum then evacuated and backflushed with N.sub.2.
Borane-dimethylsulfide (4 eq., 0.28 mmol, 0.14 mL of 2M THF
solution) was added via syringe. The reaction was stirred at
ambient temperature for 15 hours. The solvent was removed under
reduced pressure then the residue was dissolved in ethyl acetate.
The organic phase was washed with 1M NaOH then the aqueous phase
was extracted twice with ethyl acetate. The combined organic phase
was dried over anhydrous magnesium sulfate, filtered, and the
solvent removed under reduced pressure. The mono- and di-reduced
products were separated by column chromatography on silica gel,
eluting with 10% ethyl acetate in hexanes to give the title
compound.
[0228] 2) The benzodiazepine acid (0.023 mmol) was placed in a 4 mL
vial equipped with a magnetic stir bar. The vial was fitted with a
rubber septum then evacuated and backflushed with N.sub.2. Dry THF
(1 mL) and borane-dimethylsulfide (4 eq., 0.093 mmol, 46 .mu.L of
2M THF solution) were successively added via syringe and
microsyringe, respectively. The reaction was stirred at ambient
temperature for 16 hours then additional borane-dimethylsulfide (8
eq., 0.186 mmol, 92 .mu.L of 2M THF solution) was added to the
reaction. The reaction was stirred at ambient temperature for an
additional 4 hours then the solvent was removed under reduced
pressure. The residue was purified by column chromatography using a
5 g silica gel SEP-pak column, eluting with 20% ethyl acetate in
dichloromethane. The amide reduction products were further
separated by preparative TLC on a 1000 micron silica gel plate,
developed with 20% ethyl acetate in hexanes to give the title
compound.
General Procedure for the Preparation of 1,4benzodiazepine
Amides
[0229] The 1,4-benzodiazepine carboxylic acid (0.057 mmol) and EDC
(1.5 eq., 0.086 mmol, 16.5 mg) were placed in a 4 mL vial equipped
with a magnetic stir bar. The vial was fitted with a rubber septum,
then evacuated and backflushed with dry N.sub.2. Dry
dichloromethane (2 mL) was added via syringe. Once the solids
dissolved, the amine (1.5 eq, 0.086 mmol) and triethylamine (2.5
eq., 0.143 mmol, 20 .mu.L) were successively added via
microsyringe. The reaction was stirred at ambient temperature for 2
hours then the volatiles were removed under reduced pressure. The
crude product was purified by column chromatography using a 5 g
silica gel SEP-pak column eluting with 50% ethyl acetate in
dichloromethane.
Example 1
[7-Iodo-2,5-dioxo-3-(4-trifluoromethylphenyl)-1,2,3,5-tetrahydro-benzo[e][-
1,4]diazepin-4-yl]phenylacetic acid
[0230] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.68 (s,
0.4H), 10.52 (s, 0.6H), 7.79 (s, 0.4H), 7.72 (s, 0.6H), 7.52-7.22
(m, 9H), 7.00 (m, 1H), 6.63 (d, J=8.4 Hz, 0.4H), 6.53 (d, J=8.4 Hz,
0.6H) 6.36 (s, 1H), 5.96 (s, 0.6H), 5.28 (s, 0.4H). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.24H.sub.16F.sub.3N.sub.2O.sub.4I:
580.0;
[0231] Found: 580.9(M+H).
Example 2
[3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaze-
pin-4-yl]phenylacetic acid
[0232] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.74 (s,
0.6H), 10.56 (s, 0.4H), 7.78-6.89 (m, 11H), 6.64 (d, J=8.7 Hz,
0.6H), 6.56 (d, J=8.7 Hz, 0.4H), 6.30 (br s, 1H), 5.65 (s, 0.4H),
5.14 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.16N.sub.2O.sub.4ICl: 546.0; Found: 546.8(M+H).
Example 3
[3-(4-ethyl-phenyl)-7-iodo-2,5oxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-
-4-yl]-phenyl-acetic acid
[0233] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.57 (s,
0.5H), 10.40 (s, 0.5H), 7.78-6.54 (m, 12H), 6.35 (s, 0.5H), 6.31
(s, 0.5H), 5.89(s, 0.5H), 5.18 (s, 0.5H). 2.38 (m, 2 H), 1.00 (m,
3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.21N.sub.2O.sub.4I: 540.1; Found: 540.8(M+H).
Example 4
[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo[e-
][1,4]diazepin-4-yl]-phenyl-acetic acid
[0234] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.77 (s,
0.6H), 10.55 (s, 0.4H), 7.69-6.99 (m, 11H), 6.63 (d, J=8.6 Hz,
0.6H), 6.55 (d, J=8.6 Hz, 0.4H), 6.31 (br s, 1H), 5.63 (s, 0.4H),
5.18 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.16F.sub.3N.sub.2O.sub.5I: 596.0; Found:
596.8(M+H).
Example 5
[7-Iodo-3-(4-isopropyl-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]d-
iazepin-4-yl]-phenyl-acetic acid
[0235] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.58 (s,
0.6H), 10.40 (s, 0.4H), 7.63-6.54 (m, 12H), 6.30 (br s, 1 H),
5.64(s, 0.4H), 5.08 (s, 0.6H), 2.60 (m, 1H), 0.96 (m, 6H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.23N.sub.2O.sub.4I: 554.1; Found: 554.9(M+H).
Example 6
[2,5-Dioxo-3-(4-trifluoromethyl-phenyl)-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-phenyl-acetic acid
[0236] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.70 (s,
0.6H), 10.2 (s, 0.4H), 7.7-6.9 (m, 13H), 6.42 (s, 0.4H), 6.39 (s,
0.6H), 5.86 (s, 0.4H), 5.30 (s, 0.6H).
[0237] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.17F.sub.3N.sub.2O.sub.4: 454.1; Found:
455.0(M+H).
Example 7
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethyl-phenyl)-1,2,3,5-tetrahydro-benzo[-
e][1,4]diazepin-4-yl-3-phenyl-propionic acid
[0238] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.81 (s,
0.6H), 10.56 (s, 0.4H), 7.70-7.10 (m, 11H), 6.55 (m, 1H), 5.79 (s,
0.6H), 5.59 (br s, 0.6H), 5.51 (s, 0.4H), 5.31 (br s, 0.4H), 3.35
(m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.18F.sub.3N.sub.2O.sub.4I: 594.0; Found:
595.0(M+H).
Example 8
(7-Iodo-2,5-dioxo-3-phenyl-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)--
phenyl-acetic acid
[0239] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.69 (s,
0.6H), 10.47 (s, 0.4H), 7.78-6.79 (m, 12H), 6.63 (d, J=8.3 Hz,
0.6H), 6.54 (d, J=83 Hz, 0.4H), 6.38 (s, 0.6H), 6.34 (s, 0.4H),
5.83 (s, 0.4H), 5.23 (s, 0.6H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.23H.sub.17N.sub.2O.sub.4I: 512.0; Found:
513.0(M+H).
Example 9
[7-Iodo-2,5-dioxo-3-(3-trifluoromethyl-phenyl)-1,2,3,5-tetrahydro-benzo[e]-
[1,4]diazepin-4-yl]-phenyl-acetic acid
[0240] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.76 (s,
0.6H), 10.53 (s, 0.4H), 7.81-6.90 (m, 11H), 6.61 (d, J=8.7 Hz,
0.6H), 6.54 (d, J=8.6 Hz, 0.4H), 6.40 (s, 0.6H), 6.36 (s, 0.4H),
5.78 (s, 0.4H), 5.40 (s, 0.6H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.24H.sub.16F.sub.3N.sub.2O.sub.4I: 580.0; Found:
580.8(M+H).
Example 10
(7-Iodo-2,5-dioxo-3-p-tolyl-1,2,3,5-tetrahydrobenzo[e][1.4]diazepin-4-yl)--
phenylacetic acid
[0241] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.64 (s,
0.6H), 10.45 (s, 0.4H). 7.78-6.54 (m, 11H), 6.37 (s, 0.6H), 6.30
(s, 0.4H), 5.77 (s, 0.4H), 5.16 (s, 0.6H), 5.12 (s, 1H), 2.05 (s,
3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.19N.sub.2O.sub.4I: 526.0; Found: 526.8(M+H).
Example 11
[7-Iodo-3-(4methoxy-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-phenyl-acetic acid
[0242] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.64 (s,
0.6H), 10.44 (s, 0.4H), 7.78-6.54 (m, 12H), 6.37 (s, 0.6H), 6.30
(s, 0.4H), 5.72 (s, 0.4H), 5.16 (s, 0.6H), 3.61 (s, 1H), 3.55 (s,
2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.19N.sub.2O.sub.5I: 542.0; Found: 542.8(M+H).
Example 12
(7-Iodo-3-naphthalen-2-yl-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazep-
in-4-yl)-phenyl-acetic acid
[0243] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.83 (s,
0.75H), 10.72 (s, 0.25H), 8.01-7.00 (m, 14H), 6.62 (d, J=8.3 Hz,
0.75H), 6.57 (d, J=8.3 Hz, 0.25H), 6.44 (s, 0.75H), 6.21 (s,
0.25H), 5.52 (s, 0.25H), 5.26 (s, 0.75H). Mass spectrum (LCMS. ESI
pos) Calcd. for C.sub.27H.sub.19N.sub.2O.sub.4I: 562.0; Found:
562.9(M+H).
Example 13
[3-(4-tert-Butyl-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]-
diazepin-4-yl]-phenyl-acetic acid
[0244] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.61 (s,
0.6H), 10.41 (s, 0.4H, 7.78-6.54 (m, 12H), 6.32 (s, 0.6H), 6.27 (s,
0.4H), 5.76(s, 0.4H), 5.13 (s, 0.6H), 1.12(s, 3 H), 1.07 (s, 6H).
Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.27H.sub.25N.sub.2O.sub.4I: 568.1; Found: 568.9(M+H).
Example 14
[3-(2-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-phenyl-acetic acid
[0245] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.66 (s,
0.41H), 10.53 (s, 0.6H), 7.81-6.90 (m, 11H), 6.72 (s, 0.4H), 6.61
(d, J=8.7 Hz, 0.4H), 6.54 (d, J=8.6 Hz, 0.6H), 6.36 (s, 0.6H), 5.22
(s, 0.6H), 5.12 (s, 0.4H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.16N.sub.2O.sub.4ICl: 546.0; Found: 547.8(M+H).
Example 15
[3-(3-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-phenyl-acetic acid
[0246] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.74 (s,
0.6H), 10.53 (s, 0.4H), 7.79-6.76 (m, 11H), 6.65 (d, J=8.7 Hz,
0.6H), 6.56 (d, J=8.6 Hz, 0.4H), 6.34 (s, 0.6H), 6.31 (s, 0.4H),
5.72 (s, 0.4H), 5.25 (s, 0.6H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.23H.sub.16N.sub.2O.sub.4I: 546.0; Found:
546.9(M+H).
Example 16
[3-(4-Benzyloxy-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]d-
iazepin-4-yl]-phenyl-acetic acid
[0247] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.66 (s,
0.7H), 10.47 (s. 03H), 7.78-6.56 (m, 17H), 6.35 (s, 0.7H), 6.28 (s,
0.3H), 5.66 (s, 0.3H), 5.13 (s, 0.7H), 4.95 (s, 0.5H), 4.89 (s,
1.5H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.30H.sub.23N.sub.2O.sub.5I: 618.1; Found: 618.8(M+H).
Example 17
[7-Iodo-2,5-dioxo-3-(4-phenoxy-phenyl)-1,2,3,5-tetrahydro-benzo[e][1,4]dia-
zepin-4-yl]-phenyl-acetic acid
[0248] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.61 (s,
0.5H), 10.41 (s, 0.5H), 7.80-6.5 (m, 17H), 6.33 (s, 0.5H), 5.88 (s,
0.5H), 536 (s, 0.5H), 5.22 (s, 0.5H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.29H.sub.21N.sub.2O.sub.5I: 604.0; Found:
604.8(M+H).
Example 18
[7-Iodo-2,5-dioxo-3-(2-trifluoromethyl-phenyl)-1,2,3,5-tetrahydro-benzo[e]-
[1,4]diazepin-4-yl]-phenyl-acetic acid
[0249] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.72 (s,
0.5H), 10.61 (s, 0.5H), 7.81-6.54 (m, 12H), 6.40 (s, 0.5H), 5.35
(s, 0.5H), 5.29 (s, 0.5H), 5.08 (s, 0.5H). Mass spectrum (LCMS, ESI
pos) Calcd. for C.sub.24H.sub.16F.sub.3N.sub.2O.sub.4I: 580.0;
Found: 580.9(M+H).
Example 19
3-(3,4-Dichloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]d-
iazepin-4-yl]-phenyl-acetic acid
[0250] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.79 (s,
0.8H), 10.58 (s, 0.2H), 7.81-6.84 (m, 10H), 6.67 (d, J=8.5 Hz,
0.8H), 6.58 (d, J=8.5 Hz, 0.2H), 6.33 (s, 0.8H), 6.31 (s, 0.2H),
5.35 (s, 0.2H), 5.24 (s, 0.8H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.23H.sub.15N.sub.2O.sub.4ICl.sub.2: 579.9; Found:
580.8(M+H).
Example 20
(3-(3,4-Dimethoxy-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4-
]diazepin-4-yl]-phenyl-acetic acid
[0251] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.64 (s,
0.5H), 10.41 (s, 0.5H), 7.81-7.22 (m, 10H), 6.67 (d, J=8.4 Hz,
0.5H), 6.55 (d, J=8.5 Hz, 0.5H), 6.42 (s, 0.5H), 6.12 (s, 0.5H),
5.62 (s, 0.5H) 5.30 (s, 0.5H), 3.54 (s, 3H), 3.43 (s, 3H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.21N.sub.2O.sub.6I: 572.0; Found: 572.8(M+H).
Example 21
[3-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0252] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.65 (s,
0.7H), 10.46 (s, 0.3H), 7.78-6.47 (m, 11H), 6.32 (s, 0.8 H), 6.25
(s, 0.8H), 6.23 (s, 0.2H), 5.10 (s, 0.2H), 4.07 (br s. 4H). Mass
spectrum (LCMS, ESI pos) Calcd for C.sub.25H.sub.19N.sub.2O.sub.6I:
570; Found: 570.90 (M+H).
Example 22
[3-(4-Bromo-2-fluoro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][-
1,4]diazepin-4-yl]-phenyl-acetic acid
[0253] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.74 (s,
0.6H). 10.47 (s, 0.4H), 7.81-7.01 (m, 10H), 6.67 (d, J=8.7 Hz,
0.6H), 6.58 (d, J=8.6 Hz, 0.4H), 6.26 (s, 0.4H), 6.13 (s, 0.6H)
5.77 (s, 0.4H), 5.14 (s, 0.6H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.23H.sub.15N.sub.2O.sub.4IBrF: 607.9; Found:
608.8(M+H).
Example 23
[3-(2-Fluoro-4-trifluoromethyl-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0254] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.76 (s,
0.8H), 10.47 (s, 0.2H). 7.81-6.81 (m, 10H), 6.66 (d, J=8.4 Hz,
0.8H), 6.56 (d, J=8.4 Hz, 0.2H), 6.31 (s, 0.2H), 6.16 (s, 0.8H)
6.02 (s, 0.2H), 5.29 (s, 0.8H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.24H.sub.15N.sub.2O.sub.4IF.sub.4: 598.0; Found:
598.9(M+H).
Example 24
[3-(3-Fluoro-4-trifluoromethyl-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0255] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.82 (s,
0.8H), 10.61 (s, 0.2H), 7.81-6.90 (m, 10H), 6.65 (d, J=8.5 Hz,
0.8), 6.58 (d, J=85 Hz, 0.2H), 6.31 (s, 0.2H), 6.29 (s, 0.8H) 5.74
(s, 0.2H), 5.29 (s, 0.8H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.15N.sub.2O.sub.4IF.sub.4: 598.0; Found:
598.9(M+H).
Example 25
[3-(4-Chloro-3-fluoro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e]-
[1,4]diazepin-4-yl]-phenyl-acetic acid
[0256] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.75 (s,
0.8H), 10.57 (s, 0.2H), 7.81-6.60 (m, 11H), 6.27 (s, 1H), 5.67 (s,
0.2H), 5.22 (s, 0.8H). Mass spectrum (LSMS, ESI pos) Calcd. for
C.sub.23H.sub.15N.sub.2O.sub.4IClF: 564.0; Found: 564.9(M+H).
Example 26
[3-(4-Bromo-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaze-
pin-4-yl]-phenyl-acetic acid
[0257] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.76 (s,
0.6H), 10.57 (s, 0.4H), 7.80-6.82 (m, 11H), 6.64 (d, J=8.6 Hz,
0.6H), 6.54 (d, J=8.6 Hz, 0.4H), 6.32 (s, 0.6H), 6.27 (s, 0.4H)
5.58 (s, 0.4H), 5.10 (s, 0.6H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.23H.sub.16N.sub.2O.sub.4IBr: 589.9; Found:
591.8(M+H).
Example 27
[8-Chloro-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-phenyl-acetic acid
[0258] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.78 (s,
0.8H), 10.58 (s, 0.2H), 7.53-6.83 (m, 12H), 6.34 (s, 0.8H), 6.30
(s, 0.2H), 5.66 (s, 0.2H), 5.14 (s, 0.8H). Mass spectrum (LCMS, ESI
pos) Calcd. for C.sub.23H.sub.16N.sub.2O.sub.4Cl.sub.2: 454.0;
[0259] Found: 454.9(M+H).
Example 28
[7-Chloro-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-phenyl-acetic acid
[0260] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.79 (s,
0.7H), 10.58 (s, 0.3H), 7.50-6.77 (m, 12H), 6.34 (s, 0.7H), 6.31
(s, 0.3H), 5.69 (s, 0.3H), 5.15 (s, 0.7H). Mass spectrum (LCMS, ESI
pos) Calcd. for C.sub.23H.sub.16N.sub.2O.sub.4ICl.sub.2: 454.0;
Found: 454.9(M+H).
Example 29
[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]dia-
zepin-4-yl]-phenyl-acetic acid
[0261] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.81 (t,
0.7H), 10.61 (s, 0.3H), 7.59-6.92 (m, 11H), 6.80 (d, J=8.6 Hz,
0.7H), 6.72 (d, J=8.6 Hz, 0.3H), 6.33 (s, 0.7H), 6.29 (s, 0.3H)
5.60 (s, 0.3H), 5.13 (s, 0.7H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.23H.sub.26N.sub.2O.sub.4ClBr. 498.0; Found: 499.1
(M+H).
Example 30
[3-(4-Chloro-phenyl)-7-methoxy-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]d-
iazepin-4-yl]-phenyl-acetic acid
[0262] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.52 (s,
0.7H), 10.33 (a, 0.3H), 7.50-6.81 (m, 11H), 6.75 (d, J=8.9 Hz,
0.7H), 6.68 (d, J=8.9 Hz, 0.3H), 6.32 (s, 0.7H), 6.29 (s, 0.3H)
5.47 (s, 0.3H), 5.11 (s, 0.7H), 3.64 (s, 3H). Mass spectrum (LCMS,
ESI pos) Calcd. for C.sub.24H.sub.19N.sub.2O.sub.5Cl: 450.1; Found:
450.9(M+H).
Example 31
3-(4-Chloro-phenyl)-7-methyl-2,5-oxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaze-
pin-4-yl]-phenyl-acetic acid
[0263] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.59 (s,
0.6H), 10.39 (s, 0.4H), 7.50-6.85 (m, 11H), 6.72 (d, J=8.1 Hz,
0.7H), 6.65 (d, J=8.1 Hz, 0.3H), 6.33 (s, 0.7H), 6.29 (s, 0.3H)
5.55 (s, 0.3H), 5.14 (s, 0.7H), 2.14 (s, 2H), 2.13 (s, 1H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.19N.sub.2O.sub.4Cl: 434.1;
[0264] Found: 435.0(M+H).
Example 32
[3-(4-Chloro-phenyl)-2,5-dioxo-1,2,5-tetrahydro-naphtho[2,3-e][1,4]diazepi-
n-4-yl]-phenyl-acetic acid
[0265] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.87 (s,
0.6H). 10.71 (s, 0.4H), 8.21-6.98 (m, 12H), 6.38 (s, 0.6H), 6.32
(s, 0.4H) 5.52 (s, 0.4H), 5.20 (s, 0.6H) 2.14 (s, 2H) 2.13 (s, 1H).
Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.27H.sub.19N.sub.2O.sub.4Cl: 470.1; Found: 471.0(M+H).
Example 33
[8-Chloro-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0266] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.76 (s,
0.9H), 10.55 (s, 0.1H), 7.53-6.80 (m, 12H), 6.32 (s, 1H), 5.18 (s,
1H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.16N.sub.2O.sub.5Cl.sub.2F.sub.3: 504.1; Found:
505.0(M+H).
Example 34
[7-Chloro-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0267] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.81 (s,
0.5H), 10.59 (s, 0.5H), 7.50-7.00 (m, 11H), 6.85 (d, J=8.8 Hz,
0.5H), 6.77 (d, J=8.8 Hz, 0.5H), 6.32 (s, 1H), 5.67 (s, 0.5H), 5.18
(s, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd for
C.sub.24H.sub.16N.sub.2O.sub.5ClF.sub.3: 504.1; Found:
504.9(M+H).
Example 35
[7-Bromo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo[-
e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0268] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.78 (s,
0.9H), 10.56 (s, 0.1H), 7.58-6.98 (m, 11H), 6.79 (d, J=85 Hz,
0.9H), 6.70 (d, J=8.5 Hz, 0.1H), 6.33 (s, 1H), 5.75 (s, 0.1H), 5.20
(s, 0.9H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.16N.sub.2O.sub.5BrF.sub.3: 548.0; Found:
548.8(M+H).
Example 36
[7-Methoxy-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benz-
o[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0269] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.52 (s,
0.6H), 10.30 (s, 0.4H), 7.52-6.79 (m, 11H), 6.74 (d, J=8.8 Hz,
0.6H), 6.66 (d, J=8.8 Hz, 0.4H), 6.33 (s, 0.4H), 6.30 (s, 0.6H)
5.56 (s, 0.4H), 5.16 (s, 0.6H), 3.62 (s, 3H). Mass spectrum (LCMS,
ESI pos) Calcd. for C.sub.25H.sub.19N.sub.2O.sub.6F.sub.3: 500.1;
Found: 500.9(M+H).
Example 37
[7-Methyl-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0270] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.60 (s,
0.6H), 10.41 (s, 0.4H), 7.51-7.00 (m, 11H), 6.71 (d, J=8.2 Hz,
0.6H), 6.64 (d, J=8.2 Hz, 0.4H), 6.30 (s, 1H), 5.51 (s, 0.4H), 5.16
(s, 0.6H), 2.11 (s, 2H), 2.10 (s, 1H). Mass spectrum (LCMS, ESI
pos) Calcd. for C.sub.25H.sub.19N.sub.2O.sub.5F.sub.3: 484.1;
Found: 485.0(M+H).
Example 38
[2,5-Dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-naphtho[2,3-e]-
[1,4]diazepin-4yl]-phenyl-acetic acid
[0271] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.86 (s,
0.8H), 10.51 (s, 0.2H), 7.72-6.90 (m, 15H), 6.37 (s, 1H), 5.57 (s,
0.4H), 5.25 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.28H.sub.19N.sub.2O.sub.5F.sub.3: 520.1; Found:
521.0(M+H).
Example 39
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-3-phenyl-propionic acid
[0272] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.76 (s,
0.6H), 10.51 (s, 0.4H), 7.72-6.95 (m, 11H), 6.57 (d, J=8.9 Hz,
0.4H), 6.54 (d, J=8.9 Hz, 0.6H), 5.57 (br s, 1H), 5.39 (s, 0.6H)
5.28 (s, 0.4H), 3.41 (d, J=4.2 Hz, 0.8H), 3.37 (d, J=4.2 Hz, 1.2H).
Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.18N.sub.2O.sub.4ICl: 560.0; Found: 560.8(M+H).
Example 40
3-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrah-
ydro-benzo[e][1,4]diazepin-4-yl]-propionic acid
[0273] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.76 (s,
0.8H), 10.54 (s, 0.2H), 7.72-6.95 (m, 10H), 6.58(d, J=8.4 Hz,
0.2H), 6.54 (d, J=8.4 Hz, 0.8H), 5.54 (br s, 1.4H), 5.35 (s, 0.2H),
5.13 (s, 0.4H), 3.41 (d, J=44 Hz, 0.8H), 3.37 (d, J=4.4 Hz. 1.2H).
Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.17N.sub.2O.sub.4Cl.sub.2: 594.0; Found: 594.8
(M+H).
Example 41
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-3-(4-hydroxy-phenyl)propionic acid
[0274] 1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.74 (s, 0.9H),
10.5 (s, 0.1H), 9.16 (s, 0.1H), 9.11 (s, 0.9H), 7.71 (s, 0.2H),
7.62 (d, J=1.9 Hz, 0.8H), 7.49 (m, 1H), 7.15-6.96 (m, 6H), 6.57(m,
3H), 5.63 (br s, 0.8H), 5.46 (br s, 0.8H), 5.21 (br s, 0.4H), 3.25
(m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.18N.sub.2O.sub.5ICl: 576.0; Found: 576.8(M+H).
Example 42
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-3cyclohexyl-propionic acid
[0275] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.96 (s,
0.9H), 10.84 (s, 0.1H), 7.76 (d, J=2.1 Hz, 1H), 7.57 (dd, J=2.2 Hz,
8.4 Hz, 1H), 7.23 (d, J=8.6 Hz, 1H), 7.12 (d, J=8.4 Hz, 2H), 6.61
(d, J=8.6 Hz, 1H), 5.51 (br s, 1H), 5.43 (s, 1H), 1.87-0.83(m,
13H), 3.23 (d, J=5.1 Hz, 1H). Mass spectrum (LCMS, ESI pos) Calcd.
for C.sub.24H.sub.24N.sub.2O.sub.4ICl: 566.0; Found:
566.9(M+H).
Example 43
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]-3-phenyl-propionic acid
[0276] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.77 (s,
0.8H), 10.52 (s, 0.2H), 7.72-6.95 (m, 11H), 6.57 (d, J=8.6 Hz,
0.2H), 6.52 (d, J=8.6 Hz, 0.8H), 5.58 (br s, 1.2H), 5.44 (s, 0.4H),
5.29 (s, 0.4H), 3.42 (d, J=5.5 Hz, 0.8H), 3.39 (d, J=5.5 Hz, 1.2H).
Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.18N.sub.2O.sub.5IF.sub.3: 610.0; Found:
610.9(M+H);
Example 44
3-(4-Chloro-phenyl)-2-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,-
3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-propionic acid
[0277] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.76 (s,
0.811), 10.54 (s, 0.2H), 7.72-6.95 (m, 10H), 6.57(d, J=8.6 Hz,
0.2H), 6.52 (d, J=8.6 Hz, 0.8H), 5.59 (br s, 1.4H), 5.54 (s, 0.2H),
5.40 (s, 0.2H), 5.16 (s, 0.2H), 3.42 (d, J=5.2 Hz, 0.8H), 3.39 (d,
J=5.2 Hz, 1.2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.17N.sub.2O.sub.5IF.sub.3: 644.0; Found:
644.8(M+H).
Example 45
3-(3-Hydroxy-phenyl)-2-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2-
,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-propionic acid
[0278] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.76 (s, 1H),
9.15 (s, 1H), 7.60 (d, J=1.6 Hz, 4H), 7.48 (dd, J=1.9 Hz, 8.4 Hz,
3H), 7.05 (m, 3H), 6.59 (d, J=8.5 Hz, 0.6H), 6.54 (d, J=8.5 Hz,
0.4H), 5.53 (br s, 2H), 3.28 (m, 2H). Mass spectrum. (LCMS, ESI
pos) Calcd. for C.sub.25H.sub.18N.sub.2O.sub.6IF.sub.3: 626.0;
Found: 626.9(M+H).
Example 46
3-Cyclohexyl-2-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tet-
rahydro-benzo[e][1,4]diazepin-4-yl]-propionic acid
[0279] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.94 (s,
0.9H), 10.84 (s, 0.1H), 7.71 (d, J=1.9 Hz, 1H), 7.54 (dd, J=2.1 Hz,
8.4 Hz, 1H), 7.24 (d, J=8.4 Hz, 2H), 7.14 (d, J=8.4 H, 2H), 6.59
(d, J=8.6 Hz, 1H), 5.51 (br s, 2H), 1.87-0.83 (m, 13H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.24N.sub.2O.sub.5IF.sub.3: 616.1; Found:
616.9(M+H).
Example 47
[1-Benzyl-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e]-
[1,4]diazepin-4-yl]-phenyl-acetic acid
[0280] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.62-6.97 (m,
17H), 6.22 (s, 0.6H), 6.19 (s, 0.4H), 5.65 (br s, 1H), 5.40 (m,
1H), 4.80 (m, 1H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.30H.sub.22N.sub.2O.sub.4ICl: 636.0; Found: 636.9(M+H).
Example 48
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1-phenethyl-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0281] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.71 (s, 1H),
7.56 (m, 2H), 7.31 (m, 8H), 7.05 (m, 5H), 6.89 (s, 1H), 6.20 (s,
1H), 5.85 (s, 0.4H), 5.31 (s, 0.6H), 4.23 (m, 1H), 3.85 (m, 1H),
2.85 (m, 0.5H), 2.62 (m, 1.5H). Mass spectrum (LCMS, ESI-pos)
Calcd. for C.sub.31H.sub.24N.sub.2O.sub.4ICl: 650.0; Found:
650.9(M+H).
Example 49
[3-(4-Chloro-phenyl)-7-iodo-1-isobutyl-2,5-dioxo-1,2,3,5-tetrahydro-benzo[-
e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0282] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.68 (m, 1H),
7.59 (m, 1H), 7.51 (d, J=6.5 Hz, 1H), 7.39 (m, 5H), 7.12 (m, 1H),
6.95 (m, 3H), 6.26 (s, 0.6H), 6.13 (s, 0.4H), 5.57 (s, 0.6H), 5.34
(s, 0.4H), 4.10 (m, 2H), 1.60 (m, 1H), 0.65 (m, 6H). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.27H.sub.24N.sub.2O.sub.4ICl:
602.0;
[0283] Found: 602.9(M+H).
Example 50
[3-(4-Chloro-phenyl)-7-iodo-(3-methylbutyl)-2,5-dioxo-1,2,3,5-tetrahydro-b-
enzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0284] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.68 (m, 1H),
7.53 (m, 2H), 7.30 (m, 4H), 7.06 (m, 3H), 6.87 (m, 1H), 6.26 (s,
1H), 6.04 (m, 1.6H), 535 (s, 0.4H), 4.07 (m, 1H), 3.44 (m, 1H),
1.40 (m, 1H), 1.24 (m, 1H), 1.13 (m, 1H), 0.75 (m, 6H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.28H.sub.26N.sub.2O.sub.4Cl: 616.1;
[0285] Found: 616.9(M+H).
Example 51
[3-(4-Chloro-phenyl)-1-cyclobutylmethyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydr-
o-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0286] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.65 (m, 1H),
7.58 (m, 1H), 7.49 (m, 2), 7.40 (m, 4H), 7.11 (m, 2H), 6.95 (m,
2H), 6.23 (s, 0.7H), 6.10 (s, 0.7H), 5.56 (s, 0.3H), 5.33 (s,
0.3H), 4.18 (m, 1H), 3.52 (m, 1H), 2.19 (m, 1H), 1.68 (m, 4H), 1.40
(m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.28H.sub.24N.sub.2O.sub.4ICl: 614.0; Found: 614.9(M+H).
Example 52
[3-(4-Chloro-phenyl)-1-cyclopentylmethyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0287] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.66 (m, 1H),
7.53 (m, 3H), 7.38 (s, 1H), 7.25 (s, 4H), 7.02 (m, 3H), 6.85 (m,
1H), 6.34 (s, 0.7H), 6.10 (br s, 1H), 5.44 (s, 0.3H), 4.02 (m,
1.3H), 3.48 (m, 0.7H), 1.34 (m, 6H), 0.77 (m, 2H).
[0288] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.29H.sub.6N.sub.2O.sub.4ICl: 628.1; Found: 628.9(M+H).
Example 53
[3-(4-Chloro-phenyl)-1-cyclohexylmethyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydr-
o-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0289] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.64 (m, 1H),
7.53 (m, 3H), 7.35 (s, 1H), 7.27 (s, 4H), 7.05 (m, 2H), 6.85 (m,
1H), 6.34 (s, 0.7H), 6.06 (br s, 1H), 5.47 (s, 0.3H), 4.98 (m,
0.7H), 3.23 (m, 1.3H), 1.53-0.6 (m, 11H). Mass spectrum (LCMS, ESI
pos) Calcd. for C.sub.30H.sub.28N.sub.2O.sub.4ICl: 642.9; Found
643.0(M).
Example 54
[3-(4-Chloro-phenyl)-7-iodo-1-(2-methyl-benzyl)-2,5-dioxo-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0290] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.68 (s, 0.4H),
7.60 (s, 0.6H), 7.51 (d, J=7.4 Hz, 1H), 7.44 (m, 1H), 7.38 (s, 1H),
7.26 (m, 4H), 7.05 (m, 6H), 6.87 (m, 2H), 6.29 (s, 0.7H), 6.17 (s,
1H), 5.55 (s, 0.3H), 5.34 (d, J=15.8 Hz, 0.3H), 5.27 (d, J=15.8 Hz,
0.7H), 4.93 (d, J=15.8 Hz, 0.3H), 4.68 (d, J=15.8 Hz, 0.7H), 2.20
(s, 1H), 1.98 (s, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.31H.sub.24N.sub.2O.sub.4ICl: 650.0; Found: 650.9(M+H).
Example 55
[3-(4-Chloro-phenyl)-7-iodo-1-(3-methyl-benzyl)-2,5-dioxo-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0291] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.62 (s, 0.4H),
7.59 (s, 0.6H), 7.52 (d, J=7.0 Hz, 1H), 7.45 (m, 3H), 7.26 (m, 3H),
7.09 (m, 5H), 6.90 (m, 3H), 6.74 (s, 0.6H), 6.34 (s, 0.4H), 6.17
(m, 1H), 5.53 (d, J=15.6 Hz, 0.4H), 5.27 (d, J=15.6 Hz, 0.6H), 4.83
(d, J=15.6 Hz, 0.4H), 4.64 (d, J=15.6 Hz, 0.6H), 2.18 (s, 3H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.31H.sub.24N.sub.2O.sub.4ICl: 650.0; Found: 650.9(M+H).
Example 56
[3-(4-Chloro-phenyl)-7-iodo-1-(4-methyl-benzyl)-2,5-dioxo-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0292] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.57 (m, 1H),
7.43 (m, 3H), 7.31 (m, 4H), 7.10 (m, 3H), 6.99 (m, 3H), 6.84 (m,
2H), 6.35 (s, 4H), 6.19(s, 1H), 5.55 (d, J=15.1 Hz, 0.4H), 5.42 (s,
0.6H), 5.27 (d, J=15.1 Hz, 0.6H), 4.77 (d, J=15.1 Hz, 0.4H), 4.59
(d, J=15.1 Hz, 0.6H), 2.20 (s, 3H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.31H.sub.24N.sub.2O.sub.4ICl: 650.0; Found:
650.9(M+H).
Example 57
[3-(4-Chloro-phenyl)-7-iodo-1-naphthalen-2-ylmethyl-2.5-dioxo-1,2,3,5-tetr-
ahydro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0293] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.79 (m, 4H),
7.58 (m, 2H), 7.46 (m, 4H), 7.31 (m, 2H), 7.15 (s, 2H), 7.05 (m,
1H), 6.90 (m, 1H), 6.36 (m, 0.6H), 6.23 (s, 1H), 5.76 (d, J=15.8
Hz, 0.4H), 5.47 (d, J=15.8 Hz, 0.6H), 5.44 (s, 0.4H), 5.00 (d,
J=15.8 Hz, 0.4H), 4.84 (d, J=15.8 Hz, 0.6H), 2.20 (s, 3H).
[0294] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.34H.sub.24N.sub.2O.sub.4ICl: 686.0; Found: 686.9(M+H).
Example 58
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1-pyridin-2-ylmethyl-1,2,3,5-tetrahy-
dro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0295] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.48 (m, 1H),
7.73 (m, 2H), 7.65 (m, 2H), 7.53 (m, 4H), 7.34 (m, 4H), 7.09 (m,
2H), 6.90 (m, 1H), 6.32 (s, 0.6H), 6.20 (s, 1H), 5.89 (br s, 0.4H),
5.36-4.89 (m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.29H.sub.21N.sub.3O.sub.4ICl: 637.0; Found: 638.0(M+H).
Example 59
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1-pyridin-3-ylmethyl-1,2,3,5-tetrahy-
dro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0296] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.40 (m, 1H),
7.52 (m, 3H), 7.27 (m, 4H), 7.11 (m, 4H), 6.96 (m, 2H), 6.82 (m,
2H), 6.33 (s, 0.6H), 6.24 (s, 0.4H), 6.15 (s, 0.6H), 5.69 (m,
0.4H), 5.35 (s, 0.6H), 5.31 (m, 0.4H), 4.85 (m, 1H).
[0297] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.29H.sub.21N.sub.3O.sub.4ICl: 637.0; Found: 638.1(M+H).
Example 60
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1-pyridin-4-ylmethyl-1,2,3,5-tetrahy-
dro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0298] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.41 (br s,
1H), 7.64 (m, 1H), 7.48 (m, 4H), 7.32 (m, 4H), 7.11 (m, 3H), 6.91
(m, 3H), 6.34 (s, 0.6H), 6.23 (s, 0.4H), 6.16 (s, 0.4H), 5.60 (d,
J=15.5 Hz, 0.4H), 5.38 (s, 0.6H), 5.26 (d, J=15.5 Hz, 0.6H), 4.90
(d, J=15.5 Hz, 0.4H), 4.77 (d, J=15.5 Hz, 0.6H). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.29H.sub.21N.sub.3O.sub.4ICl:
637.0; Found: 638.1(M+H).
Example 61
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]-acetic acid methyl ester
[0299] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.04 (m, 1.7H),
7.87.(m, 0.3H), 7.50 (s, 1H), 7.42-7.10 (m, 6H), 7.00 (m, 1H), 6.83
(s, 0.8H), 6.73 (d, J=8.4 Hz, 1.2H), 6.44 (d, J=8.4 Hz, 0.8H), 6.37
(d, J=8.4 Hz, 0.2H), 5.34 (m, 0.2H), 5.28 (s, 0.8H), 3.84 (s,
0.6H), 3.83 (s, 2.4H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.17N.sub.2O.sub.4ICl.sub.2: 594.0; Found:
594.8(M+H).
Example 62
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0300] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.64 (s,
0.6H), 10.53 (s, 0.4H), 7.81 (s, 0.6H) 7.73 (s, 0.4H), 7.52-7.15
(m, 4H), 7.07 (d, J=7.9 Hz, 3H), 6.81 (m, 2H), 6.63 (d, J=8.6 Hz,
0.6H), 6.54 (d, J=8.6 Hz, 0.4H), 6.25 (m, 1H), 5.81 (br s, 0.4H),
5.22 (s, 0.6H). Mass spectrum (LCMS, EST pos) Calcd. for
C.sub.23H.sub.15N.sub.2O.sub.4ICl.sub.2: 579.9; Found:
580.8(M+H).
Example 63
[3-(4-Chloro-phenyl)-7-iodo-1-methyl-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e]-
[1,4]diazepin-4-yl]-phenyl-acetic acid
[0301] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.63 (m, 2H),
7.49 (m, 1H), 7.29 (m, 4H), 7.09 (s, 2H), 7.00 (d, J=7.7 Hz, 1H),
6.82 (m, 1H), 6.72 (m, 1H), 6.28 (m, 1H), 5.92 (s, 0.5H) 5.31 (s,
0.5H), 3.12 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.18N.sub.2O.sub.4ICl: 560.0; Found: 560.9(M+H).
Example 64
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1-(3-phenyl-propyl)-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0302] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.70 (m, 1H),
7.49 (m, 3H), 7.17 (m, 11H), 6.80 (s, 2H), 6.36 (m, 0.6H), 6.15 (s,
0.4H), 6.01 (s, 0.6H), 5.31 (s, 0.4H), 4.50 (m, 1H), 4.34 (m, 1H),
2.31 (m, 1H), 2.24 (m, 1H), 1.58, (m, 1H), 1.45 (m, 1H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.32H.sub.26N.sub.2O.sub.4ICl: 664.1; Found: 665.2(M+H).
Example 65
2-{2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tet-
rahydro-benzo[e][1,4]diazepin-4-yl]-acetylamino}-3-methyl-butyric
acid
[0303] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.80-7.75 (m,
1H), 7.58-7.40 (m, 5H), 7.17-7.11 (m, 2H), 6.97 (d, J=8.0 Hz, 1H),
6.92 (d, J=8.0 Hz, 1H), 6.67-6.52 (m, 2H), 5.15 (s, 0.5 H), 4.94
(s, 0.5H), 4.07-3.95 (m, 1H), 2.05 (s, 1H), 0.84 (d, J=6 Hz, 3H),
0.79-0.71 (m, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.28H.sub.24Cl.sub.2IN.sub.3O.sub.5: 679.01; Found: 679.69
(M+H).
Example 66
3-[3-(4-Chloro-phenyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]dia-
zepin-4-yl]-3-phenyl-propionic acid
[0304] .sup.1H NMR (400 MHz, DMS-d.sub.6): .delta. 10.90 (s, 0.8H),
10.71 (s, 0.2H), 7.81 (s, 1H) 7.66 (m, 1H), 7.61-7.53 (m, 3H),
7.42-7.27 (m, 4H), 6.99 (d, J=8.8 Hz, 1.6 H), 6.61 (d, J=8.7 Hz,
0.4H), 6.50 (m, 2H), 5.24 (s, 1H), 3.18 (m, 2H). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.24H.sub.18N.sub.2O.sub.4ICl:
560.0; Found: 560.9(M+H).
Example 67
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-N-methyl-2-phenyl-acetamide
[0305] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.06 (d, J=2.1
Hz, 0.8H), 8.02 (m, 0.6H), 7.98 (s, 0.6H), 7.50-7.30 (m, 6H),
7.16-7.07 (m, 4H), 6.50 (m, 1H), 6.34 (d, J=8.4 Hz, 1H), 5.96 (m,
0.5H), 5.61 (s, 0.5H), 2.91 (s, 1.5H), 2.90 (s, 1.5H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.19N.sub.3O.sub.3ICl: 559.0; Found: 559.9(M+H).
Example 68
(7-Iodo-2,5-dioxo-3-pyridin-2-yl-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin--
4-yl)-phenyl-acetic acid
[0306] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.60 (s,
0.6H), 10.52 (s, 0.4H), 8.56 (m, 0.4H), 8.46 (m, 0.6H), 8.06 (s,
0.4H), 7.85 (m, 1H), 7.76 (dd, J=2.2 Hz, 8.2 Hz, 1H), 7.61 (m,
0.6H), 7.51 (m, 1H), 7.40 (m, 2H), 7.30 (m, 1H), 7.10 (m, 2H), 6.70
(m, 2H), 6.63 (d, J=8.6 Hz, 0.6H), 6.56 (d, J=8.6 Hz, 0.4H), 5.67
(s, 0.4H), 5.58 (s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.22H.sub.16N.sub.3O.sub.4I: 513.0; Found: 514.0(M+H).
Example 69
(7-Iodo-2,5-dioxo-3-pyridin-3-yl-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin--
4-yl-phenyl-acetic acid
[0307] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.72 (s,
0.5H), 10.36 (s, 0.5H), 8.33 (m, 1H), 8.35-7.00 (m, 10H), 6.63 (d,
J=8.6 Hz, 0.6H), 6.56 (d, J=8.6 Hz, 0.4H), 6.35 (s, 1H), 5.82 (s,
0.4H), 5.30(s, 0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.22H.sub.16N.sub.3O.sub.4I: 513.0; Found: 514.1(M+H).
Example 70
(7-Iodo-2,5-dioxo-3-thiophen-3-yl-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin--
4-yl)-phenyl-acetic acid
[0308] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.59 (s,
0.9H), 10.43 (s, 0.1H), 7.78 (s, 1H), 7.54 (m, 3H), 7.35 (m, 4H),
7.15 (m, 1H), 6.72 (m, 1H), 6.38 (s, 1H), 6.30 (s, 1H), 5.15 (s,
0.1H), 5.12 (s, 0.9H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.21H.sub.15N.sub.2O.sub.4IS: 518.0; Found: 518.9(M+H).
Example 71
[7-Iodo-3-5-methyl-thiophen-2-yl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,-
4]diazepin-4-yl]-phenyl-acetic acid
[0309] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.56 (s, 1H),
7.83 (s, 1H), 7.61 (m, 1H), 7.45 (m, 2H), 7.33 (m, 3H), 6.76 (d,
J=8.6 Hz, 1H), 6.33 (s, 1H), 6.23 (m, 1H), 6.02 (s, 1H), 5.24 (s,
1H), 2.11 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.22H.sub.17N.sub.2O.sub.4IS: 532.0; Found: 532.9(M+H).
Example 72
[7-Iodo-3-(3-methyl-thiophen-2-yl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1-
,4]diazepin-4-yl]-phenyl-acetic acid
[0310] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.54 (s, 1H),
7.99 (s, 1H), 7.68 (m, 1H), 7.34 (m, 4H), 7.00 (m, 1H), 6.77 (m,
1H), 6.39 (m, 1H), 6.27 (s, 1H), 6.02 (s, 1H), 5.36 (s, 1H), 1.69
(s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.22H.sub.17N.sub.2O.sub.4IS: 532.0; Found: 532.8(M+H).
Example 73
[3-(4-Bromo-thiophen-2-yl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,-
4]diazepin-4-yl]-phenyl-acetic acid
[0311] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.71 (s,
0.7H), 10.57 (s, 0.3H). 7.83 (d, J=2.2 Hz, 0.7H), 7.77 (d, J=2.2
Hz, 0.3H), 7.65 (m, 1H), 7.47 (d, J=7.0 Hz, 2H), 7.33 (m, 4H), 7.00
(m, 1H), 6.78 (d, J=8.6 Hz, 0.7H), 6.68 (d, J=8.6 Hz, 0.3H), 6.36
(s, 0.7H), 6.24 (s, 0.3H), 5.87 (s, 0.3H), 5.32 (s, 0.7H).
[0312] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.21H.sub.14N.sub.2O.sub.4ISBr: 595.9; Found: 596.8(M+H).
Example 74
(3-[2,2']Bithiophenyl-5-yl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,-
4]diazepin-4-yl-phenyl-acetic acid
[0313] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.73 (s,
0.8H), 10.57 (s, 0.2H), 7.86 (d, J=2.0 Hz, 0.8H), 7.79 (d, J=2.0
Hz, 0.2H), 7.63 (m, 1H), 7.52 (d, J=7.4 Hz, 2H), 7.39 (m, 5H), 7.01
(m, 1H), 6.79 (m, 2H), 6.40 (s, 1H), 6.27 (m, 1H), 5.88 (s, 0.2H),
5.30 (s, 0.8H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.17N.sub.2O.sub.4IS.sub.2: 600.0; Found:
601.9(M+H).
Example 75
[7-Iodo-3-(3-methyl-benzo[b]thiophen-2-yl)-2,5-dioxo-1,2,3,5-tetrahydro-be-
nzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0314] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.74 (s,
0.5H), 10.56 (s, 0.5H), 8.00 (s, 1H), 7.69 (m, 2H), 7.46 (m, 2H),
7.26 (m, 4H), 6.94 (m, 1H), 6.77 (m, 1H), 6.70 (s, 0.5H), 6.63 (d,
J=8.6 Hz, 1H), 6.28 (s, 0.5H), 5.60 (s, 0.5H), 5.48 (s, 0.5H), 1.90
(s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.19N.sub.2O.sub.4IS: 582.0; Found: 583.9(M+H).
Example 76
{3-[5-(2-Chloro-phenyl)-furan-2-yl]-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-be-
nzo[e][1,4]diazepin-4-yl}-phenyl-acetic acid
[0315] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.70 (s,
0.8H), 10.9 (s, 0.2H), 7.90 (d, J=2.1 Hz, 1H), 7.70 (dd, J=2.1 Hz,
8.3 Hz, 2H), 7.37 (m, 5H), 6.85 (m, 4H), 6.67 (d, J=3.5 Hz 1H),
6.41 (s, 1H), 5.62 (s, 1H), 5.32 (s, 1H).
[0316] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.27H.sub.18N.sub.2O.sub.5ICl: 612.0, Found: 613.1(M+H).
Example 77
{3-[5-(3-Chloro-phenyl)-furan-2-yl]-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-be-
nzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0317] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.70 (s, 1H),
7.91 (d, J=23 Hz, 2H), 7.68 (dd, J=2.1 Hz, 8.3 Hz, 2H), 7.49 (d,
J=7.2 Hz, 2H), 7.30 (m, 5H), 6.89 (d, J=8.6 Hz, 1H), 6.63 (d, J=3.5
Hz, 1H), 6.44 (s, 1H), 5.49 (s, 1H), 5.35 (s, 1H.). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.27H.sub.18N.sub.2O.sub.5ICl:
612.0; Found: 612.9(M+H).
Example 78
(7-Iodo-2,5-dioxo-3-quinolin-3-yl-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-
-4-yl)phenyl-acetic acid
[0318] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.72 (s,
0.8H), 10.61 (s, 0.2H), 9.02 (d, J=2.0 Hz, 1.5 H), 8.82 (d, J=2.0
Hz, 0.5H), 8.45 (s, 1.5 H), 8.36 (s, 0.5H), 8.05 (d, J=8.5 Hz,
1.5H), 7.98 (d, J=8.5 Hz, 0.5H), 7.84-6.84 (m, 7H), 6.72 (s, 0.8H),
6.62 (d, J=8.6 Hz, 0.8H), 6.56 (d, J=8.6 Hz, 0.2H), 6.45 (s, 0.2H),
5.68 (s, 0.2H), 5.10 (s, 0.8H.). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.26H.sub.18N.sub.3O.sub.4I: 563.0; Found:
564.1(M+H).
Example 79
[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]dia-
zepin-4-yl]-(4-chloro-phenyl)-acetic acid
[0319] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.79 (s,
0.5H), 10.63 (s, 0.5H), 7.58 (m, 1H) 7.52 (d, J=8.6 Hz 1H), 7.41
(m, 4H), 7.17 (m, 3H), 6.98 (m, 1H), 6.79 (d, J=8.6 Hz, 0.5H), 6.72
(d, J=8.6 Hz, 0.5H), 6.29 (s, 0.5H), 6.24 (s, 0.5H), 5.68 (s,
0.5H), 5.23 (s, 0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.15N.sub.2O.sub.4BrCl.sub.2: 534.0; Found:
534.9(M+H).
Example 80
2-[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]d-
iazepin-4-yl]-3-(4-trifluoromethyl-phenyl)-propionic acid
[0320] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.77 (s,
0.8H), 10.51 (s, 0.2H), 7.30-7.20 (m, 6H), 7.35 (m, 1H), 7.15 (m,
3H), 6.96 (m, 2H), 6.72 (m, 1H), 5.60 (br s, 2H). Mass spectrum
(LCMS, ESI pos) Calcd. for
C.sub.25H.sub.17N.sub.2O.sub.4BrF.sub.3Cl: 580.0; Found:
581.0(M+H).
Example 81
2-[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]d-
iazepin-4-yl]-3-phenyl-propionic acid
[0321] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.81 (s,
0.8H), 10.56 (s, 0.2H), 7.48 (s, 1H) 7.42-7.30 (m, 4H), 7.22 (m,
3H), 7.13 (m, 2H), 6.95 (m, 1H), 6.69 (m, 1H), 5.54(m, 1.4H), 5.40
(s, 0.3H), 5.30 (br s, 0.3H), 3.40 (m, 1.5H), 3.20 (m, 0.5H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.18N.sub.2O.sub.4BrCl: 512.0; Found: 513.0(M+H).
Example 82
2-[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]d-
iazepin-4-yl]-3-(4-chloro-phenyl)-propionic acid
[0322] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.80 (s,
0.8H), 10.58 (s, 0.2H), 7.50 (s, 1H), 7.43-7.37 (m, 3H), 7.22-7.12
(m, 4H), 6.92 (m, 2H), 6.69 (m, 1H), 5.57(m, 0.8H), 5.53 (s, 0.8H),
5.37 (s, 0.2H), 5.16 (br s, 0.2H), 3.40 (m, 1.5H), 3.20 (m, 0.5H).
Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.17N.sub.2O.sub.4BrCl.sub.2: 546.0; Found: 547.0
(M+H).
Example 83
2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrah-
ydro-benzo[e][1,4]diazepin-4-yl]-acetamide
[0323] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.75 (s,
0.6H), 10.65 (s, 0.4H), 7.77 (m, 1H), 7.71 (m, 1H), 7.56 (m, 1H),
7.52-7.45 (m, 3H), 7.38-7.07 (m, 4H), 6.91 (d, J=8.4 Hz, 1H),
6.64-6.55 (m, 1H), 6.41 (s, 0.6H), 5.51 (s, 0.4H), 4.96 (s, 0.6H),
4.70 (s, 0.4H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.16N.sub.3O.sub.3ICl.sub.2: 579.0; Found:
580.1(M+H).
Example 84
[7-Chloro-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-(4-chloro-phenyl)-acetic acid
[0324] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.77 (s,
0.8H), 10.61 (s, 0.2H), 7.52 (m, 1H) 7.46-7.39 (m, 4H), 7.32 (m,
2H), 7.15 (d, J=9.0 Hz, 2H), 6.97 (m, 1H), 6.86 (d, J=8.4 Hz,
0.6H), 6.78 (d, J=8.4 Hz, 0.4H), 6.28 (s, 0.4H), 6.23 (s, 0.6H),
5.72 (br s, 0.4H), 5.23 (s, 0.6H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.23H.sub.15N.sub.2O.sub.4Cl.sub.3: 488.0; Found:
489.0(M+H).
Example 85
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-methyl-2,5-dioxo-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0325] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.53 (s,
0.6H), 10.37 (s, 0.4H), 7.50 (d, J=8.4 Hz, 1H), 7.41-7.29 (m, 4H),
7.17-7.00 (m, 4H), 6.91 (m, 1H), 6.72 (d, J=8.4 Hz, 0.6H), 6.64 (d,
J=8.4 Hz, 0.4H), 6.34 (s, 0.4H), 6.25 (s, 0.61), 5.71 (s, 0.4H),
5.25 (s, 0.6H), 2.14 (s, 2H), 2.12 (s, 1H). Mass spectrum (LCMS,
ESI pos) Calcd. for C.sub.24H.sub.18N.sub.2O.sub.4Cl.sub.2: 468.1;
Found: 469.0(M+H).
Example 86
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-naphth-
o[2,3-e][1,4]diazepin-4-yl]-acetic acid
[0326] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.79 (s,
0.6H), 10.64 (s, 0.4H), 8.21 (s, 0.6H), 8.17 (s, 0.4H), 7.88 (m,
3H), 7.69 (m, 1H) 7.55 (d, J=8.4 Hz, 1H), 7.49-7.39 (m, 4H), 7.29
(s, 1H), 7.21 (m, 1H), 7.01 (m, 2H), 6.41 (s, 0.4H), 6.32 (s,
0.6H), 5.81 (s, 0.4H), 5.32 (s, 0.6H). Mass spectrum (LCMS, ESI
pos) Calcd. for C.sub.27H.sub.18N.sub.2O.sub.4Cl.sub.2: 504.1;
Found: 505.0(M+H).
Example 87
[8-Chloro-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-(4-chloro-phenyl)-acetic acid
[0327] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.73 (s,
0.8H), 10.58 (s, 0.2H), 7.52 (m, 2H), 7.40 (m, 1H), 7.14 (m, 4H),
7.00 (m, 1H), 6.91 (m, 3H), 6.30 (s, 0.2H), 6.25 (s, 0.8H) 5.76 (s,
0.2H), 5.22 (s, 0.8H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.15N.sub.2O.sub.4Cl.sub.3: 488.0; Found:
489.0(M+H).
Example 88
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-ethynyl-2,5-oxo-1,2,3,5-tetrahydr-
o-benzo[e][1,4]diazepin-4-yl]acetic acid
[0328] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.83 (s,
0.5H), 10.66 (s, 0.5H), 7.52 (m, 2H) 7.43-7.29 (m, 4H), 7.15 (m,
3H), 6.96 (m, 1H), 6.83 (d, J=8.4 Hz, 0.6H), 6.75 (d, J=8.4 Hz,
0.4H), 6.29 (s, 0.4H), 6.23 (s, 0.6H), 5.74 (br s, 0.4H), 5.21 (s,
0.6H), 4.16 (s, 0.6H), 4.14 (s, 0.4H). Mass spectrum (LCMS, ESI
pos) Calcd. for C.sub.23H.sub.16N.sub.2O.sub.4ICl.sub.2: 478.0;
Found: 479.0(M+H).
Example 89
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-1,4yl]-p-tolyl-acetic acid
[0329] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.64 (s,
0.8H), 10.46 (s, 0.2H), 7.81 (s, 1H), 7.50 (m, 2H), 7.36 (d, J=7.9
Hz, 2H), 7.20 (m, 1H), 7.08 (m, 3H), 6.81 (d, J=8.4 Hz, 1H), 6.63
(d, J=8.6 Hz, 1H), 6.27 (s, 1H), 5.83 (br s, 0.2H), 5.16 (s, 0.8H),
2.22 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.18N.sub.2O.sub.4ICl: 560.0; Found: 561.0(M+H).
Example 90
(4-Chloro-3-fluoro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-t-
etrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0330] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.65 (s,
0.9H), 10.60 (s, 0.1H), 7.79 (s, 1H), 7.52 (m, 3H), 7.35 (m, 2H),
7.13 (m, 2H), 6.95 (d, J=8.0 Hz, 1H), 6.63 (d, J=8.6 Hz, 1H), 6.29
(s, 0.1H), 6.14 (s, 0.9H), 5.80 (s, 0.1H). 5.29 (s, 0.9H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.14N.sub.2O.sub.4ICl.sub.2F: 597.9; Found:
598.9(M+H).
Example 91
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-(2-fluoro-4-trifluoromethyl-phenyl)-acetic acid
[0331] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.65 (br s,
1H), 7.80 (s, 1H), 7.74-7.53 (m, 5H), 7.12 (d, J=8.8 Hz, 2H), 6.85
(d, J=8.1 Hz, 1H), 6.63 (d, J=8.6 Hz, 1H), 6.45 (s, 1H), 5.60 (s,
0.1H), 5.24 (s, 0.9H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.14N.sub.2O.sub.4IClF.sub.4: 632.0; Found:
633.0(M+H).
Example 92
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-ethyl-2,5-dioxo-1,2,3,5-tetrahydr-
o-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0332] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.50 (s,
0.8H), 10.32 (s, 0.2H), 7.52 (d, J=8.4 Hz, 1H), 7.36 (m, 3H),
7.17-7.03 (m, 4H), 6.83 (d, J=8.0 Hz, 1H), 6.63 (d, J=8.6 Hz, 1H),
6.72 (d, J=8.4 Hz, 1H), 6.37 (s, 0.2H), 6.29 (m, 0.8H), 5.74 (s,
0.2H), 5.26 (s, 0.8H), 2.42 (m, 2H), 1.00 (m, 3H). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.25H.sub.20N.sub.2O.sub.4Cl.sub.2:
482.1; Found: 483.1(M+H).
Example 93
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-isopropyl-2,5-dioxo-1,2,3,5-tetra-
hydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0333] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.49 (s,
0.8H), 10.27 (s, 0.2H), 7.53 (d, J=8.4 Hz, 1H) 7.36 (m, 2H)
7.17-7.03 (m, 3H), 6.98 (d, J=8.4 Hz, 1H), 6.78 (d, J=8.1 Hz, 1H),
6.72 (d, J=8.4 Hz, 1H), 6.38 (s, 0.2H), 6.31 (m, 0.8H), 5.76 (s,
0.2H), 5.29 (s, 0.8H), 2.72 (m, 1H), 1.02 (m, 6H). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.25H.sub.20N.sub.2O.sub.4Cl.sub.2:
496.1; Found: 497.1(M+H).
Example 94
[7-tert-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,-
4]diazepin-4-yl]-4-chloro-phenyl)-acetic acid
[0334] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.45 (s,
0.8H), 10.25 (s, 0.2H), 7.52 (d, J=8.4 Hz, 1H), 7.44 (m, 1H),
7.40-7.31 (m, 3H), 7.22-7.03 (m, 3H), 6.98 (d, J=8.6 H, 1H), 6.78
(d, J=8.4 Hz, 1H), 6.72 (d, J=8.6 Hz, 1H), 6.37 (s, 0.2H), 6.29 (m,
0.8H), 5.75 (s, 0.2H), 5.27 (s, 0.8H), 1.13 (s, 8H), 1.11 (s, 1H).
Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.27H.sub.24N.sub.2O.sub.4Cl.sub.2: 510.1; Found:
511.1(M+H).
Example 95
[3-(4-Chloro-phenyl)-7-ethyl-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]dia-
zepin-4-yl]-phenyl-acetic acid
[0335] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.58 (s, 1H),
7.48 (d, J=7.0 Hz, 1H), 7.35 (m, 6H), 7.09 (d, J=8.6 Hz, 2H), 6.92
(d, J=8.1 Hz, 2H), 6.74 (d, J=8.1 Hz, 1H), 6.32 (s, 1H), 5.12 (s,
1H), 2.43 (q, J=7.7 Hz, 2H), 1.00 (t, J=7.5 Hz, 3H). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.25H.sub.21N.sub.2O.sub.4Cl.sub.2:
448.1; Found: 449.1(M+H).
Example 96
[3-(4-Chloro-phenyl)-7-isopropyl-2,5-dioxo-2,5-tetrahydro-benzo[e][1,4]dia-
zepin-4-yl]-phenyl-acetic acid
[0336] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.55 (s, 1H),
7.48 (d, J=7.0 Hz, 2H), 7.35(m, 3H), 7.07 (m, 3H), 6.91 (d, J=8.4
Hz, 2H), 6.73 (d, J=8.4 Hz, 2H), 6.31 (s, 1H), 5.11 (s, 1H), 2.74
(m, 1H), 1.03 (d, J=7.0 Hz, 6H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.26H.sub.23N.sub.2O.sub.4Cl: 462.1; Found:
463.1(M+H).
Example 97
[7-tert-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,-
4]diazepin-4-yl]-phenyl-acetic acid
[0337] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.54 (s, 1H),
7.50 (d, J=7.0 Hz, 2H), 7.37 (m, 3H), 7.24 (dd, J=2.4, 8.6 Hz, 2H),
7.06 (d, J=8.6 Hz, 2H), 6.90 (d, J=7.9 Hz, 2H), 6.72 (d, J=8.6 Hz,
1H), 6.32 (s, 1H), 5.10 (m, 1H), 1.13 (s, 9H). Mass spectrum (LCMS,
ESI pos) Calcd. for C.sub.27H.sub.25N.sub.2O.sub.4Cl.sub.2: 476.2;
Found: 477.1(M+H).
Example 98
[7-sec-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4-
]diazepin-4-yl]-phenyl-acetic acid
[0338] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.51 (s, 1H),
7.49 (d, J=7.0 Hz, 2H), 7.36 (m, 4H), 7.20 (m, 1H), 7.03 (m, 3H),
6.86 (m, 1H), 6.73 (m, 1H), 6.31 (s, 1H), 5.11 (s, 1H), 2.45 (m,
1H), 1.44 (m, 1H), 1.28 (m, 1H), 1.06 (m, 3H), 0.45 (m, 3H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.27H.sub.25N.sub.2O.sub.4Cl: 476.2; Found: 477.1(M+H).
Example 99
[7-sec-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4-
]diazepin-4-yl]-(chloro-phenyl)-acetic acid
[0339] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.54 (s, 1H),
7.53 (d, J=8.6 Hz, 2H), 7.44 (m, 3H), 7.21-6.99 (m, 5H), 6.71 (m,
1H), 6.19 (s, 1H), 5.23 (s, 1H), 2.44 (m, 1H), 1.45 (m, 1H), 1.29
(m, 1H), 1.05 (m, 3H), 0.45 (m, 3H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.27H.sub.24N.sub.2O.sub.4Cl.sub.2: 510.1; Found:
511.1(M+H).
Example 100
(4-Bromo-phenyl-3-(4-chloro-phenyl)-7-isopropyl-2,5-oxo-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]acetic acid
[0340] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.53 (s,
0.7H), 10.34 (s, 0.3H), 7.54 (m, 2H), 7.46 (d, J=8.6 Hz, 2H),
7.36-7.24(m, 2H), 7.09 (m, 3H), 6.96 (m, 1H), 6.72 (d, J=8.4 Hz,
0.7H), 6.64 (d, J=8.4 Hz, 0.3H), 6.30 (s, 0.3H), 6.17 (s, 0.7H),
5.65 (s, 0.3H), 5.24 (s, 0.7H), 2.72 (m, 1H), 1.03 (m, 6H).
[0341] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.22N.sub.2O.sub.4ClBr: 540.0; Found: 541.0(M+H).
Example 101
[3-(4-Bromo-phenyl)-7-isopropyl-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]-
diazepin-4-yl]-(4chloro-phenyl)-acetic acid
[0342] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.52 (s,
0.7H), 10.34 (s, 0.3H), 7.52 (d, J=8.4 Hz, 1H), 7.41 (m, 3H),
7.28-7.21(m, 3H), 7.12-7.03 (m, 2H), 6.91 (m, 1H), 6.72 (d, J=8.6
Hz, 0.7H), 6.64 (d, J=8.6 Hz, 0.3H), 6.30 (s, 0.3H), 6.17 (s,
0.7H), 5.65 (s, 0.3H), 5.24 (s, 0.7H), 2.73 (m, 1H), 1.03 (m, 6H).
Mass spectrum (LCMS, EST pos) Calcd. for
C.sub.26H.sub.22N.sub.2O.sub.4ClBr: 540.0; Found: 541.0(M+H).
Example 102
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-cyclopropyl-2,5-dioxo-1,2,3,5-tet-
rahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0343] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.53 (s,
0.7H), 10.35 (s, 0.3H), 7.50 (d, J=8.4 Hz, 1H), 7.39 (m, 2H),
7.21-7.09 (m, 4H), 6.92 (m, 3H), 6.70 (d, J=8.4 Hz, 0.7H), 6.61 (d,
J=8.4 Hz, 0.3H), 6.31 (s, 0.3H), 6.22 (s, 0.7H), 5.67 (s, 0.3H),
5.23 (s, 0.7H), 1.80 (m, 1H), 0.86 (m, 2H), 0.5 (m, 1H), 0.42 (m,
1H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.20N.sub.2O.sub.4Cl.sub.2: 494.1; Found:
495.0(M+H).
Example 103
[3-(4-Chloro-phenyl)-7-cyclopropyl-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1-
,4]diazepin-4-yl]phenyl-acetic acid
[0344] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.51 (s,
0.7H), 10.30 (s, 0.3H), 7.47 (d, J=7.0 Hz, 2H), 7.38-7.08 (m, 5H),
7.04 (d, J=8.6 Hz, 2H), 6.88 (m, 2H), 6.70 (d, J=8.4 Hz, 0.7H),
6.61 (d, J=8.4 Hz, 0.3H), 6.34 (br s, 1H), 5.71 (s, 0.3H), 5.16 (s,
0.7H), 1.79 (m, 1H), 0.85 (m, 2H), 0.53 (m, 1H), 0.44(m, 1H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.21N.sub.2O.sub.4Cl: 460.1; Found: 461.1(M+H).
Example 104
[3-(4-Chloro-3-fluoro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e]-
[1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
[0345] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.56 (s,
0.9H), 10.36 (s, 0.1H), 7.50 (m, 3H), 7.34 (m, 2H), 7.17 (m, 2H),
7.05-6.80 (m, 3H), 6.37 (s, 1H), 5.19 (s, 1H). Mass spectrum (LCMS,
ESI pos) Calcd. for C.sub.23H.sub.14N.sub.2O.sub.4Cl.sub.2F: 597.9;
Found: 598.9(M+H).
Example 105
(2,5-Dioxo-3-phenyl-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-phenyl--
acetic acid
[0346] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.79 (s,
0.9H), 10.61 (s, 0.1H), 7.77 (s, 1H), 7.53 (m, 4H), 7.38 (m, 4H),
7.03 (m, 2H), 6.81 (m, 2H), 6.67 (d, J=8.6 Hz, 0.9H), 6.58 (d,
J=8.6 Hz, 0.1H), 6.27 (s, 0.1H), 6.16 (s, 0.9H), 5.64 (s, 0.1H),
5.30 (s, 0.9H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.18N.sub.2O: 386.1; Found: 387.1(M+H).
Example 106
[3-(4-Chlorophenyl)-7-phenyl-2,5-dioxo-1,2,3,5tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-phenylacetic acid
[0347] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.60 (s,
0.8H), 10.50 (s, 0.2H), 7.82 (s, 1H), 7.52 (m, 4H), 7.41(m, 2H),
7.33 (m, 5H), 7.02 (d, J=8.2 Hz, 2H), 6.91 (d, J=8.3 Hz, 1H), 6.82
(m, 2H), 6.39 (bs, 1H), 5.25 (bs, 1H).
[0348] Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.29H.sub.21ClN.sub.2O.sub.4: 496.10. Found: 497.0 (M+H).
Example 107
[3-(4-Chlorophenyl)-7-(4-methylphenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[-
e][1,4]diazepin-4-yl]-phenylacetic acid
[0349] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.67 (bs, 1H),
7.77 (m, 1H). 7.49 (m, 3H), 7.41 (m, 4H), 7.25 (m, 4H), 7.06 (m,
2H), 6.90 (d, J=8.9 Hz, 2H), 6.39 (bs, 1H), 5.20 (bs 1H), 2.32 (s,
3H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.30H.sub.23ClN.sub.2O.sub.4: 510.10. Found: 511.0 (M+H).
Example 108
[3-(4-Chlorophenyl)-7-(3-methylphenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[-
c][1,4]diazepin-4-yl]-phenylacetic acid
[0350] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.60 (bs, 1H),
7.92 (m, 1H), 7.63 (m, 2H), 7.43 (m, 4H), 7.29 (m, 5H), 7.16 (m,
1H), 7.04 (m, 1H), 6.89 (m, 2H), 6.53 (bs, 1H), 5.40 (bs, 1H), 2.40
(s, 3H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.30H.sub.23ClN.sub.2O.sub.4: 510.10. Found: 511.0 (M+H).
Example 109
[3-(4-Chlorophenyl)-7-(4-hydroxyphenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]-phenylacetic acid
[0351] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.73 (bs,
0.85H), 10.56 (s, 0.15H), 9.62 (s, 1H), 7.68 (s, 1H), 7.52 (m, 3H),
7.36 (m, 4H), 7.17 (m, 1H), 7.10 (m, 2H), 6.97 (d, J=7.7 Hz, 2H),
6.87 (d, J=8.5 H, 2H), 6.81 (d, J=8.6 Hz, 2H), 6.37 (bs, 1H), 5.14
(bs, 1H), 2.40. Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.29H.sub.21ClN.sub.2O.sub.5: 512.15. Found: 513.1 (M+H).
Example 110
[3-(4-Chlorophenyl)-7-(4-hydroxycarbonylphenyl)-2,5-dioxo-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]-phenylacetic acid
[0352] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.1 (bs, 1H),
10.80 (bs, 0.4H), 10.59 (s, 0.6H), 7.98 (d, J=6.5 Hz, 2H), 7.85 (d,
J=9.5 Hz, 1H), 7.65 (m, 3H), 7.50 (d, J=8.0 Hz, 1H), 7.34 (m, 4H),
7.24 (d, J=7.2 Hz, 1H), 7.14 (d, J=8.6 Hz, 1H), 7.07 (d, J=7.7 Hz,
1H), 6.94 (m, 1H), 6.37 (d, J=14.8 Hz, 1H), 5.76 (s, 1H). Mass
spectrum (LCMS, ESI pos.) Calcd. For
C.sub.30H.sub.21ClN.sub.2O.sub.6: 540.16. Found: 541.0 (M+H).
Example 111
(4-Chlorophenyl)-[3-(4-chlorophenyl)-7-iodo-5-oxo-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]acetic acid
[0353] .sup.1H NMR (400 MHz, d.sub.6-DMSO): Major (75%): .delta.
8.25 (d, J=2.2 Hz, 1H), 7.22 (d, J=8.4 Hz, 2H), 7.19 (dd, J=8.8 Hz,
J=2.2 Hz, 1H), 7.08 (d, J=8.3 Hz, 2H), 6.99 (d, J=8.4 Hz, 2H), 6.93
(br m, 1H), 6.77 (d, J=7.9 Hz, 2H), 6.27 (d, J=8.7 Hz, 1H), 6.15
(br s, 1H), 5.02 (s, 1H), 3.89 (br m, 2H). Minor (25%): 7.97 (d,
J=2.1 Hz, 1H), 7.43 (d, J=8.6 Hz, 2H), 7.36 (d, J=8.5 Hz, 1H), 7.14
(d, J=8.4 Hz, 2H), 7.11 (dd, J=8.8 Hz, J=2.2 Hz, 2H), 6.93 (br m,
1H), 6.19 (d, J=8.8 Hz, 1H), 6.15 (br s, 1H), 5.23 (s, 1H), 3.89
(br m, 2H). Mass Spectrum (LCMS, ESI pos.): Calcd. For
C.sub.23H.sub.17Cl.sub.2IN.sub.2O.sub.3: 565.97; found: 566.94
(M+H).
Example 112
[3-(4-Chlorophenyl)-2,5-dioxo-8-phenyl-1,2,3,5-tetrahydro-benzo[e][1,4]dia-
zepin-4-yl]-phenylacetic acid
[0354] .sup.1H NMR (400 MHz, d.sub.6-DMSO): .delta.10.41 (s, 1H),
7.73-7.61 (m, 1H), 7.57-7.32 (m, 8H), 7.28-7.02 (m, 5H), 6.98 (d,
J=8.7 Hz, 1H), 6.72 (d, J=7.8 Hz, 1H), 6.32 (s, 1H), 5.29 (s, 1H).
Mass Spectrum (LCMS, ESI pos.): Calcd. for
C.sub.29H.sub.21ClN.sub.2O.sub.4: 496.12; found: 497.12 (M+H).
Example 113
[7-Benzo[1,3]dioxol-5-yl-2,5-dioxo-3-(4-trifluoromethyl-phenyl)-1,2,3,5-te-
trahydro-benzo[c][1,4]diazepin-4-yl]-phenylacetic acid
[0355] .sup.1H NMR (400 MHz, d.sub.6-DMSO): Major (67%): .delta.
10.84 (s, 1H), 7.65 (d, J=2.1 Hz, 1H), 7.56-7.34 (m, 9H), 7.23 (d,
J=8.1 Hz, 1H), 7.05 (s, 1H), 6.99-6.93 (m, 2H), 6.86 (d, J=8.5 Hz,
1H), 6.37 (s, 1H), 5.20 (s, 1H). Minor (33%): 10.69 (s, 1H), 7.70
(d, J=2.1 Hz, 1H), 7.56-7.34 (m, 9H), 7.23 (d, J=8.1 Hz, 1H), 7.09
(s, 1H), 6.99-6.93 (m, 2H), 6.81 (d, J=8.3 Hz, 1H), 6.34 (s, 1H),
5.40 (s, 1H). Mass Spectrum (LCMS, ESI pos.): Calcd. for
C.sub.31H.sub.21F.sub.3N.sub.2O.sub.6: 574.14; found: 574.98
(M+H).
Example 114
3-(4-Chloro-phenyl)-3-[3-(4-chloro-phenyl)-7-iodo-5-oxo-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]-propionic acid
[0356] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.17 (d, J=2.0
Hz, 1H), 7.33 (d, J=8.8 Hz, 2H), 7.19-6.96 (m, 4H), 6.75 (d, J=8.8
Hz, 1H), 6.39-6.29 (m, 1H), 6.21 (d, J=8.8 Hz, 1H), 4.92 (d, J=5.2
Hz, 1H), 4.08-3.96 (m, 1H), 3.46-3.36 (m, 2H), 2.93-2.75 (m,
2H).
[0357] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.19O.sub.2IN.sub.2O.sub.3: 579.98; Found: 580.8
(M+H).
Example 115
2-[3-(4-Chloro-phenyl)-7-iodo-2,3-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4yl]-3-naphthalen-2-yl-propionic acid
[0358] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.77 (s, 0.7
H), 10.42 (s, 0.3 H), 7.87-7.84 (m, 1.0 H), 7.82-7.68 (m, 3.0 Hz),
7.66-7.62 (m, 0.7 H), 7.58 (bs, 0.3 H), 7.55 (d, J=2.0 Hz, 1.0 H),
7.51-7.36 (m, 3.0H), 7.20-7.07 (m, 3.0 H), 6.92 (bs, 1.0H),
6.56-6.52 (m, 1.0 H), 5.80 (bs, 0.7 H), 5.58 (bs, 0.7H), 5.44 (bs,
0.3H) 5.38 (bs, 0.3H) 3.62-3.08 (m, 2.0H). Mass spectrum (LCMS, ESI
pos.) Calcd For C.sub.28H.sub.20ClIN.sub.2O.sub.4: 610.02 Found:
610.94 (M+H).
Example 116
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]-3-naphthalen-2-yl-propionic acid
[0359] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.77 (s,
0.7H), 10.44 (s, 0.3H), 7.92-7.55 (m, 5.0 H), 7.56-7.36 (m, 4.0H),
7.31-7.19 (bs, 1.0 H), 7.12-6.96 (m, 2.0H), 6.93-6.82 (m, 1.0H),
6.58-6.46 (m, 1.0H), 5.80 (bs, 0.7H), 5.67-5.57 (m, 0.7H), 5.49 (s,
0.3H), 5.43-5.35 (m, 0.3H), 3.71-3.52 (m, 1.0H), 3.21-3.08 (m,
1.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.29H.sub.20F.sub.3IN.sub.2O.sub.5: 660.04. Found: 660.98
(M+H).
Example 117
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-3-naphthalen-1-yl-propionic acid
[0360] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.94 (s,
0.7H), 10.39 (s, 0.3H), 8.32 (d, J=8.8 Hz, 0.7 H), 8.27-8.15 (m,
0.3H), 7.97-7.83 (m, 1.0H), 7.84-7.73 (m, 0.3H), 7.73-7.65 (m,
0.7H), 7.62-7.44 (m, 3.0H), 7.40-7.23 (m, 3.0H), 7.22-7.07 (m,
3.0H), 6.64-6.54 (m, 1.0H), 5.87 (bs, 1.0H), 5.62 (bs, 1.0H), 5.36
(bs, 0.6H), 5.20 (bs, 0.4H), 3.89-3.52 (m, 2.0H). Mass spectrum
(LCMS, ESI pos.) Calcd. For C.sub.28H.sub.20ClIN.sub.2O.sub.4:
610.02. Found: 610.92 (M+H).
Example 118
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]-3-naphthalen-1-yl-propionic acid
[0361] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.94 (s,
0.7H), 10.40 (s, 0.3H), 8.34 (d, J=8.4 Hz, 0.7H), 8.21 (b, 0.3H),
7.88 (d, J=8.0 Hz, 1.0H), 7.78 (d, J=7.2 Hz, 0.3H), 7.69 (d, J=8.4
Hz, 0.7H), 7.72-7.68 (m, 5.0H), 7.67-7.22 (m, 4.0H), 7.07 (d, J=8.4
Hz, 1.0H), 7.04-7.00 (m, 0.3H), 6.58 (d, J=8.8 Hz, 0.7H), 5.90 (bs,
0.7H), 5.70-5.63 (m, 0.7H), 5.46-5.37 (m, 0.3H), 5.26-5.16 (m,
0.3H), 3.97-3.60 (m, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd.
For C.sub.29H.sub.20F.sub.3IN.sub.2O.sub.5: 660.04; Found:
660.99(M+H).
Example 119
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e[1,4]diaze-
pin-4-yl]-(4-fluoro-phenyl)-acetic acid
[0362] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.62 (s,
0.6H), 10.50 (s, 0.4H), 7.80 (d, J=2 Hz, 0.6H), 7.72 (d, J=2.4 Hz,
0.4H), 7.58-7.47 (m, 2.0H), 7.44-7.32 (m, 1.0H), 7.25-7.03 (m,
4.0H), 6.87-6.75 (m, 1.0H), 6.64 (d, J=8.4 Hz, 0.6H), 6.55 (d,
J=8.4 Hz, 0.4H), 6.29 (d, J=6 Hz, 1.0H), 5.80 (s, 0.6H), 5.76 (s,
0.4H, 5.22 (1.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.23H.sub.15ClFIN.sub.2O.sub.4: 563.97; Found: 564.84
(M+H).
Example 120
(4-Fluoro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5--
tetrahydrobenzo[e][1,4]diazepin-4-yl]-acetic acid
[0363] .sup.1H NMR (400 DMSO-d.sub.6): .delta. 10.63 (s, 0.7H),
10.48 (s, 0.3H), 7.75 (d, J=2 Hz, 0.7H), 7.67 (d, J=2 Hz, 0.3H),
7.59-7.46 (m, 2.3H), 7.43-7.36 (m, 0.7H), 7.29 (d, J=8.4 Hz, 0.7H),
7.16-7.06 (m, 2.3H), 7.03-6.97 (d, J=8.4 Hz, 1.0H), 6.93-6.87 (d,
J=8.4 Hz, 1.0H), 6.63 (d, J=8.8 Hz, 0.7H), 6.53 (d, J=8.8 Hz,
0.3H), 6.32 (s, 0.3H), 6.28 (s, 0.7H), 5.83 (s, 1.0H), 5.76 (s,
0.3H), 5.25 (s, 0.7H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.24H.sub.15F.sub.4IN.sub.2O.sub.5: 614.00; Found:
614.94(M+H).
Example 121
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5tetrahydrobenzo[e-
][1,4]diazepin-4-yl]-3-(4-iodo-phenyl)-propionic acid
[0364] .sup.1H NMR (400 M&z, DMSO-d.sub.6): .delta. 10.72 (s,
0.8H), 10.49 (s, 0.2H), 7.68 (s, 0.4H), 7.60-7.49 (m, 2.6H),
7.49-7.43 (m, 1.0H), 7.27-7.20 (m, 3.0H), 7.11-7.04 (m, 3.0H), 7.00
(d, J=8 Hz, 0.2H), 6.53 (d, J=8.8 H, 0.8H), 5.73 (s, 1.0H),
5.56-5.45 (m, 0.8H), 5.40 (s, 0.2H), 2.95-2.84 (m, 2.0H). Mass
spectrum (LCMS, ESI pos.) Calcd. For
C.sub.25H.sub.17F.sub.3I.sub.2N.sub.2O.sub.5: 735.92. Found: 736.83
(M+H).
Example 122
3-(4-Bromo-phenyl)-2-[7-iodo-2,5-dioxo-3(4-trifluoromethoxy-phenyl)-1,2,3,-
5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-propionic acid
[0365] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.70 (s,
0.4H), 10.47 (s, 0.6H), 7.69 (d, J=2Hz, 0.6H), 7.48 (d, J=2 Hz,
0.4H), 7.51-7.43 (m, 1.0H), 7.39-7.33 (m, 2.0H), 7.29-7.12 (m,
3.0H), 7.09-6.99 (m, 2.0H), 6.60-6.50 (m, 1.0H), 5.76 (s, 1.0H),
5.53 (bs, 0.6H), 5.39 (s, 0.4H), 5.10 (bs, 1.0H), 3.17 (d, J=5.12
Hz, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.25H.sub.17BrF.sub.3IN.sub.2O.sub.5: 687.93. Found: 688.80
(M+H).
Example 123
3-(4-Bromo-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5dioxo-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]-propionic acid
[0366] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.73 (s,
0.61H), 10.50 (s, 0.4H), 7.73 (d, J=2 Hz, 0.4H), 7.60 (d, J=2 Hz,
0.6H), 7.55-7.45 (m, 1.0H), 7.41-7.32 (m, 2.0), 7.25-7.03 (m,
6.0H), 6.55 (d, J=8.4 Hz, 1.0H), 5.70 (s, 0.6H), 5.55-5.46 (m,
0.6H), 5.35 (s, 0.4H), 5.10 (bs, 0.4H), 3.20-2.84 (m, 2.0H),
[0367] Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.24H.sub.17BrClIN.sub.2O.sub.4: 637.91. Found:
638.82(M+H).
Example 124
2-[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]-3-thiophen-2-yl-propionic acid
[0368] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.83 (s,
0.7H), 10.59 (s, 0.3H), 7.73 (bs, 0.3H), 7.70-7.66 (m, 0.7H),
7.60-7.55 (m, 0.3H), 7.51 (dd, J=2.0 Hz, 8.0 Hz, 0.7H), 7.32 (d,
J=5.2 Hz, 0.3H), 7.30-7.25 (m, 1.7H), 7.19-7.04 (m, 4.0H),
6.92-6.84 (m, 2.0H), 5.69 (s, 0.7H), 5.48-5.41 (m, 1.0H), 5.19 (bs,
0.3H), 3.56-3.15 (m, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd.
For C.sub.23H.sub.16FIN.sub.2O.sub.5S: 615.98. Found: 616.75
(M+H).
Example 125
[3-4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaze-
pin-4-yl]-(4-trifluoromethyl-phenyl)-acetic acid
[0369] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.61 (s,
0.6H), 10.58 (s, 0.4H), 7.80 (d, J=2.4 Hz, 0.6H), 7.73 (d, J=2.0
Hz, 0.4H), 7.72-7.62 (m, 3.0H), 7.58-7.50 (m, 2.0H), 7.18 (s,
2.0H), 7.06 (d, J=8.4 Hz, 1.0H), 6.88-6.82 (m, 1.0H), 6.63 (d,
J=8.4 Hz, 0.6H), 6.53 (d, J=8.4 Hz, 0.4H), 6.37 (s, 0.4H), 6.27 (s,
0.6H), 5.76 (s, 0.4H), 5.28 (s, 0.6H). Mass spectrum (LCMS, ESI
pos.) Calcd. For C.sub.24H.sub.15ClF.sub.2N.sub.2O.sub.4: 613.97.
Found: 614.86 (M+H).
Example 126
2-[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-3-thiophen-2-yl-propionic acid
[0370] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.85 (s,
0.7H), 10.59 (s, 0.3H), 7.75-7.71 (m, 1.0H), 7.70-7.66 (m, 1.0H),
7.60-7.49 (m, 1.0H), 7.32 (d, J=5.2 Hz, 0.3H), 7.30-7.25 (m, 0.7H),
7.19-7.03 (m, 3.0H), 6.93-6.84 (m, 1.0H), 6.78 (d, J=8.0 Hz, 0.7H),
6.65 (d, J=8.8 Hz, 0.3H), 6.58 (d, J=8.4 Hz, 1.0H), 5.57 (s, 0.7H),
5.53-5.47 (m, 0.7H), 5.41 (s, 0.3H), 5.28-5.21 (bs, 0.3H),
3.62-3.54 (m, 2.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.22H.sub.16ClIN.sub.2O.sub.4S: 565.96. Found: 566.90 (M+H),
591.32 (M+Na).
Example 127
[7-Iodo-2,5-dioxo-3-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo[e][1-
,4]diazepin-4-yl]-(4-trifluoromethyl-phenyl)-acetic acid
[0371] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.66 (s,
0.8H), 10.57 (s, 0.2H), 7.79-7.74 (d, J=2.0 Hz, 1.0H), 7.73-7.61
(m, 4.0H), 7.56-7.49 (dd, J=1.6 Hz, 8.4 Hz, 1.0H), 7.03-6.92 (m,
3.01H), 6.62 (d, J=8.4 Hz, 2.0H), 6.27 (bs, 1.0H), 5.93 (s, 0.4H),
5.38 (s, 0.6H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.25H.sub.15F.sub.6IN.sub.2O.sub.5: 663.99. Found: 664.89
(M+H).
Example 128
(4-Chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5--
tetrahydrobenzo[e][1,4]diazepin-4-yl]-acetic acid
[0372] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.53 (s,
0.6H), 10.49 (s, 0.4H), 7.74 (d, J=2.3 Hz, 0.6H), 7.66 (d, J=2.1
Hz, 0.4H), 7.53-7.47 (m, 2.0H), 7.38-7.32 (m, 2.0H), 7.28 (d, J=8.8
Hz, 1.0H), 7.09 (d, J=8.8 Hz, 1.0H), 7.05-6.88 (m, 3.0H), 6.62 (d,
J=8.8 Hz, 0.6H), 6.53 (d, J=9.6 Hz, 0.4H), 6.28 (s, 0.4H), 6.20 (s,
0.6H), 5.89 (s, 0.4H), 5.23 (s, 0.6H). Mass spectrum (LCMS, ESI
pos.) Calcd. For C.sub.24H.sub.15ClF.sub.3N.sub.2O.sub.5: 629.97.
Found: 630.89 (M+H).
Example 129
(4-Chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethyl-phenyl)-1,2,3,5-t-
etrahydrobenzo[e][1,4]diazepin-4-yl]-acetic acid
[0373] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.60 (s,
0.6H), 10.53 (s, 0.4H), 7.78 (d, J=2.0 Hz, 0.6H), 7.70 (d, J=2.0
Hz, 0.4H), 7.56-7.45 (m, 3.0H), 7.43-7.31 (m, 4.0H), 7.10-7.00 (m,
1.0H), 6.62 (d, J=8.8 Hz, 1.0H), 6.52 (d, J=8.8 Hz, 0.6H), 6.31 (s,
0.4H), 6.24 (s, 0.6H); 6.02-5.96 (m, 0.4H), 5.31-5.25 (m, 1.0H).
Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.24H.sub.15ClF.sub.3IN.sub.2O.sub.4: 613.97. Found:
614.86(M+H).
Example 130
[3-(4-Bromo-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaze-
pin-4-yl]-(4-chloro-phenyl)-acetic acid
[0374] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.60 (s,
0.7H), 10.48 (s, 0.3H), 7.80 (d, J=2.4 Hz, 0.7H), 7.72 (d, J=2.0
Hz, 0.3H), 7.56-7.45 (m, 2.0H), 7.40-7.27 (m, 3.0H), 7.25-7.18 (m,
1.0H), 7.15-7.09 (m, 1.0H), 6.77 (m, 1.0H), 6.63 (d, J=8.8 Hz,
0.3H), 6.54 (d, J=4.8 Hz, 0.7H), 6.27 (s, 0.3H), 6.22 (s, 0.7H).
5.84 (bs, 1.0H), 5.16 (s, 1.0H). Mass spectrum (LCMS, ESI pos.)
Calcd. For C.sub.23H.sub.15BrClIN.sub.2O.sub.4: 623.89. Found:
626.77 (M+H).
Example 131
[3-(4-Bromo-phenyl)-2,5-dioxo-7-phenyl-1,2,3,5-tetrahydro-benzo[e][1,4]dia-
zepin-4-yl]-(4-chloro-phenyl)-acetic acid
[0375] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.67 (s,
0.7H), 10.53 (s, 0.3H), 7.82 (d, J=2.0 Hz, 0.7H), 7.74 (d, J=2.0
Hz, 0.3H), 7.58-7.49 (m, 4.0H), 7.47-7.40 (m, 3.0H), 7.38-7.30 (m,
3.0H), 7.29-7.24 (m, 1.0H), 7.21-7.14 (m, 2.0H), 6.91 (d, J=8.4 Hz,
1.0H), 6.86-6.79 (m, 1.0H), 6.40 (s, 0.3H), 6.34 (s, 0.7H), 5.81
(s, 0.3H), 5.26 (s, 0.7H). Mass spectrum (LCMS, ESI pos.) Calcd.
For C.sub.29H.sub.20BrClN.sub.2O.sub.4: 574.03. Found: 574.90
(M+H).
Example 132
(4-Chloro-phenyl)-[2,5-dioxo-7-phenyl-3-(4-trifluoromethyl-phenyl)-1,2,3,5-
-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0376] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.69 (s,
0.5H), 10.55 (s, 0.5H), 7.79-7.68 (m, 2.0H), 7.58-7.29 (m, 11.0H),
7.16 (bs, 2.0H), 6.94-6.85 (m, 0.5H), 6.80 (d, J=8.4 Hz, 0.5H),
6.40 (bs, 0.5H), 6.30 (bs, 0.5H), 5.95 (bs, 0.5H), 5.33 (bs, 0.5H).
Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.30H.sub.20ClF.sub.3N.sub.2O.sub.4: 564.11. Found: 565.02
(M+H).
Example 133
(4-Chloro-phenyl)-[2,5-dioxo-7-phenyl-3-(4-trifluoromethoxy-phenyl)-1,2,3,-
5-tetrahydrobenzo[e][1,4]diazepin-4-yl]-acetic acid
[0377] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.63 (s,
0.4H), 10.50 (s, 0.6H), 7.73 (d, J=2.4 Hz, 0.4H), 7.66 (d, J=2.4
Hz, 0.6H), 7.60-7.28 (m, 11.0H), 7.05 (d, J=8.4 Hz, 2.0H), 6.99 (s,
1.0H), 6.90 (d, J=8.0 Hz, 0.6H), 6.80 (d, J=8.4 Hz, 0.4H), 6.40
(bs, 0.6H), 6.29 (bs, 0.4H), 5.87 (bs, 0.6H), 5.30 (bs, 0.4H). Mass
spectrum (LCMS, ESI pos.) Calcd. For
C.sub.30H.sub.20ClF.sub.3N.sub.2O.sub.5: 580.10. Found: 581.00
(M+H).
Example 134
(4-Chlorophenyl)-[3-(4-chloro-phenyl)-2,5-dioxo-7-phenyl-1,2,3,5-tetrahydr-
o-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0378] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.62 (s,
0.4H), 10.51 (s, 0.6H), 7.81 (d, J=1.6 Hz, 0.4H), 7.73 (d, J=2.4
Hz, 0.6H), 7.59-7.48 (m, 4.0H), 7.47-7.30 (m, 5.0H), 7.23 (d, J=8.4
Hz, 1.0H), 7.13. (d, J=8.4 Hz, 2.0H), 7.06(d, J=8.8 Hz, 2.0H), 6.91
(d, J=8.0 Hz, 1.0H), 6.82 (d, J=8.4 Hz, 1.0H), 6.39 (bs, 0.6H),
6.33 (bs, 0.4H), 5.84 (bs, 0.4H), 5.27 (bs, 0.6H). Mass spectrum
(LCMS, ESI pos.) Calcd For C.sub.29H.sub.20Cl.sub.2N.sub.2O.sub.4:
530.08. Found: 531.01(M+H).
Example 135
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-thiophen-2-yl-acetic acid
[0379] .sup.1H NMR (400 MHz, DMSO-d.sub.4): .delta. 10.62 (s,
0.8H), 10.52 (s, 0.2H), 7.80 (d, J=2.4 Hz, 0.8H), 7.73 (d, J=2.4
Hz, 0.21H), 7.56-7.51 (m, 1.0H), 7.37 (d, J=8.4 Hz, 1.0H),
7.19-7.15 (m, 1.0H), 7.10 (d, J=8.6 Hz, 2.0H), 6.95-6.91 (m, 1.0H),
6.80 (d, J=8.4 Hz, 2.0H), 6.65 (d, J=8.6 Hz, 0.8H), 6.58 (d, J=8.4
Hz, 0.2H), 6.44 (bs, 0.6H), 5.85 (bs, 0.4H), 5.50 (bs, 1.0H).
[0380] Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.21H.sub.14ClIN.sub.2O.sub.4S: 551.94. Found: 552.83
(M+H).
Example 136
[7-Iodo-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo[e-
][1,4]diazepin-4-yl]-thiophen-2-yl-acetic acid
[0381] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.65 (s,
0.8H), 10.52 (s, 0.2H), 7.74 (d, 2.0 Hz, 0.8H), 7.68 (d, J=2.0 Hz,
0.2H), 7.55-7.49 (m, 1.0H), 7.42-7.37 (m, 1.0H), 7.28 (d, J=8.4 Hz,
0.2H), 7.20 (d, J=2.8 Hz, 0.8H), 7.13-6.99 (m, 2.0H), 6.96-6.87 (m,
3.0H), 6.64 (d, J=8.8 Hz, 0.8H), 6.56 (d, J=8.8 Hz, 0.2H), 6.44
(bs, 0.8), 5.88 (bs, 0.2H), 5.55 (bs, 1.0H). Mass spectrum (LCMS,
ESI pos.) Calcd. For C.sub.22H.sub.14F.sub.2N.sub.2O.sub.5S:
601.96. Found: 602.81(M+H).
Example 137
(3-Biphenyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl-
}-(4chloro-phenyl)-acetic acid
[0382] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.63 (s,
0.7H), 10.52 (s, 0.3H), 7.82 (d, J=2.0 Hz, 0.7H), 7.74 (d, J=2.4
Hz, 0.3H), 7.57-7.22 (m, 12.0H), 6.86 (d, J=7.6 Hz, 2.0H), 6.66 (d,
J=7.6 Hz, 0.7H), 6.56 (d, J=8.8 Hz, 0.3H), 6.33 (bs, 0.7H), 5.95
(bs, 0.3H), 5.29 (bs, 1.0H). Mass spectrum (LCMS, ESI pos.) Calcd.
For C.sub.29H.sub.20ClIN.sub.2O.sub.4: 622.02. Found: 622.91
(M+H).
Example 138
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-(4-ethyl-phenyl)-acetic acid
[0383] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.68 (s,
0.8H), 10.51 (s, 0.2H), 7.79 (d, J=2.0 Hz, 0.8H), 7.73 (d, J=2.0
Hz, 0.2H), 7.56-7.49 (m, 1.0H), 7.39 (d, J=8.0 Hz, 2.0H), 7.29-7.15
(m, 1.0H), 7.12 (d, J=8.0 Hz, 2.0H), 7.06 (d, J=8.4 Hz, 1.0H), 6.77
(d, J=8.0 Hz, 2.0), 6.64 (d, J=8.4 Hz, 0.8H), 6.55 (d, J=8.8 Hz,
0.2H), 6.30 (bs, 1.0H), 5.82 (bs, 0.2H), 5.21 (bs, 0.8H), 2.62-2.51
(m, 2.0H), 1.21-1.14 (m, 3.0H). Mass spectrum (LCMS, ESI pos.)
Calcd. For C.sub.25H.sub.20ClIN.sub.2O.sub.4: 574.02. Found: 574.94
(M+H).
Example 139
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-(3,4-dichloro-phenyl)acetic acid
[0384] .sup.1H NMR (400 DMSO-d.sub.6): .delta. 10.70 (s, 0.6H),
10.64 (s, 0.4H), 7.79 (d, J=2.0 Hz, 1.0H), 7.81-7.78 (m, 1.0H),
7.61-7.46 (m, 2.0H), 7.40-7.31 (m, 1.0H), 7.18 (s, 1.0H), 7.13 (d,
J=8.4 Hz, 1.0H), 7.04-7.00 (m, 1.0H), 6.63 (d, J=8.4 Hz, 1.0H),
6.56 (d, J=8.8 Hz, 0.6H), 6.29 (bs, 0.4H), 6.12 (bs, 0.6H), 5.80
(bs, 0.4H), 5.32 (bs, 1.0H). Mass spectrum (LCMS, ESI pos.) Calcd.
For C.sub.23H.sub.14Cl.sub.3IN.sub.2O.sub.4: 613.91. Found: 614.84
(M+H).
Example 140
(2-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0385] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.61 (s,
0.2H), 10.55 (s, 0.8H), 7.77 (d, J=2.4 Hz, 1.0H), 7.60-7.49 (m,
2.0H), 7.44-7.30 (m, 4.0H), 7.16 (d, J=8.8 Hz, 1.0H), 7.11 (d,
J=8.4 Hz, 0.2H), 6.89 (d, J=8.0 Hz, 0.8H), 6.61 (d, J=8.8 Hz,
1.0H), 6.55 (d, J=8.8 Hz, 1.0H), 6.29 (bs, 1.0H), 5.23 (bs, 0.8H),
5.10 (bs, 0.2H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.23H.sub.15Cl.sub.2IN.sub.2O.sub.4: 579.95. Found: 580.92
(M+H).
Example 141
(4-tert-Butyl-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrah-
ydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0386] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.62 (s,
0.7H), 10.55 (s, 0.3H), 7.77 (d, J=2.0 Hz, 0.7H), 7.75-7.67 (m,
0.3H), 7.55-7.48 (m, 1.0H), 7.39 (d, J=8.4 Hz, 2.0H), 7.29 (d,
J=8.4 Hz, 2.0H), 7.25-7.14 (m, 1.0H), 7.02 (d, J=8.0 Hz, 2.0H),
6.92 (d, J=8.0 Hz, 0.3H), 6.73-6.62 (m, 3.0H), 6.54 (d, J=8.4 Hz,
0.7H), 6.27 (s, 1.0H), 5.92 (bs, 0.3H), 5.27 (bs, 0.7H), 1.27 (s,
1.0H), 1.20 (s, 9.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.27H.sub.24ClIN.sub.2O.sub.4: 602.05. Found: 602.99 (M+H).
Example 142
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-4-isopropyl-phenyl)acetic acid
[0387] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.69 (s,
0.8H), 10.54 (s, 0.2H), 7.79 (d, J=2.0 Hz, 0.8H), 7.73 (d, J=2.0
Hz, 0.2H), 7.57-7.50 (m, 1.0H), 7.39 (d, J=8.0 Hz, 2.0H), 7.27 (d,
J=8.0 Hz, 0.8H), 7.21 (d, J=8.4 Hz, 0.2H), 7.14 (d, J=8.0 Hz,
2.0H), 7.03 (d, J=8.4 Hz, 2.0H), 6.72 (d, J=8.8 Hz, 1.0H), 6.65 (d,
J=8.8 Hz, 1.0H), 6.54 (d, J=8.8 Hz, 0.2H), 6.30 (bs, 0.8H), 5.86
(s, 0.2H), 5.27 (bs, 0.8H), 2.88-2.76 (m, 1.0H), 1.18 (d, J=8.8 Hz,
1.2H), 1.11 (d, J=6.8 Hz, 6.0H). Mass spectrum (LCMS, ESI pos.)
Calcd. For C.sub.26H.sub.22ClIN.sub.2O.sub.4: 588.03. Found: 588.95
(M+H).
Example 143
(3-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0388] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.69 (s,
0.7H). 10.60 (s, 0.3H), 7.80 (d, J=2.0 Hz, 0.7H), 7.73 (d, J=2.4 Hz
0.3H), 7.57-7.50 (m, 2.0H), 7.49-7.44 (m, 0.7H), 7.41 (s, 0.3H),
7.35-7.29 (m, 3.0H), 7.18 (s, 1.0H), 6.92 (d, J=8.0 Hz, 2.0H), 6.63
(d, J=8.8 Hz, 0.7H), 6.56 (d, J=8.4 Hz, 0.3H), 6.31 (bs, 0.3H),
6.23 (bs, 0.7H), 5.84 (bs, 0.3H), 5.26 (bs, 0.7H). Mass spectrum
(LCMS, ESI pos.) Calcd. For
C.sub.23H.sub.15Cl.sub.2IN.sub.2O.sub.4: 579.95. Found: 581.00
(M+H).
Example 144
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-(4-trifluoromethoxy-phenyl)-acetic acid
[0389] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.72 (s,
0.8H), 10.59 (s, 0.2H), 7.80 (d, J=2.0 Hz, 0.8H), 7.74 (d, J=2.0
Hz, 0.2H), 7.61 (d, J=8.8 Hz, 2.0H), 7.57-7.48 (m, 2.0H), 7.28 (d,
J=8.4 Hz, 2.0H), 7.18 (s, 1.0H), 7.07 (d, J=8.4 Hz, 1.0H),
6.85-6.12 (m, 1.0H), 6.65 (d, J=8.4 Hz, 0.8H), 6.55 (d, J=8.4 Hz,
0.2H), 6.35 (bs, 0.2H), 6.31 (bs, 0.8H), 5.77 (bs, 0.2H), 5.31 (bs,
0.8H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.24H.sub.15ClF.sub.3IN.sub.2O.sub.5: 629.97. Found: 630.95
(M+H).
Example 145
(4-Bromo-phenyl)-[3-(4-chlorophenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-b-
enzo[e][1,4]diazepin-4-yl]-acetic acid
[0390] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.69 (s, 0.7),
10.56 (s, 0.3H), 7.79 (d, J=2.0 Hz, 0.7H), 7.73 (d, J=2.0 Hz,
0.3H), 7.58-7.41(m, 5.0H), 7.32 (d, J=8.4 Hz, 1.0H), 7.23 (s,
1.0H), 7.11 (d, J=8.8 Hz, 1.0H), 6.94-6.85 (m, 1.0H), 6.64 (d,
J=8.4 Hz, 0.7H), 6.55 (d, J=8.0 Hz, 0.3H), 6.29 (bs, 0.3H), 6.23
(bs, 0.7H), 5.78 (bs, 0.3H), 5.23 (bs, 0.7H). Mass (LCMS, ESI pos.)
Calcd. For C.sub.21H.sub.15BrClN.sub.2O.sub.4: 623.89. Found:
624.90 (M+H).
Example 146
[3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[c][1,4]diaze-
pin-4-yl]-(3-hydroxy-phenyl)-acetic acid
[0391] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.48 (s,
1.0H), 9.50, (s, 1.0H), 7.78 (d, J=2.0 Hz, 1.0H), 7.54 (dd, J=2.0
Hz, 8.0 Hz, 1.0H), 7.08 (d, J=8.4 Hz, 3.0H), 6.91 (s, 2.0H),
6.84-6.76 (m, 2.0H), 6.69-6.59 (m, 2.0H), 6.26 (bs, 1.0H), 5.24
(bs, 1.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.23H.sub.16ClIN.sub.2O.sub.5: 561.98. Found: 562.89 (M+H).
Example 147
[3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaze-
pin-4-yl]-(4-hydroxy-phenyl)-acetic acid
[0392] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.58 (s,
0.7H), 10.43 (s, 0.3H), 9.43 (s, 0.7H), 9.38 (s, 0.3H) 7.76 (d,
J=2.4 Hz, 1.0H), 7.70 (d, J=1.6 Hz, 0.3H), 7.50 (m, 0.7H), 7.25 (d,
J=8.4 Hz, 2.0H), 7.23-7.11 (m, 3.0H), 7.07 (d, J=2.4 Hz, 1.0H),
6.83-6.76 (m, 1.0H), 6.68-6.60 (m, 2.0H), 6.22 (bs, 1.0H), 6.17 (b,
0.3H), 5.14 (bs, 0.7H). Mass spectrum (MS, ESI pos.) Calcd. For
C.sub.23H.sub.16ClIN.sub.2O.sub.5: 561.98. Found: 562.80 (M+H).
Example 148
(4-Chloro-phenyl)-[3-(4-chloro-3-trifluoromethyl-phenyl)-7-iodo-2,5-dioxo--
1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0393] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.80 (s,
0.6H), 10.63 (s, 0.4H), 7.76-7.69 (m, 1.0H), 7.61-7.44 (m, 3.0H),
7.40 (s, 1.0H), 7.36-7.21 (m, 1.0H), 7.17 (d, J=8.0 Hz, 1.0H),
6.67-6.51 (m, 2.0H), 6.38-6.19 (m, 1.0H), 5.63 (bs, 0.4H), 5.50
(bs, 0.6H), 5.17 (bs, 1.0H). Mass spectrum (LCMS, ESI pos.) Calcd.
For C.sub.24H.sub.14Cl.sub.2F.sub.3IN.sub.4: 647.93. Found:
648.91(M+H).
Example 149
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-cyclohexyl-acetic acid
[0394] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.99 (s,
1.0H), 7.74 (d, J=1.6 Hz, 1.0H), 7.57 (dd, J=2.0 Hz, 8.4 Hz, 1.0H),
7.22 (d, J=8.8 Hz, 2.0H), 6.96 (d, J=8.4 Hz, 2.0H), 6.62 (d, J=8.8
Hz, 1.0H), 5.90 (bs, 1.0H), 5.17-5.10 (m, 1.0H), 1.89-0.87 (m,
11.0H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.23H.sub.22ClIN.sub.2O.sub.4: 552.03. Found: 552.90 (M+H).
Example 150
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-8-methyl-2,5-dioxo-1,2,3,5-t-
etrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0395] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.63 (s,
0.4H), 10.51 (s, 0.6H), 7.93 (s, 0.4H), 7.85 (s, 0.6H), 7.50 (d,
J=8.8 Hz, 1.0H), 7.41-7.31 (m, 3.0H), 7.18 (s, 2.0H), 7.09 (d,
J=8.8 Hz, 1.0H), 6.86-6.81 (m, 0.6H), 6.77 (s, 0.4H), 6.68 (s,
1.0H), 6.35-6.27 (m, 1.0H), 5.78 (bs, 0.6H), 5.25 (bs, 0.4H) 2.18
(s, 1.8H), 2.17 (s, 12H). Mass spectrum (LCMS, ESI pos.) Calcd. For
C.sub.24H.sub.17Cl.sub.2IN.sub.2O.sub.4: 593.96 (M+H). Found:
594.89.
Example 151
[3-(4-Chloro-phenyl)-7,8-difluoro-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,-
4]diazepin-4-yl]-phenyl-acetic acid
[0396] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.6-7.7 (m,
2H), 7.4-7.5 (m, 1H), 7.2-7.4 (m, 4H), 6.9-7.0 (m, 2H), 6.6-6.8 (m,
4H), 5.7 (s, 0.13H), 5.4 (s, 0.87H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.23H.sub.15ClF.sub.2N.sub.2O.sub.4: 456.1; Found:
457.0 (M+H).
Example 152
[7,8-Difluoro-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-b-
enzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0397] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.6 (m, 2H),
7.2-7.5 (m, 5H), 6.6-6.9 (m, 6H), 5.8 (s, 0.1H), 5.4 (s, 0.9H).
(LCMS, ESI pos) Calcd. for C.sub.24H.sub.15F.sub.5N.sub.2O.sub.5:
506.1; Found: 507.1 (M+H).
Example 153
[3-(4-Chloro-phenyl)-7-fluoro-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]di-
azepin-4-yl]-phenyl-acetic acid
[0398] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.6-7.7 (m,
2H), 7.2-7.4 (m, 5H), 6.9-7.1 (m, 2H), 6.6-6.9 (m, 6H), 5.7 (m,
0.1H), 5.4-5.5 (s, 0.9H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.16ClFN.sub.2O.sub.4: 438.1; Found: 439.0 (M+H).
Example 154
[7-Fluoro-2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-benzo-
[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0399] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.6-7.7 (m,
2H), 7.4-7.5 (m, 1H), 7.2-7.4 (m, 5H), 6.9-7.0 (m, 2H), 6.6-6.9 (m,
7H), 5.7 (s, 0.2H), 5.5 (s, 0.8H).). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.24H.sub.16F.sub.4N.sub.2O.sub.5: 488.1; Found:
489.1 (M+H).
Example 155
[7-Acetylamino-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5tetrahydro-benzo[e][1,-
4]diazepin-4-yl]-phenyl-acetic acid
[0400] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.4-7.9 (m,
5H), 7.0-7.3 (m, 3H), 6.6-6.9 (m, 7H), 5.4-5.8 (m, 1H), 1.9-2.2 (s,
3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.20ClN.sub.3O.sub.5: 477.1; Found: 478.0 (M+H).
Example 156
[7-Acetylamino--2,5-dioxo-3-(4-trifluoromethoxy-phenyl)-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0401] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.6-7.9 (m,
3H), 7.2-7.5 (m, 5H), 6.6-6.9 (m, 6H), 5.7 (br s, 1H), 1.9-2.2 (s,
1H). (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.20F.sub.3N.sub.3O.sub.6: 527.1; Found: 528.1
(M+H).
Example 157
[3-(4-Chloro-phenyl)-7-(3-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benz-
o[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0402] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.8-7.9 (s,
1H), 7.6-7.7 (n, 2H), 7.2-7.5 (m, 8H), 6.8-6.9 (m, 3H), 6.7-6.8 (m,
3H), 5.4 (s, 1H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.29H.sub.20Cl.sub.2N.sub.2O.sub.4: 530.1; Found: 531.0
(M+H).
Example 158
[3-(4-Chloro-phenyl)-7-(4-methyl-thiophen-2-yl)-2,5-dioxo-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0403] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.8 (s, 1H),
7.6-7.7 (s, 1H), 7.4-7.5 (m, 5H), 7.2-7.4 (m, 2H), 6.6-6.9 (m, 5H),
5.7 (s, 0.4H), 5.4-5.5 (s, 0.6H), 2.2 (3 H, s). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.28H.sub.21ClN.sub.2O.sub.4S:
516.1; Found: 517.0 (M+H).
Example 159
[3-(4-Chloro-phenyl)-2,5-dioxo-7-thiophen-3-yl-1,2,3,5-tetrahydro-benzo[e]-
[1,4]diazepin-4-yl]-phenyl-acetic acid
[0404] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.9 (s, 1H),
7.6 (s, 1H), 7.4-7.55 (m, 4H), 7.2-7.4 (m, 5H), 7.0-7.1 (m, 1H),
6.8-6.9 (m, 2H), 6.7-6.8 (m, 2H). 5.7 (s, 0.5H), 5.4 (s, 0.5H).
Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.27H.sub.19ClN.sub.2O.sub.4S: 502.1; Found: 503.0 (M+H).
Example 160
[3-(4-Chloro-phenyl)-7-furan-3-yl-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,-
4]diazepin-4-yl]phenyl-acetic acid methyl ester
[0405] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.9 (s, 1H),
7.8 (s, 1H), 7.4-7.7 (m, 8H), 7.0-7.3 (s, 3H), 6.7-6.9 (m, 3H), 5.3
(s, 0.4H), 5.2 (s, 0.6H), 3.8 (s, 3H).
[0406] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.28H.sub.21ClN.sub.2O.sub.5: 500.0; Found: 501.0 (M+H).
Example 161
[3-(4-Chloro-phenyl)-7-furan-3-yl-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,-
4]diazepin-4-yl]-phenyl-acetic acid
[0407] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.8-7.9 (m,
2H), 7.6-7.7 (m, 1H), 7.2-7.5 (m, 7H), 7.0-7.1 (m, 1H), 6.6-6.9 (m,
5H), 5.7 (s, 0.4H), 5.5 (m, 0.6H).
[0408] Mass spectrum (LCMS, ESI pos) Calcd for
C.sub.27H.sub.19ClN.sub.2O.sub.5: 486.1; Found: 487.0 (M+H).
Example 162
[3,7-Bis-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaze-
pin-4-yl]-phenyl-acetic acid methyl ester
[0409] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.8-7.9 (s,
1H), 7.4-7.7 (m, 11H), 7.1-7.2 (m, 1H), 6.8-7.0 (m, 4H), 6.7 (m,
1H), 5.3 (s, 0.18H), 5.25 (s, 0.82H), 3.8 (s, 3H). Mass spectrum
(LCMS, ESI pos) Calcd for C.sub.30H.sub.22Cl.sub.2N.sub.2O.sub.4:
544.1; Found: 545.0 (M+H).
Example 163
[3,7-Bis-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaze-
pin-4-yl]-phenyl-acetic acid
[0410] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.8-7.9 (m,
1H), 7.6-7.7 (m, 1H), 7.4-7.5 (m, 4H), 7.2-7.4 (m, 6H), 7.0-7.1 (m,
1H), 6.7-6.9 (m, 4H), 5.7 (s, 0.5H), 5.45 (s, 0.5H). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.29H.sub.20Cl.sub.2N.sub.2O.sub.4:
530.1; Found: 531.0 (M+H).
Example 164
[7-(3Amino-phenyl)-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[-
e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0411] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.8-7.9 (m,
1H), 7.6-7.7 (s, 1H), 7.2-7.5 (m, 5H), 7.0-7.1 (m, 4H), 6.5-6.9 (m,
6H), 5.7 (s, 0.4H), 5.5 (br s, 0.6H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.29H.sub.22ClN.sub.3O.sub.4: 511.1; Found: 512.1
(M+H).
Example 165
[3-(4-Chloro-phenyl)-7-(3-isopropyl-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-b-
enzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
[0412] .sup.1H-NMR (400 DMSO-d.sub.6): .delta. 7.8-7.9 (m, 1H),
7.6-7.7 (m, 1H), 7.4-7.5 (m, 3H), 7.2-7.4 (m, 6H), 7.0-7.1 (m, 1H),
6.6-6.9 (m, 5H), 5.7 (s, 0.3H), 5.5 (s, 0.7H), 2.9-3.0 (m, 1H),
1.2-1.3 (m, 6H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.32H.sub.27ClN.sub.2O.sub.4: 538.2; Found: 539.1 (M+H).
Example 166
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-5-oxo-2-thioxo-1,2,3,5-tetra-
hydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0413] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 12.3-12.5 (br
s, 1H), 7.7-7.8 (m, 1H), 7.5-7.6 (m, 2H), 7.2-7.4 (m, 6H), 7.1-7.2
(m, 2H), 6.6-6.8 (m, 1H), 6.4 (s, 0.7H), 6.2 (s, 0.7H), 5.7 (m,
0.6H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.15Cl.sub.2IN.sub.2O.sub.3S: 595.9; Found: 596.9
(M+H).
Example 167
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-2,5-dioxo-7-vinyl-1,2,3,5-tetrahydr-
o-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0414] .sup.1H NMR (400 MHz, DMSO-d.sub.6): 10.67 (s, 0.6H), 10.52
(s, 0.4H), 7.54-7.36 (m, 6H), 7.19-7.05 (m, 3H), 6.95 (m, 1H), 6.82
(d, J=8.4 Hz 0.6H), 6.72 (d, J=8.4 Hz, 0.4H), 6.64-6.55 (m, 1H),
6.32 (br s, 0.6H), 6.25 (br s, 0.4H), 5.73 (brs, 0.4H), 5.70-5.66
(m, 1H), 5.26 (s, 0.6H), 5.19-5.16 (n, 1H). Mass spectrum (LCMS,
ESI pos) Calcd for C.sub.25H.sub.18N.sub.2O.sub.4Cl.sub.2: 480.06;
Found: 481.07(M+H).
Example 168
(4-Chloro-phenyl)-[3-4-chloro-phenyl)-7-cyano-2,5-dioxo-1,2,3,5-tetrahydro-
-benzo[e][1,4]diazepin-4-yl]acetic acid
[0415] .sup.1H NMR (400 MHz, DMSO-d.sub.6): 11.13 (s, 0.7H), 10.97
(s, 0.3H), 7.88 (m, 1H), 7.68 (m, 1H), 7.50-7.41 (m, 4H), 7.17 (m,
3H), 7.01 (m, 2H), 6.28 (br s, 0.3H), 6.27 (br s, 0.7H), 5.70 (brs,
0.3H), 5.25 (s, 0.7H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.15N.sub.3O.sub.4Cl.sub.2: 479.04; Found:
479.9(M+H).
Example 169
[3-(1-Chloro-cuban-4-yl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]-
diazepin-4-yl]-(4-chlorophenyl)-acetic acid
[0416] .sup.1H NMR (400 MHz, DMSO-d.sub.6): 10.64 (s, 1H), 8.03 (d,
J=2.2 Hz, 1H), 7.86 (dd, J=8.4 Hz and J=2.2 Hz, 1H), 7.47 (d, J=8.7
Hz, 2H), 7.37 (d, J=8.8 Hz, 2H), 6.88 (d, J=8.7 Hz, 1H), 4.62 (s,
1H), 4.16 (s, 1H), 3.80-3.73 (m, 3H), 3.70-3.64 (m, 3H). Mass
spectrum (LCMS, ESI pos.): Calcd for
C.sub.25H.sub.17Cl.sub.2IN.sub.2O.sub.4: 605.96; found: 606.99
(M+H).
Example 170
3-(4-Chloro-phenyl)-4-[1(4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo-1,3,4,5--
tetrahydrobenzo[e][1,4]diazepin-2-one
[0417] .sup.1H NMR (400 MHz, CDCl.sub.3): 7.50 (br s, 1H), 7.45
(dd, J=8.3 Hz and J=2.0 Hz, 1H), 7.33 (d, J=8.4 Hz, 2H), 7.29 (d,
J=8.8 Hz, 2H), 7.26 (d, J=8.8 Hz, 2H), 7.23 (d, J=8.5 Hz, 2H), 7.12
(d, J=1.9 Hz, 1H), 6.49 (d, J=8.3 Hz, 1H), 5.14 (s, 1H), 4.08-4.00
(m, 1H), 3.95-3.85 (m, 2H), 3.89 (d, J=14.9 Hz, 1H), 3.58 (d,
J=14.8 Hz, 1H), 2.02-1.99 (m, 1H). Mass spectrum (LCMS, ESI pos.):
Calcd. for C.sub.23H.sub.19Cl.sub.2IN.sub.2O.sub.2: 551.99; found:
552.90 (M+H).
Example 171
3-(4-chloro-phenyl)-4-[1-(4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo-1,2,3,4-
-tetrahydro-benzo[e][1,4]diazepin-5-one
[0418] .sup.1H NMR (400 MHz, CDCl.sub.3): 8.52(d, J=2.1 Hz, 1H),
7.36 (dd, J=8.6 Hz and J=2.2 Hz, 1H), 7.20-7.14 (m, 4H), 7.08 (d,
J=8.5 H, 2H), 6.81 (d, J=8.4 Hz, 2H), 6.18 (d, J=8.6 Hz, 1H),
5.48-5.45 (m, 1H), 4.73 (d, J=6.0 Hz, 1H), 4.47-4.40 (m, 1H),
4.33-4.24 (m, 1H), 4.22-4.15 (m, 1H), 3.83-3.75 (m, 1H), 3.71-3.64
(m, 1H), 3.14-3.08 (m, 1H). Mass spectrum (LCMS, ESI pos.): Calcd.
for C.sub.23H.sub.19Cl.sub.2IN.sub.2O.sub.2: 551.99; found: 552.8
(M+H).
Example 172
3-(4-Chlorophenyl)-4-(2-hydroxy-1-phenyl-ethyl)-7-iodo-3,4-dihydro-1H-benz-
o[e][1,4]diazepin-2,5-dione
[0419] .sup.1H NMR (400 MHz, DMSO-d.sub.6): 10.82 (br s, 1H), 7.80
(d, J=2.1 Hz, 1H), 7.5 (dd, J=8.5 Hz and J=2.1 Hz, 1H), 7.51 (d,
J=7.4 Hz, 2H), 7.40-7.26 (m, 3H), 7.03 (d, J=8.6 Hz, 2H), 6.64-6.58
(m, 3H), 6.13-6.05 (m, 1H), 5.17 (s, 1H), 5.05 (t, J=5.0 Hz, 1H),
4.11-3.97 (m, 2H). Mass spectrum (LCMS, ESI pos.): Calcd. for
C.sub.23H.sub.18ClIN.sub.2O.sub.3: 532.01; found: 532.95 (M+H).
Example 173
3-(4-Chloro-phenyl)-4-(3-hydroxy-1-phenyl-propyl)-7-iodo-3,4-hydroxy-1H-be-
nzo[c][1,4]diazepin-2,5-dione
[0420] .sup.1H NMR (400 MHz, DMSO-d.sub.6): 10.94 (s, 1H), 7.80 (d,
J=2.1 Hz, 1H), 7.59 (d, J=7.3, 2H), 7.54 (dd, J=8.5 Hz and J=2.1
Hz, 1H), 7.37 (t, J=7.4 Hz, 2H), 7.30 (t, J=7.3 Hz, 1H), 6.99 (d,
J=8.6 Hz, 2H), 6.64 (d, J=8.5 Hz, 1H), 6.45 (d, J=8.7 Hz, 2H), 6.33
(t, J=7.7 Hz, 1H), 5.25 (s, 1H), 4.61 (t, J=4.9 Hz, 1H), 3.48-3.39
(m, 2H), 2.28-2.20 (m, 2H). Mass spectrum (LCMS, ESI pos.): Calcd.
for C.sub.24H.sub.20ClIN.sub.2O.sub.3: 546.02; found: 546.91
(M+H).
Example 174
2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrah-
ydro-benzo[e][1,4]diazepin-4-yl]-N-2-hydroxy-ethyl)-acetamide
[0421] .sup.1H NMR (400 MHz, DMSO-d.sub.6): 10.73 (s, 1H), 8.25 (t,
J=5.6 Hz, 1H), 7.78 (d, J=2.1 Hz, 1H), 7.56 (dd, J=8.5 Hz and J=2.1
Hz, 1H), 7.50-7.43 (m, 4H), 7.13 (d, J=8.6 Hz, 2H), 6.91 (d, J=7.8
Hz, 2H), 6.64 (d, J=8.5 Hz, 1H), 6.48 (s, 1H), 5.00 (s, 1H), 4.65
(t, J=5.3 Hz, 1H), 3.42-3.37 (m, 2H), 3.29-3.05 (m, 2H). Mass
spectrum (LCMS, ESI pos.): Calcd. for
C.sub.25H.sub.20Cl.sub.2IN.sub.3O.sub.4: 622.99; found: 623.75
(M+H).
Example 175
3-(4-Chloro-phenyl)-3-[3-(4-chloro-phenyl)-7-iodo-2,5-oxo-1,2,3,5-tetrahyd-
ro-benzo[e][1,4]diazepin-4-yl]-propionic acid
[0422] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.10.90 (s, 1H),
7.81 (d, J=2.4 Hz, 1H), 7.64 (d, J=8.4 Hz, 2H), 7.56 (dd, J=8.0 Hz,
2.0Hz, 1H), 7.41 (d, J=8.4 Hz, 2H), 7.05 (d, J=8.4 Hz, 2H), 6.61
(d, J=8.4 Hz, 1H), 6.54 (d, J=8.8 Hz, 2H), 6.42 (t, J=8.0 Hz, 1H),
5.31 (s, 1H), 3.15 (d, J=7.2 Hz, 1). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.24H.sub.17Cl.sub.2IN.sub.2O.sub.4: 593.96; Found:
594.90 (M+H).
Example 176
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diaz-
epin-4-yl]-(6-chloro-pyridin-3-yl)-acetic acid
[0423] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.64 (s,
0.7H), 10.61 (s, 0.3H), 8.46 (d, J=2.4 Hz, 0.7H), 8.34 (d, J=2.4
Hz, 0.3H), 7.93-7.90 (m, 0.7H), 7.81-7.80 (m, 0.3H), 7.78 (d, J=2
Hz, 0.7H), 7.71 (d, J=2.4 Hz, 0.3H), 7.54-7.51 (m, 1H), 7.46-7.41
(m, 1H), 7.19-7.13 (m, 2.6H), 7.04-7.02 (m, 1.4H), 6.62 (d, J=8.8
Hz, 0.7H), 6.56 (d, J=8.8 Hz, 0.3H), 6.25 (s, 0.3H), 6.04 (s,
0.7H), 5.81 (s, 0.3H), 5.40 (s, 0.7H). Mass spectrum (LCMS, ESI
pos) Calcd. for C.sub.22H.sub.14Cl.sub.2IN.sub.3O.sub.4: 580.94;
Found: 581.93 (M+H).
Example 177
2-(4-Chlorophenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahy-
dro-benzo[e][1,4]diazepin-4-yl]-N-hydroxy-acetamide
[0424] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.10.83 (s, 1H),
7.73 (d, J=2.0 Hz, 1H), 7.76 (dd, J=8.0 Hz, 2.0 Hz, 1H), 7.52-7.45
(m, 3H), 7.20 (d, J=8.8 Hz, 2H), 7.07 (d, J=8.8 Hz, 2H), 6.64 (d,
J=8.4 Hz, 1H), 6.20 (s, 1H), 5.24 (s, 1H). Mass spectrum (LCMS, ESI
neg) Calcd. for C.sub.23H.sub.16Cl.sub.2IN.sub.3O.sub.4: 594.96;
Found: 578.9.
Example 178
[7-Bromo-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]dia-
zepin-4-yl]-(4-chloro-phenyl)-acetic acid
[0425] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.68 (s, 1H),
7.60 (d, J=2.4 Hz, 1H), 7.50 (d, J=8.4 Hz, 2H), 7.44-7.39 (m, 3H),
7.10 (d, J=8.8 Hz, 2H), 6.93-6.85 (m, 2H), 6.78 (d, J=8.8 Hz, 1H),
6.24 (s, 1H), 5.22 (s, 1H). Mass spectrum (LCMS, ESI pos) Calcd.
for C.sub.23H.sub.15BrCl.sub.2N.sub.2O.sub.4: 531.96; Found 532.90
(M+H).
Example 179
[8-Chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e]-
1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid
[0426] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.78 (s, 1H),
7.98 (s, 1H), 7.49 (d, J=8.4 Hz, 2H), 7.33 (d, J=8.4 Hz, 2H), 7.10
(d, J=8.4 Hz, 2H), 7.04 (s, 1H), 6.82 (d J=8.4 Hz, 2H), 6.26 (s,
1H), 5.21 (s, 1H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.14Cl.sub.3IN.sub.2O.sub.4: 613.91; Found: 614.8
(M+H).
Example 180
2-{2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tet-
rahydro-benzo[e][1,4]diazepin-4-yl]-acetylamino}-3-methyl-butyric
acid
[0427] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.10.80-10.69 (m,
1H), 8.58-8.47 (m, 1H), 7.62-7.29 (m, 3H), 7.25-6.83 (m, 5H),
6.80-6.50 (m, 2H), 5.04 (s, 0.5H), 4.86 (s, 0.5H), 4.27-4.08 (m,
1H), 2.07-1.97 (m, 1H), 0.92-0.81 (m, 6H).
[0428] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.28H.sub.24Cl.sub.2IN.sub.3O.sub.5: 679.01; Found 679.66
(M+H).
Example 181
3-(4-Chloro-phenyl)-3-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrah-
ydro-benzo[e][1,4]diazepin-4-yl]propionic acid
[0429] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.10.88 (s, 1H),
7.80 (d, J=2.4 Hz, 1H), 7.59-7.50 (m, 3H), 7.35 (d, J=8.0 Hz, 2H),
7.05 (d, J=8.0 Hz, 2H). 6.64-6.58 (m, 3H), 6.42-6.36 (m, 1H), 5.10
(s, 1H) 2.95-2.86 (m, 1H), 2.41-2.34 (m, 1H).
Example 182
5-{2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-oxo-1,2,3,5-tetra-
hydro-benzo[e][1,4]diazepin-4-yl]-acetylamino}-pentanoic acid
[0430] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.00 (s, 1H),
10.72 (s, 1H), 8.25 (t, J=5.6 Hz, 1H), 7.77 (d, J=2.0 Hz, 1H),
7.60-7.52 (m, 1H), 7.50-7.41 (m, 4H), 7.13 (dd, J=8.0 Hz, 2.0 Hz,
2H), 6.90 (dd, J=8.0 Hz, 1.2 Hz, 2H), 6.64 (d, J=8.4 Hz, 1H), 6.42
(s, 1H), 4.98 (s, 1H), 3.22-2.98 (m, 2H), 2.23-2.17 (m, 2H),
1.52-1.34 (m, 4H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.28H.sub.24Cl.sub.2IN.sub.3O.sub.5: 679.01; Found: 679.86
(M+H).
Example 183
3-{2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tet-
rahydro-benzo[e][1,4]diazepin-4-yl}acetylamino}-propionic acid
[0431] .sup.1H NMR (400 MHz, DMSO-.sub.6): .delta. 10.73 (s, 1H),
8.37-8.28 (m, 1H), 7.77 (d, J=2.0 Hz, 1H), 7.58-7.53 (m, 1H),
7.46-7.42 (m, 4H), 7.13 (d, J=8.4 Hz, 2H), 6.91 (d, J=8.4 Hz, 2H),
6.64 (d, J=8.4 Hz, 1H), 6.43 (s, 1H), 4.97 (s, 1H), 3.17 (d, J=5.6
Hz, 2H), 2.42-2.38 (m, 2H). Mass spectrum (LCMS, ESI pos) Calcd.
for C.sub.26H.sub.20Cl.sub.2IN.sub.3O.sub.5: 650.98; Found: 651.68
(M+H).
Example 184
(4-Chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-trifluoromethylsulfanyl-phenyl)-1-
,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0432] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.15ClF.sub.3IN.sub.2O.sub.4S: 645.94; Found: 646.96
(M+H).
Example 185
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-2,5-dioxo-7-(1H-pyrrol-3-yl)-1,2,3,-
5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0433] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.94 (s, 1H),
10.60 (s, 1H), 7.66-7.35 (m, 6H), 7.22-7.03 (m, 5H), 6.79-6.72 (m,
2H), 6.34-6.28 (m, 1H), 6.21 (s, 1H), 5.25 (s, 1H).
[0434] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.27H.sub.19Cl.sub.2N.sub.3O.sub.4: 519.08; Found 520.00
(M+H).
Example 186
3-[4-[Carboxy-(4-chloro-phenyl)-methyl]-3-(4-chloro-phenyl)-7-iodo-2,5-dio-
xo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-yl]-propionic
acid
[0435] .sup.1H NMR (400 MHz, CD.sub.3OD-d.sub.6): .delta. 8.06-7.89
(m, 1.2H), 7.83 (d, J=8.4 Hz, 0.6H), 7.74-7.68 (m, 0.6H), 7.56 (d,
J=8.0 Hz, 1H), 7.47-7.24 (m, 3H), 7.08-6.93 (m, 2H), 6.82-6.57 (m,
2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.19Cl.sub.2IN.sub.2O.sub.6: 651.97; Found: 652.90
(M+H).
Example 187
6-{2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tet-
rahydro-benzo[e][1,4]diazepin-4-yl]-acetylamino}-hexanoic acid
[0436] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.98 (s, 1H),
10.72 (s, 1H), 8.29-8.15 (m, 1H), 7.77 (d, J=2.0 Hz, 1H), 7.59-7.53
(m, 1H), 7.51-7.42 (m, 4H), 7.13 (d, J=8.8 Hz, 2H), 6.91 (d, J=7.6
Hz, 2H), 6.64 (d, J=8.4 Hz, 1H), 6.41 (s, 1H), 4.98 (s, 1H),
3.20-2.95 (m, 2H), 2.16 (t, J=7.6 Hz, 2H), 1.53-1.31 (m, 4H),
1.26-1.15 (m, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.29H.sub.26Cl.sub.2IN.sub.3O.sub.5: 693.03; Found: 693.82
(M+H).
Example 188
[1-(2-tert-Butoxycarbonylamino-ethyl)-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-
-1,2,3,5-tetahydro-benzo[e][1,4]diazepin-4-yl]-4-chloro-phenyl)-acetic
acid
[0437] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 7.94 (d, J=2.0
Hz, 1H), 7.53 (d, J=8.4 Hz, 2H), 7.47 (dd, J=8.4 Hz, 2.0 Hz, 1H),
7.29 (d, J=8.0 Hz, 2H), 6.93 (d, J=8.8 Hz, 2H), 6.73 (dd, J=8.0 Hz,
1.6 Hz, 2H), 6.61 (d, J=8.4 Hz, 1H), 6.50 (s, 1H), 5.27 (s, 1H),
3.55-3.49 (m, 2H), 3.50-3.45 (m, 1H), 3.15-3.10 (m, 1H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.30H.sub.28Cl.sub.2N.sub.3O.sub.6: 723.04; Found: 723.70
(M+H).
Example 189
(4-Chloro-phenyl)-{7-iodo-2,5-dioxo-3-[5-(3-trifluoromethl-phenyl)furan-2--
yl]-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin4-yl}-acetic acid
[0438] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.8.03 (s, 1H),
7.68-7.56 (m, 4H), 7.57-7.44 (m, 4H), 7.40-733 (m, 2H), 6.79 (d,
J=8.4 Hz,1H), 6.73 (s, 1H 6.48 (d, J=3.2 Hz, 1H), 5.61-5.57 (m,
1H),: 5.49 (s, 1H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.28H.sub.17ClF.sub.3IN.sub.2O.sub.5: 679.98; Found: 680.77
(M+H).
Example 190
(4-(Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1-(2-pyridin-2-yl-
-ethyl)-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic
acid
[0439] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.30H.sub.22Cl.sub.2IN.sub.3O.sub.4: 685.00; Found: 686.18
(M+H).
Example 191
(4-Chlorophenyl)-[3-(4-chloro-phenyl)-7-iodo-1-methylcarbamoylmethyl-2,5
dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]-acetic acid
[0440] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.7.84-7.81 (m,
1H), 7.52-7.46 (m, 3H), 7.33-7.27 (m, 2H), 6.91 (d, J=8.4 Hz, 2H),
6.80 (d, J=8.4 Hz, 1H), 6.69 (d, J=8.8 Hz, 2H), 6.57 (s, 1H), 5.33
(s, 1H), 4.50 (m, 1H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.20Cl.sub.2IN.sub.3O.sub.5: 650.98; Found: 651.94
(M+H).
Example 192
(4-Chloro-phenyl)-[3-(4-difluoromethoxy-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-t-
etrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0441] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.93 (d, J=2.0 Hz,
0.6H), 7.89 (d, J=2.0 Hz, 0.4H), 7.59 (d, J=8.0 Hz, 1H), 7.54-7.48
(m, 1H), 7.45 (d, J=8.4 Hz, 0.6H), 7.37-7.30 (m, 2.4H), 7.13-7.05
(m, 0.4H), 6.85 (d, J=8.4 Hz, 0.6H), 6.82-6.70 (m, 2.3H), 6.68-6.65
(m, 0.6H), 6.64-6.58 (m, 1H), 5.70 (s, 0.3H), 5.37 (s, 1H). Mass
spectrum (LCMS, ESI pos) Calcd for
C.sub.24H.sub.16ClF.sub.2IN.sub.2O.sub.5: 611.98; Found: 612.80
(M+H).
Example 193
[1-(2-tert-Butoxycarbonylamino-ethyl)3-(4-chloro-phenyl)-7-iodo-2,5-dioxo--
1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic
acid
[0442] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.84 (d, J=2.0 Hz,
1H), 7.57-7.45 (m, 3H), 7.37 (d, J=8.4 Hz, 2H), 7.12 (d, J=8.4Hz,
2H), 7.00 (d, J=8.8 Hz, 2H), 6.82 (d, J=8.8 Hz, 1H), 6.56 (s, 1H),
5.76 (s, 1H), 4.11-3.98 (m, 1H), 3.78-3.65 (m, 1H), 3.16-3.08 (m,
2H), 1.39 (s, 9H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.30H.sub.28Cl.sub.2IN.sub.3O.sub.6: 723.04; Found: 745.90
(M+Na)
Example 194
(3-Benzofuran-2-yl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazep-
in-4-yl)-(4-chloro-phenyl)-acetic acid
[0443] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.8.01 (d, J=1.6 Hz,
1H), 7.64 (d, J=8.8 Hz, 2H), 7.58-7.51 (m, 1H), 7.49-7.44 (m, 1H),
7.40-7.32 (m, 2H), 7.26-6.95 (m, 4H), 6.83-6.72 (m, 1H), 5.92 (s,
0.7H), 5.80 (s, 0.3H), 5.64, (s 0.3H), 5.56 (s, 0.7H). Mass
spectrum (LCMS, ESI pos) Calcd for
C.sub.25H.sub.16ClIN.sub.2O.sub.5: 585.98; Found: 586.93 (M+H)
Example 195
(4-Chloro-phenyl)-[3-(4chloro-phenyl)-7-iodo-1-methyl-2,5-dioxo-1,2,3,5-te-
trahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0444] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.84 (d, J=2.0 Hz,
1H), 7.62-7.54 (m, 3H), 7.34 (d, J=8.4 Hz, 2H), 6.95 (d, J=8.8 Hz,
2H), 6.82 (d, J=8.8 Hz, 1H), 6.68 (dd, J=8.8 Hz, 1.2 Hz, 2H), 6.53
(s, 1H), 5.38 (s, 1H), 3.44 (s, 3H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.24H.sub.17Cl.sub.2IN.sub.2O.sub.4: 593.96; Found
594.95 (M+H).
Example 196
(4-Chloro-phenyl)-[3-(4-cyano-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro--
benzo[e][1,4]diazepin-4-yl]-acetic acid
[0445] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.91 (d, J=2.0 Hz,
1H), 7.59 (d, J=8.4 Hz, 1H), 7.55-7.42 (m, 3H), 739-7.27 (m, 3H),
6.98 (d, J=8.4 Hz, 1H), 6.65 (d, J=7.6 Hz, 1H), 6.59 (d, J=8.4 Hz,
0.5H), 6.51 (d, J=8.8 Hz, 0.5H), 5.77 (s, 0.5H), 5.44 (s,
0.5H).
[0446] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.15ClIN.sub.3O.sub.4: 570.98; Found: 571.80 (M+H).
Example 197
[1-Carboxymethyl-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-b-
enzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid methyl
ester
[0447] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.7.73-6.75 (m,
11H), 6.24 (s, 1H), 5.42 (s, 1H), 4.53-4.25 (m, 1H), 4.16-3.86 (m,
1H), 3.78 (s, 3H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.19Cl.sub.2IN.sub.2O.sub.6: 651.97; Found: 652.87
(M+H).
Example 198
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-(2-hydroxy-ethyl)-2,5-dioxo-1,2,3-
,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0448] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.10.46 (s, 1H),
7.62-7.26 (m, 4H), 7.08-6.96 (m, 3H), 6.82-6.66 (m, 3H), 6.30 (s,
1H), 5.29 (s, 1H), 4.59 (s, 1H), 3.45-3.39 (m, 2H), 2.55 (t, J=8.8
Hz, 2H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.20Cl.sub.2N.sub.2O.sub.5: 498.07; Found: 498.95
(M+H).
Example 199
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-1-(2(R),3-dihydroxy-propyl)-7-iodo--
2,5-dioxo1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic
acid
[0449] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.21Cl.sub.2IN.sub.2O.sub.6: 653.98; Found 654.81
(M+H).
Example 200
(4-Chloro-phenyl)-[3-(6-chloro-pyridin-3-yl)-7-iodo-2,5-dioxo-1,2,3,5-tetr-
ahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0450] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.63-7.57 (m, 2H),
7.30 (d, J=8.4 Hz, 2H), 7.00-6.89 (m, 3H), 6.78-6.65 (m, 4H), 5.41
(s, 1H).
Example 201
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-hydroxymethyl-2,5-dioxo-1,2,3,5-t-
etrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0451] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.10.52 (s, 1H),
7.57-7.42 (m, 2H), 7.41-7.23 (m, 3H), 7.22-6.96 (m, 4H), 6.87-6.67
(m, 3H), 6.33 (s, 1H), 5.18 (s, 1H), 4.38-4.27 (m, 2H).
[0452] Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.24H.sub.18Cl.sub.2N.sub.2O.sub.5: 484.06; Found 485.00
(M+H).
Example 202
(4-Chloro-phenyl)-{7-iodo-2,5-dioxo-3-[4-(1,1,2,2-tetrafluoro-ethoxy)-phen-
yl]-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl}-acetic acid
[0453] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.96 (d, J=2.0 Hz,
0.4H), 7.80 (d, J=2.0Hz, 0.6H), 7.54-7.47 (m, 1H), 7.39 (d, J=8.4
Hz, 2H), 7.29-7.12 (m, 5H), 7.06 (d, J=8.4 Hz, 2H), 6.85 (t, J=8.0
Hz, 1.8H), 6.62 (s, 0.7H), 5.96 (s, 0.6H), 5.79 (s, 0.4H),
5.36-5.28 (m, 1H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.16ClF.sub.4IN.sub.2O.sub.5: 661.97; Found: 662.90
(M+H).
Example 203
(4-Chloro-phenyl)-[7-iodo-3-(4-methylsulfanyl-phenyl)-2,5-dioxo-1,2,3,5-te-
tahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0454] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.92 (s, 0.7H),
7.88 (s, 0.3H), 7.58 (d, J=8.0 Hz, 1H), 7.56-7.41 (m, 1.7H),
7.38=7.29 (m, 1.71H), 7.20 (d, J=8.0 Hz 0.7H), 7.08 (d, J=8.0
.sub.Hz, 0.3H), 7.02-6.89 (m, 1H), 6.86-6.69 (m, 1H), 6.70-6.63 (m,
1.3H), 6.60 (d, J=8.8 Hz, 0.7H), 6.51 (d, J=8.8 Hz, 0.3H), 5.70 (s,
0.3H), 5.35 (s, 0.7H), 2.34 (s, 1H), 2.29 (s, 2H). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.24H.sub.18ClIN.sub.2O.sub.4S:
591.97; Found: 592.90 (M+H).
Example 204
(4-Chloro-phenyl)-[7-iodo-2,5-dioxo-3-(4-pyrrolidin-1-yl-phenyl)-1,2,3,5-t-
etrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid
[0455] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.8.18-8.08 (m, 1H),
7.98-7.85 (m, 1H), 7.59 (d, J=1.2 Hz, 1H), 7.52-7.42 (m, 2H),
7.39-7.28 (n, 3H), 7.06 (d, J=8.0 Hz, 1H, 6.74-6.45 (m, 1H), 6.29
(d, J=8.4 Hz, 1H), 6.09 (dd, J=8.0 Hz, 1.2 Hz, 1H), 5.66 (s, 0.5H),
5..sub.36 (s, 0.5H), 3.17-3.02 (m, 4H), 1.99-1.87 (m, 4H). Mass
spectrum LCMS, ESI pos) Calcd. for
C.sub.27H.sub.23ClIN.sub.3O.sub.4: 615.04; Found: 616.07 (M+H).
Example 205
2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrah-
ydro-benzo[e][1,4]diazepin-4-yl]-N,N-bis-2-hydroxy-ethyl)-acetamide
[0456] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.8.65 (s, 0.5H),
8.20 (s, 0.5H, 8.00 (d, J=1.6 Hz, 0.5H), 7.94 (d, J=2.0 Hz, 0.5H),
7.52-7.42 (m,2.5H), 7.37 (d, J=8.8 Hz, 1H), 7.24 (dd, J=5.6 Hz,
1h), 7.10-6.99 (m, 2H); 6.95 (s, 1H), 6.85 (d, J=8.0 Hz, 0.5H),
6.46-6.35 (m, 1H), 5.32 (s, 0.5H), 5.12 (s, 0.5H), 4.04-3.06 (m,
8H). Mass spectrum, ESI pos) Calcd. for
C.sub.27H.sub.24Cl.sub.2IN.sub.3O.sub.5: 667.01; Found: 667.85
(M+H).
Example 206
(4-Chloro-phenyl)-{7-iodo-2,5-dioxo-3-[4-(1,1,2,2-tetrafluoro-ethoxy)-phen-
yl]-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl)-acetic acid
[0457] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.83-7.74(m,
0.7H), 7.60 (d, J=8.4 Hz, 0.6H), 7.52-7.45 (m, 0.7H), 7.42-7.30 (m,
2H), 7.27 (d, J=8.4Hz, 1H), 7.17 (d, J=7.6 Hz, 2H), 7.09-6.97 (m,
3H), 6.89-6.78 (m, 2H), 6.63 (s, 0.6H), 6.46 (s, 0.4H), 5.97 (s,
0.5H), 5.60-5.51 (m, 0.6H), 5.37-5.27 (m, 0.7H), 4.66-4.58 (m,
0.5H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.25H.sub.16ClF.sub.4IN.sub.2O.sub.5: 661.97; Found: 662.89
(M+H).
Example 207
[3-(4-Chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4-diaz-
epin-4-yl](6-methyl-pyridin-3-yl)acetic acid
[0458] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.10.76 (s, 1H),
8.53 (d, J=2.0 Hz, 1H), 7.78-7.72 (m, 2H), 7.60-7.53 (m, 1H),
7.26-7.16 (m, 3H), 7.10-7.03 (m, 2H), 6.65 (d, J=8.8 Hz, 1H), 6.16
(s, 1H), 5.33 (s, 1H), 2.42 (s, 3H). Mass spectrum (LCMS, ESI pos)
Calcd. for C.sub.23H.sub.17ClIN.sub.3O.sub.4: 561.00, Found: 562.01
(M+H).
Example 208
3-{2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tet-
rahydro-benzo[e][1,4]diazepin-4-yl]-acetylamino}-propionic acid
methyl ester
[0459] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.10.74 (s, 1H),
8.35 (t, J=6.0 Hz, 1H), 7.77 (d, J=2.0 Hz, 1H), 7.61-7.51 (m, 1H),
7.45 (s, 2H), 7.13 (d, J=8.4 Hz, 2H), 6.91 (d, J=7.8 Hz 2H), 6.64
(d, J=7.8 Hz, 1H), 6.42 (s, 1H), 4.98 (s, 1H), 3.56 (s, 3H),
3.48-3.36 (m, 1H), 3.31-3.21 (m, 1H), 2.48-2.40. (m, 2H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.27H.sub.22Cl.sub.2IN.sub.3O.sub.5: 665.00, Found 665.70
(M+H).
Example 209
[7-Amino-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]dia-
zepin-4-yl]-(4-chloro-phenyl)-acetic acid
[0460] .sup.1H NMR (400 Mz DMSO-d.sub.6): .delta.12.00 (s, 1H),
10.20 (s, 1H), 7.53-7.35 (m, 3H), 7.27 (d, J=8.4 Hz, 0.4H),
7.19-6.96 (m, 2.8H), 6.88-6.66 (m, 1.2H0, 6.54-6.39 (m, 1.4H), 6.10
(s, 0.7H), 5.18 (s, 0.8H), 5.00 (s, 1.0H), 4.42 (s, 0.4H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.23H.sub.17Cl.sub.2N.sub.3O.sub.4: 469.06; Found: 470.00
(M+H).
Example 210
2-(4-Chloro-phenyl)-2-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrah-
ydro-benzo[e][1,4]diazepin-4-yl]-N-(2-hydroxyguanidino-ethyl)-acetamide
[0461] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.10.95 (s, 1H),
10.75 (s, 1H), 8.41 (m, 1H), 7.77 (d, J=2.0 Hz, 1H), 7.57 (dd,
J=8.4 Hz, 2.4 Hz, 1H), 7.53-7.44 (m, 3H), 7.14 (d, J=8.8 Hz, 2H),
6.93 (d, J=8.4 Hz, 2H), 6.65 (d, J=8.8 Hz, 1H), 6.43 (s, 1H), 4.99
(s, 1H), 3.80 (t, J=5.6 Hz, 2H), 3.46-3.36 (m, 4H). Mass spectrum
(LCMS, ESI pos) Calcd. for C.sub.26H.sub.23Cl.sub.2IN.sub.6O.sub.4:
680.02; Found 681.00 (M+H).
Example 211
(4-Chloro-phenyl)-[3-(5-chloro-thiophen-2-yl)-7-iodo-2,5-dioxo-1,2,3,5-tet-
rahydo-benzo[e][1.4]diazepin-4-yl]-acetic acid
[0462] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.99-7.89 (m,
1H);,7.67-7.51 (m, 2H), 7.44-7.32 (m, 2H), 7.27-6.99 (m, 1H),
6.90-6.82 (m, 0.5H). 6.73 (d, J 8.4 Hz, 0.5H), 6.67-6.41 (m, 2H),
6.23-6.18 (m, 0.5H), 5.44-5.38 (m, 0.5H). Mass spectrum (LCMS, ESI
pos) Calcd. for C.sub.21H.sub.13Cl.sub.2IN.sub.2O.sub.4S: 585.90;
Found 586.72 (M+H).
Example 212
(4-Chloro-phenyl)-[7-iodo-3-(4-isopropenyl-cyclohex-1-enyl)-2,5-dioxo-1,2,-
3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-acetic acid
[0463] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.10.31 (s, 0.8H),
10.15 (s, 0.2H), 7.93-7.78 (m, 1H), 7.72-7.64 (m, 1H), 7.44-7.24
(m, 4H), 6.83-6.73 (m, 1H), 6.20-6.11 (m, 1H), 5.05-4.93 (m, 1H),
4.57-4.44 (m, 2H), 4.35-4.24 (m, 1H), 1.71-1.21 (m, 10H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.24ClIN.sub.2O.sub.4: 590.05; Found: 591.00 (M+H).
Example 213
(4-Chloro-phenyl)-[3-(4-chloro-phenyl)-1-(2(S),3-dihydroxy-propyl)-7-iodo--
2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic
acid
[0464] .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.7.87-7.80 (m, 1H),
7.61-7.45 (m, 3H), 7.38-7.28 (m, 2H), 7.19-6.91 (m, 4H), 6.80-6.71
(m, 1H), 6.62 (s, 0.3H), 5.89 (s, 0.6H), 4.30-3.38 (m, 5H). Mass
spectrum (LCMS, ESI pos) Calcd. for
C.sub.26H.sub.21Cl.sub.2IN.sub.2O.sub.6: 653.98; Found: 637.20.
Example 214
5-[4-[Carboxy-(4-chloro-phenyl)-methyl]-3-(4-chloro-phenyl)-7-iodo-2,5-dio-
xo2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-yl)pentanoic acid
[0465] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.7.97-7.91 (m,
1H), 7.66 (d, J=8.4 Hz, 1H), 7.46-7.41 (m, 4H), 7.03 (d, J=8.4 Hz,
2H), 6.73 (d, J=8.4 Hz, 1H), 6.67 (s, 1H), 6.64 (d, J=8.4 Hz, 2H),
5.48 (s, 1H), 4.57-4.45 (m, 1H), 3.75-3.65 (m, 1H), 2.49-2.39 (m,
2H), 1.75-1.55 (m, 4H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.28H.sub.23Cl.sub.2IN.sub.2O.sub.6: 680.00; Found: 680.85
(M+H).
Example 215
5-{3-(4-Chloro-phenyl)-4-[1-4-chloro-phenyl)-2-hydroxy-ethyl]-7-iodo-2,5-d-
ioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-yl}-pentanoic
acid
[0466] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.7.85 (d, J=2 Hz,
1H), 7.61-7.52 (m, 3H), 7.38 (d, J=8.4 Hz, 2H), 6.97-6.87 (m, 3H),
6.58 (dd, J=2.0 Hz, 8.0 Hz, 2H), 6.28-6.20 (m, 1H), 5.39 (s, 1H),
4.36-4.24 (m, 2H), 4.20-4.12 (m, 1H), 3.83-3.72 (m, 1H), 2.23-2.11
(m, 2H), 1.84-1.65 (m, 2H), 1.64-1.52 (m, 2H). Mass spectrum (LCMS,
ESI pos) Calcd. for C.sub.28H.sub.25Cl.sub.2IN.sub.2O.sub.5:
666.02; Found: 666.97 (M+H).
Example 216
5-{3-(4-Chloro-phenyl)-4-[(4-chloro-phenyl)-diethylcarbamoyl-methyl]-7-iod-
o-2,5-dioxo-2,3,4,5-tetrahydro
benzo[e][1,4]diazepin-1-yl)-pentanoic acid
[0467] .sup.1H NMR (400 MHz DMSO-d.sub.6): .delta.7.65 (d, J=2.4 Hz
1H), 7.62-7.55 (m, 3H), 7.53-7.48 (m, 2H), 7.12-7.06 (m, 2H),
6.94-6.87 (m, 2H), 6.60 (s, 1H), 4.89 (s, 1H), 4.24-4.14 (m, 1H),
3.74-3.63 (m, 1H), 3.57-3.47 (m, 2H), 3.17-3.08 (m, 2H), 2.23-2.13
(m, 2H), 1.85-1.73 (m, 1H), 1.67-1.58 (m, 1H), 1.49-1.40 (m, 2H),
1.10-0.98 (m, 6H). Mass spectrum (LCMS, ESI pos) Calcd. for
C.sub.32H.sub.32Cl.sub.2IN.sub.3O.sub.5: 735.08; Found: 735.82
(M+H).
Example 217
Fluorescent Peptide Assay
[0468] The inhibition of MDM2 binding to p53 was measured using a
p53 peptide analogue binding to MDM2 residues 17-125. The published
crystal structure of this complex (Kussie et al., Science
274:948-953 (1996)) validates this fragment as containing the p53
binding site, and we have solved the x-ray structure of the p53
peptide analogue MPRFMDYWEGLN, described to be a peptide inhibitor
of the MDM2 p53 interaction (Bottger et al., J. Mol. Biol.
269-744-756 (1997)). The assay uses N terminal fluorescein
RFMDYWEGL peptide (Fl 9mer).
[0469] The mdm2 17-125 was produced as a glutathione S transferase
fusion as follows: CDNA encoding residues 17-125 were cloned into
pGEX4t-3 (Pharmacia) as follows. PCR was performed using ATCC item
number 384988 containing partial human mdm2 sequence as template
and the following primers: Forward: 5'-CTC TCT CGG ATC CCA GAT TCC
AGC TTC GGA ACA AGA G; Reverse: 5'-TAT ATA TCT CGA GTC AGT TCT CAC
TCA CAG ATG TAC CTG AG. The PCR product was then digested with
BamHI and XhoI (sequence recognition sites underlined in primers),
gel purified, and ligated into pGEX4t-3 which had also been
digested with BamHI and XhoI. Plasmids were transfected into E.
coli X90 strain, grown to an OD of 1.0 in TB 0.2% glucose 100
.mu.g/mL ampicillin and induced with 1 mM IPTG. Cells were
harvested 5 hours post induction, centrifuged, and resuspended in
PBS 10 mL/g cell paste. Cells were lysed in an Avestin
microfluidizer, centrifuged, and the supernatant bound to a
glutathione sepharose 4B resin (Pharmacia). The resin was washed
with PBS and the MDM2 17-125 cleaved from the GST by the addition
of 2 .mu.g/mL thrombin (Enzyme Research Labs). The cleaved MDM2 was
further purified on Sepharose SP Fast Flow resin (Pharmacia),
eluting with 20 mM 1HEPES pH 7.5 150 mM NaCl. Glutathione was added
to 5 mM, and the protein stored at -70.degree. C.
[0470] Test compound was incubated for 15 minutes with 30 nM
fluorescin peptide Fl 9mer and 120 nM MDM2 17-125 in 50 mM HEPES pH
7.5, 150 mM NaCl, 3 mM octyl glucoside. The polarization of the
fluorescein label was thereafter measured by excitation at 485 nm
and emission at 530 nm. Polarization was expressed as a percent of
a no compound control, using buffer with Fl 9mer but without MDM2
as background.
[0471] Compounds of the present invention inhibited the binding of
p53 to MDM2. The potency of the compounds was measured as
IC.sub.50, which is a measure of the concentration of the test
compound required to inhibit 50% binding between MDM2 and p53. The
IC.sub.50 values for compounds of the present invention ranged from
0.1. .mu.M to >100 .mu.M. Table 1 provides representative data
for compounds of the invention. TABLE-US-00001 TABLE 1 Inhibition
of MDM2 binding to p53 Example No. IC.sub.50 (.mu.M) 1 1.7 4 1.8 10
13 12 56 27 7.8 32 10.1 39 11.7 46 10.5 56 1.9 74 10 88 0.87 102
1.7 111 0.58 125 0.62 130 0.47 145 0.62
Example 218
Tablet Preparation
[0472] Tablets containing 25.0, 50.0, and 100.0 mg, respectively,
of the compound of Example 1 ("active compound") are prepared as
illustrated below: TABLE-US-00002 TABLET FOR DOSES CONTAINING FROM
25-100 MG OF THE ACTIVE COMPOUND Amount-mg Active compound 25.0
50.0 100.00 Microcrystalline cellulose 37.25 100.0 200.0 Modified
food corn starch 37.25 4.25 8.5 Magnesium stearate 0.50 0.75
1.5
[0473] All of the active compound, cellulose, and a portion of the
corn starch are mixed and granulated to 10% corn starch paste. The
resulting granulation is sieved, dried and blended with the
remainder of the corn starch and the magnesium stearate. The
resulting granulation is then compressed into tablets containing
25.0, 50.0, and 100.0 mg, respectively, of active ingredient per
tablet.
Example 219
Intravenous Solution Preparation
[0474] An intravenous dosage form of the compound of Example 1
("active compound") is prepared as follows: TABLE-US-00003 Active
compound 0.5-10.0 mg Sodium citrate 5-50 mg Citric acid 1-15 mg
Sodium chloride 1-8 mg Water for injection (USP) q.s. to 1 ml
[0475] Utilizing the above quantities, the active compound is
dissolved at room temperature in a previously prepared solution of
sodium chloride, citric acid, and sodium citrate in Water for
Injection (USP, see page 1636 of United States
Phamacopeial/National Formulary for 1995, published by United
States Pharmacopeial Convention, Inc., Rockville, Md. (1994).
[0476] Having now fully described this invention, it will be
understood by those of ordinary skill in the art that the same can
be performed within a wide and equivalent range of conditions,
formulations and other parameters without affecting the scope of
the invention or any embodiment thereof. All patents and
publications cited herein are fully incorporated by reference
herein in their entirety.
* * * * *